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ABSTRACT
Hormone replacement therapy (HRT) has been studied as a protective factor for
cognitive decline and dementia.   However, study findings have been inconsistent.
Variation in study findings may be due to differences in study designs, small sample
size, exposure ascertainment, diagnostic procedures, and inclusion of relevant risk and
confounding factors.  Moreover, there may be significant differences between the
characteristics of women choosing to use HRT and those opting not to use the therapy.
Using a large-scale, population-based, cohort study, we examined the
relationship between HRT and cognition while paying particular attention to moderating
and confounding factors.  The main outcomes of interest were to assess differences in
risk for cognitive impairments and dementia between HRT user and never user groups;
examine HRT’s impact on age of onset of dementia; and explore the relationship
between duration of HRT and cognitive decline.   Logistic regression and Cox
Proportional Hazards models were used to test HRT as a predictor for cognitive
impairments, Alzheimer’s disease and vascular dementia, as well as to assess the effect
of duration.  Linear regression was used to consider the putative relationship between
age at onset of dementia and HRT status.   HRT use was found to be a statistically
significant predictor for Alzheimer’s disease and vascular dementia.  Overall, HRT use
did not significantly predict for milder cognitive impairments, although significant
interaction effects indicate that HRT may be protective at least for specific sub-groups
of women.  No durational effect was found for any of the outcomes.  Neither did HRT
appear to predict for age at onset of dementia.  Notably, a large proportion of women in
the current study reported using estrogen-only hormone supplements, and therefore
generalizations regarding the findings are likely limited to estrogen-only preparations,
not combination estrogen-progestin therapies.  These findings must be considered
within the context of the other known and potential risks and benefits that HRT may
afford.
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1CHAPTER 1:  INTRODUCTION
1.1   Introduction
Seniors are one of the fastest growing population groups in Canada.  As the
population ages, the number of people with cognitive impairment and dementia-related
illnesses will markedly increase.  With this growth, Canada can expect an increased
social and economic burden resulting from the intensified need for health care services,
long-term care facilities, and the cost of both formal and informal caregiving.  Because
the effects of dementia on our society are far-reaching and health reform is focusing on
cost-containment, the need for immediate interventions and effective treatments is
evident.
In 1994, the Canadian Study of Health and Aging (CSHA) prevalence estimates
suggested that 252,600 Canadian seniors (8%) met the criteria for dementia (1).  Each
year there will be approximately 60,150 new cases of dementia in Canada – 36,320 will
be women and 23,830 will be men, and 46, 670 will occur in the community and 13,
480 in institutions (2).  The occurrence of dementia-related illness is not randomly
distributed throughout the senior population.  Jorm demonstrated an age-related
increase in the prevalence of dementia, doubling approximately every 5 years after age
60 (3).  A large portion of the older adult population is at risk for developing this illness
in their lifetimes.
At the individual level, dementia sufferers are at an increased risk for poor
health and mortality (4).  Though estimates of survival range from 5 to 9.3 years, after
accounting for length bias, Wolfson et al. (2001) report a mean survival of just 3.3 years
following the onset of the disease (5).  In a five-year follow-up study, after a diagnosis
of possible or probable AD, only 21% of individuals survived (5).  While there is no
known cure for dementia, research efforts are aimed towards understanding the
2mechanism of dementia and possible interventions that will delay or prevent the
progression of this illness.
More women than men, of all ages, are diagnosed with dementia.  The female:
male ratio is 2:1(6). In terms of Alzheimer’s disease (AD), women are 2-3 times more
likely than men to develop this illness after age 70 (7).  Initially, it was believed that the
differential gender distribution might be due to women’s longer life expectancy.
However, life-table studies have suggested that higher risk of AD in women is not
solely due to greater longevity (8).  This suggests the possibility of an alternative
explanation for the increased number of cases of dementia in women.  There may be a
gender-specific variable, such as postmenopausal estrogen levels, impacting the
progression and development of dementia in women.
Research has indicated that pre-clinical cognitive deficits exist prior to the
discernible clinical onset of dementias such as Alzheimer’s disease (AD) (9-11).  The
picture emerging is that some dementias such as AD are characterized by early declines
in a variety of cognitive areas and that these declines persist over time.  Labels such as
“mild cognitive impairment”, “age-associated memory impairment”, and “cognitive
impairment no dementia” have been used to depict this pre-clinical phase of
impairment.
In the CSHA, “cognitive impairment no dementia” (CIND) is a broad category
used to classify cognitive impairments that do not meet dementia criteria for a range of
reasons including, but not limited to, severity (12).  CIND is broken down into many
sub-types based on the cause of impairment, such as those due to chronic alcoholism,
visual or auditory impairments, psychiatric illness, vascular disease, and socio-cultural
factors.  Furthermore, a distinction was made between CIND and “cognitive loss no
dementia” (CLoND).  CLoND is used when participants with either CIND or “no
cognitive loss” (NCL) experience significant loss in cognitive functioning between
study phases, but still do not meet the criteria for a dementia diagnosis (13).  A CIND
diagnosis is thought to increase one’s risk of developing dementia in the future, whereas
the importance of the CLoND classification in determining dementia susceptibility is
not yet known.
3Cognitive Impairment No Dementia (CIND) is twice as common as dementia in
seniors and is independently associated with functional disability and increased risk of
mortality (14).  In CSHA, the prevalence of CIND was 16.8% (15).  After five years,
47% of participants with CIND progressed to dementia, while only 15% of individuals
who were cognitively normal at baseline developed the disease (16).  When enhanced
treatment options are discovered, CIND will be an important marker to identify when
therapy should begin (17).  For this reason, CIND is an important component of
dementia-related research.
Hormone replacement therapy (HRT), particularly estrogen, has been studied as
a protective factor for cognitive decline and dementia. However, the findings have been
inconsistent.  The benefits of estrogen on women’s health are known, but there is debate
as to whether these benefits outweigh the risks.  Estrogen has been found to exert a
wide range of effects on the reproductive system, cardiovascular system, skeletal
system, and neuronal systems serving cognitive functions, especially memory (18).
There are several plausible mechanisms through which estrogen might benefit cognition
(19), both in the short and long-term.  If HRT is found to protect women from dementia,
or to delay the onset of this illness, this would reduce the time spent with disability, and
lengthen and improve quality of life.  Chapter 2 provides an up-to-date review of the
current literature on HRT use.
The goal of this thesis work was to examine the role of HRT in cognition and
cognitive decline, while paying particular attention to moderating and confounding
variables reported in the literature.  Data was used from the first and second wave of a
large-scale cohort study, the Canadian Study of Health and Aging (CSHA).  The CSHA
has followed the physical, mental, and social health of seniors (65 years and older)
throughout Canada over a 10-year period. Because of its large and representative
sample (n=10, 263), stringent diagnostic process, and longitudinal nature, the CSHA
offers a unique opportunity to study HRT as a protective factor for CIND and dementia.
Understanding the relationship between HRT and cognition is highly important to
health professionals, researchers, and women in general.  This thesis adds to the
literature by reconciling a number of the methodological problems that limit the validity
of previous study conclusions, thereby strengthening confidence in research on this
4topic.  Once the effects of HRT are more accurately known, women will be able to
make more informed decisions regarding the use of this particular therapy.  And, as
Henderson points out, “considering the distressingly high prevalence of AD among
older women and the exorbitant social and economic costs associated with this disorder,
a true risk reduction would be of tremendous public health importance” (19).
1.1   Study Hypothesis
 HRT use protects postmenopausal women from developing cognitive decline
and impairments (CIND, CLoND, AD, and VaD).  However, the strength of this
association will be biased if risk and confounding factors are not controlled for in
analysis.
1.2   Objectives
The objectives of this thesis were to determine:
1. If the characteristics of HRT users differ from those of never users.
2. If there is an increased diagnosis of cognitive impairment no dementia (CIND),
Cognitive Loss No Dementia (CLoND), Alzheimer’s disease, or vascular
dementia in women never using HRT as compared to HRT users.
3. If HRT use is a significant predictor for CLoND, CIND, Alzheimer’s disease or
vascular dementia.
4. If the age of onset of dementia is earlier in women never using HRT than in
women who have used HRT.
5. If there a dose-response relationship between HRT usage and CIND, CLoND,
AD and vascular dementia.
While examining the relationship between HRT and cognition, known risk factors for
dementia such as age, education, income, NSAID use, head injury, APOE-4 presence,
lifestyle factors, environmental exposures, and chronic health conditions will be
controlled for in the analyses.  This will be done in an effort to ascertain HRT’s true
effect on cognition by adjusting for factors occurring to a greater or lesser degree in the
user group.
5CHAPTER 2:  LITERATURE REVIEW
2.1 Important Concepts
Estrogen Replacement Therapy:
Estrogen replacement therapy (ERT) has been prescribed for decades as a means
of treating the symptoms of menopause by using estrogen to stabilize declining
hormone levels in women. Because of the increased cancer risk associated with its use,
it is now usually only given to women with a hysterectomy who are not at risk for
endometrial cancer.  There are two types of ERT, natural and synthetic, which are
distinguishable by their chemical composition (20).  Each type of estrogen and the form
it is administered through (eg. pill, patch, cream) has different absorption
characteristics, with oral forms increasing total plasma estrogen levels more than
vaginal creams (21).  Estradiol, estrone, estriol, and their conjugates, as well as
conjugated equine estrogens are all natural estrogens that are used in ERT (20); while
ethinyl estradiol, mestranol, quinesterol, diethystilbesterol, and raloxifene are included
in the synthetic class (20). Although there are many types of ERT, Premarin ™, or
conjugated estrogen, is the most frequently prescribed preparation today (20).
Hormone Replacement Therapy:
Hormone replacement therapy (HRT) is the combination of both estrogen and
progesterone in the form of a pill, patch, cream, gel, injection, implant or vaginal ring.
The addition of progestins was a response to growing evidence that estrogen alone may
promote cancers of the reproductive tract.  With the addition of progestins, the
transformation of ERT into HRT hoped to circumvent earlier discovered negative health
consequences, such as endometrial cancer.  However, the progestins added have been
linked to an increase risk for breast cancer (22).
For simplicity, the term HRT will be used when referring to all types of
hormone therapy.  Notably, estrogen-only preparations have been used most frequently
6in the past and by women with a hysterectomy, but in recent years combination
therapies are becoming increasingly common.
Menopause:
Menopause is the time following a woman’s last menstrual period.  A woman
must go 12 consecutive months without her period before she is said to be in
menopause.  In Western industrialized countries, the median age at menopause is
currently 50 years of age (23), although the age of onset will differ greatly from
woman-to-woman.  In CSHA, menopausal status was determined by each participant,
but was not directly included in analysis.
Dementia:
Dementia is a broad category that includes AD, vascular dementia, and other
specific dementias.  Approximately two-thirds of all dementia cases are due to AD, with
vascular dementia being the second most common form(1).  According to DSM-IV-TR,
the most recent diagnostic criteria, a dementia diagnosis must include (24):
-multiple cognitive deficits including memory impairment, and at least one of:
-aphasia (language disturbance)
-apraxia (impaired motor activities despite intact motor function)
-agnosia (inability to recognize objects despite intact sensory function)
-disturbance in executive functioning (i.e. planning, organizing, sequencing)
Cognitive deficits must also:
-be sufficiently severe to cause impairment in occupational or social functioning
-represent a  significant decline from a previously higher level of functioning
-not occur exclusively during the course of a delirium
In the CSHA, each dementia diagnosis includes a measure of severity.  At the init al
phase of CSHA, a three-point scale was used to specify the severity of dementia
observed in each participant.  From CSHA-2 forward, this is indicated by a rating on the
Reisberg’s Gobal Deterioration Scale (25).  The scale has a range from stage 1 to stage
7, moving from cognitively normal to severe cognitive decline with interference in all
activities of daily living (ADLs).
7Alzheimer’s disease (AD):
AD is an age-related and irreversible brain disorder that occurs gradually and results
in memory loss, changes in behaviour and personality, and a decline in thinking abilities
(26).  It is a disease that belongs to the broader category of dementia.  It is characterized
by gradual onset and continuing cognitive decline; is not due to other conditions such as
cerebrovasular disease, Parkinson’s disease, hypothyroidism, vitamin B12 deficiency,
nor is it substance-induced; and the disturbance is not better accounted for by another
Axis I disorder such as schizophrenia or Major Depressive Disorder (24).  In this thesis,
I confine the discussion to late-onset AD where the incidence greatly increases with
age, especially after 65 years.
Because most research on HRT and dementia is limited to AD, the most common
form of dementia, a large portion of this thesis is focused on this specific type of
dementia.  However, HRT’s effect on other dementias and CIND is an important and
largely unanswered clinical question deserving attention.
Vascular Dementia (VaD):
Aside from AD, VaD is the next most common form of dementia.  After a
dementia diagnosis is made, it is determined whether or not there is a vascular etiology.
For a diagnosis of VaD, there must be the presence of cerebrovascular disease (as
demonstrated by history, clinical exam or neuroimaging) and it must be thought to be
causally related to the dementia (27).  There is, however, debate about the degree of
overlap occurring between the AD and VaD pathologies (28).
Cognitive Impairment No Dementia (CIND):
A diagnosis of CIND is used for persons not meeting the criteria for dementia,
but who have short or long term memory impairment and at least one of the following:
impairment in abstract thinking, impaired judgment, disturbance of higher cortical
functions (aphasia, apraxia, agnosia), or personality change (12).  Similar to dementia,
CIND is associated with increased risk for mortality and functional disability.  Although
research has not conclusively established its relationship to dementia, it appears that
CIND may be an important precursor to disease development.  Causes of CIND may
fall into one of the following categories:  delirium, chronic alcohol abuse, chronic drug
intoxication, depression, psychiatric disease, mental retardation, cerebral vascular
8(stroke), general vascular, Parkinson’s disease, brain tumour, multiple sclerosis,
epilepsy, socio-cultural, social isolation, blind/deaf, and unknown.  As previously
stated, CIND is a more general category of cognitive decline not meeting the criteria for
dementia.
Cognitive Loss But No Dementia (CLoND):
During CSHA, CLoND was used to record declines from a previously higher
level of cognitive functioning when the drop was not severe enough to be classified as
dementia. The criteria for CLoND is assessed independently after it has been
determined that the participant has either no cognitive impairment or CIND.  It also
must not occur exclusively during the course of a delirium (13).  CLoND is used in an
effort to identify more subtle changes (losses) in cognition from one assessment to the
next.
2.2   Hormone Replacement Therapy (HRT)
Interest in HRT has been evident since the 1960s when physicians were already
prescribing these drugs (29). In recent years, HRT use by postmenopausal women has
become increasingly common.  HRT is one of the most frequently prescribed
medications for postmenopausal women in the United States and Canada (30).
According to the 1994/95 National Population Health Survey (NPHS), approximately
22% of Canadian women aged 45 –64 reported using HRT following menopause (31).
More recent estimates from the CCHS found that 4% of women ages 40 and over
reported currently using hormones.  Aside from its potential to reduce the acute
symptoms of menopause, HRT is believed to offer women protection from many long-
term illnesses.  Interestingly, research findings on the health benefits are not conclusive,
and often contradictory, creating concern about the mass prescription of this therapy.
In the short term, women may differ in their experiences with HRT.  It may
alleviate early menopausal symptoms – hot flashes, insomnia, irritability, urinary
incontinence, vaginal dryness – as well as lead to unpleasant side effects such as weight
gain, breakthrough bleeding, and breast tenderness.  The compliance and continuation
of HRT will differ from woman-to-woman, with breakthrough bleeding, expense,
preference for the natural, and health concerns being some of the more common reasons
9for discontinuing treatment (20).  Often more women with a hysterectomy begin HRT
treatment and continue for longer durations than women without.
Over time HRT is postulated to protect women from a variety of chronic health
conditions.  Osteoporosis, cardiovascular disease, colon cancer, and Alzheimer’s
disease are some of the health problems that are currently being investigated.  Studies
have shown HRT to be associated with a significant reduction in colon cancer (30% in
ever users and 46% for recent use) (32, 33), morbidity and mortality from coronary
heart disease (CHD) (34, 35), cardiovascular disease (36), and bone loss (23).  Research
findings such as these have stimulated the use of HRT as a preventative treatment for
many age-related illnesses.
The protective effects of HRT have been publicized by the media and supported
by physicians, thereby legitimizing its use.  In 1996 alone, the popular press in Canada
mentioned HRT 152 times (37).  In a study by Parker Jones (2000) surveying 425
primary care physicians for women, most responded that HRT was extremely or
moderately important in the prevention of osteoporosis (99%) and cardiovascular
conditions (96%) (38).  Regardless of physicians’ endorsement of this technology, there
are questions about the safety of HRT and its implications for women’s health.
A recent study, The Heart and Oestrogen-Progestin Replacement Study, found a
52% increase in adverse cardiovascular events in the first year of therapy in patients
with a history of heart disease who used HRT (39).  Distressingly, some studies have
also found HRT to increase a women’s risk for breast, gallbladder, endometrial, and
ovarian cancers, depending on the length of use and whether or not progestins have
been added (40) (41) (42) (43) (44).  Using individual data from a large meta-analysis
(n=52,705), a group of investigators found no increase in breast cancer risk with HRT
use for 4 years or less, although use for 5 years or longer was associated with a
statistically significant increase (RR=1.35; 95% CI 1.21-1.49)(30).  Although less
common after the first year of use, venous thromboembolism has also been found to be
more frequent in HRT users than non-users (23). Pre-existing health conditions, the
duration of treatment and the preparation used may determine the health consequences
and benefits postmenopausal women receive from hormonal supplements.
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During the compilation of this thesis work, the Women’s Health Initiative
(WHI) stopped its E trogen plus Progestin Trial, a sub-component of the larger study.
The WHI is a large, double blind, randomized, placebo-controlled, clinical trial
studying the effects of HRT on postmenopausal women over an eight-year period.  As
one of the largest and lengthiest clinical trials to date, this multi-centre trial found a
26% increase in breast cancer which caused the study to be halted (45).  Furthermore,
the combination hormone therapy resulted in a 41% increase in strokes, 29% increase in
heart attacks, and a two-fold increase in blood clots of the legs and lungs (45).  In terms
of positive health effects, there was a 37% decrease in colorectal cancer and 24% fewer
total fractures (45).  These combined results led investigators to conclude that “the
overall health risks of estrogen plus progestin therapy exceeded benefits” and “the risk-
benefit profile found is not consistent with the requirements for a viable intervention for
primary prevention of chronic diseases” (p.15) (46).  However, it should be noted that
the increased breast cancer risk for each individual women participating in the study
was small (>0.10% / year) (45).  Recently, data obtained from the WHI on dementia and
mild cognitive impairment found that general dementia risk doubled for women in the
estrogen plus progestin group (47). At present, this is the first finding that HRT
increases risk for dementia.  No treatment effect was observed for Mild Cognitive
Impairment (MCI).  The risks and benefits of using estrogen-only hormone therapy in
women who have had a hysterectomy are not yet known; this study is still being carried
out by the WHI since no negative health consequences have been found as yet.
Nonetheless, there is much uncertainty surrounding the benefits and risks associated
with HRT use.  Further research and consideration is necessary before this treatment
should be endorsed by the medical community, a fact that is increasingly being
recognized.
2.3  The Neuropathology of AD
In the past decade, our understanding of Alzheimer’s disease and its
development have advanced significantly.  The neurodegenerative process leading to
the onset of AD is complex and may be initiated many years before its clinical onset
(48).  As research into the etiology and pathology of AD accumulates, the knowledge
11
gained allows for new interventions that may delay or halt the progression of this
illness.
Theories about causation and the development of AD involve a combination of
genetics, environmental exposures, and neurological insults impacting on the brain’s
physiology (49).  Multiple factors appear to play a role in AD.  Prominent theories
include four main premises:  it is a result of aging; the processes may result from
physical trauma, aggravated by genetic factors, which inhibit repair mechanisms; a
pathology resulting from the accumulation of toxins; and an inflammatory process (49).
It may be that no one theory can fully explain the AD process, but instead it is likely
that many interrelated factors result in disease development (48).
The major neuropathological features of AD are deposits of amyloid plaques,
intraneuronal neurofibrillary tangles, synapse loss and the death of neurons (48, 50).
The presence of plaques and tangles are required for a definite diagnosis of AD (51).
These may occur over 10 years prior to dementia expression (50).  Plaques are complex
extracellular deposits in the neuropil containing ß-amyloid, which is produced in normal
cells by the ß-amyloid precursor protein (48).  It is not known what causes the plaques
to form.  Still, plaque deposition can be affected in many ways indicating that there may
be several different mechanisms leading to a final common pathology (48).  ß –amyloid
can have a toxic effect on brain functioning.  It increases the vulnerability of neurons to
other insults such as excitatory amino acids, glucose deprivation, and oxidative stress
(52).  Although the role of plaques in AD pathogenesis is still unclear, ß -amyloid is an
essential process in AD but does not appear causative (50).  These findings lend support
for ß -amyloid as an important antecedent in AD pathology.
In addition to plaques, neurofibrillary tangles are bundles of long protein
filaments in the cytoplasm of neurons (48) and are also a necessary condition for the
development of AD.  Tangles are a result of the abnormal processing of tau protein(s)
(48).  In AD tau is chemically modified, and this changed tau twists into paired helical
filaments, which then combine to form neurofibrillary tangles (26).  This change may
result in malfunctions in communication between nerve cells and then contributes to
neuronal death and the development of dementia (26).  Even though tangles are
dispersed throughout the brain in AD patients, they are particularly concentrated in the
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structures associated with memory processing (48, 53).  The duration and severity of
AD are directly correlated with the numbers of neurofibrillary tangles and synapse loss
(48, 53).
The final characteristic of AD pathology is synapse loss and cell death. Plaques
and tangles may both contribute to neuronal and cellular death (26).   Synapse loss and
neuronal death affects multiple neurotransmitter systems leading to multifaceted
presentation of symptoms in AD patients (54), but the nucleus basalis of Meynert, the
source of cholinergic function, and the septal nucleus, which provides cholingeric
innervation to the hippocampus are particularly affected (55, 56).  For this reason, many
therapies for AD aim to improve acetylcholine function (48), including widely used
drugs such as donepezil and rivastigmine.  Rather than being separate pathologies, it’s
likely that plaques, tangles, synapse and cell loss are part of a complex, interrelated
process imperative to the way that the brain ages and copes with damage (48).
Because AD’s neurodegenerative process may take decades to unfold (48), any
interventions slowing or preventing the production of tangles and plaques, and
subsequent synapse loss and cell death, would be of great consequence.  Current
therapies operate by slowing the disease’s progression, but do not reverse the damage
already done.  If HRT fosters neurological functioning and acts in a preventative
manner, its use following menopause may be highly significant to women’s cognitive
health and quality of life.
2.4  HRT’s Mechanism of Action
It is thought that ovarian factors are important to the normal maintenance of
brain function in women, and therefore the time after menopause is critical to cognitive
health(54).  In recent years, HRT has been studied extensively as a protective factor for
cognitive health.  It has been shown to modify many of the factors contributing to the
neurodegenerative process, although much of the evidence relating to a mechanism of
action has been obtained through animal studies (57).
Studies have found endogenous estrogen levels to be lower in postmenopausal
women with AD than in women without dementia (58).   Although the mechanism by
which HRT protects cognition is not yet fully understood, many plausible theories are
being validated by recent research.  Honjo (2001) suggests a combination of four
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mechanisms to explain the beneficial effects of hormone therapy (59).  These include
improved mood leading to better test performance on cognitive screens; vascular
dilation in the CNS making neurons more active; activation of acetylcholine
metabolism, including the hippocampus and the hypothalamus; development of glia,
which helps neurons in the CNS (59).  HRT is also believed to have anti-inflammatory
properties and to mediate the negative impact of ApoE-4 on the brain (26). Because of
estrogen’s important biological role, it is possible that it affects many of the processes
eventually leading to the development of dementia.
The declining estrogen levels that accompany menopause may initiate or
accelerate neuropathological processes.  This neurodegenerative transformation may be
slowed through HRT’s actions.  HRT is believed to attenuate the adverse effects of ß-
amyloid, thereby preventing plaque formation.  For instance, one study found that
cerebrospinal fluid levels of estrogen were significantly lower in AD patients than in
controls; within the AD group estrogen levels were inversely correlated with ß -amyloid
concentrations, providing evidence for an influence of estrogen on ß -amyloid
metabolism (60). It is also suggested that estrogen may decrease production of ß -
amyloid and help to concentrate it into focal deposits, although it is not found to be
effective in actually clearing ß -amyloid (61).
Estrogen has both anti-inflammatory and antioxidant effects.  Conjugated
estrogen has been found to antagonize inflammatory damage triggered by ß–amyloid
peptide (62, 63), a response which may be similar to the protective effects of non-
steriodal anti-inflammatory drugs (NSAIDs).  Moreover, the excess production of free
radicals, which occur during normal metabolism, causes oxidative stress that can injure
cells and result in damage (26).  The reported antioxidant properties of estrogen might
attenuate oxidative damage induced by ß–amyloid (64).  Once ß -amyloid accumulates
as plaques, estrogen treatment seems to make little difference in the brain.
 Not only is estrogen a factor in reducing plaque formation and lessening ß -
amyloid’s inflammatory and oxidative stress, but it may have a significant effect on
neurotransmitter systems.  Estrogen is able to restore plasma acetylcholine transferase
levels in postmenopausal women (65).  Acetylcholine is considered the most important
neurotransmitter involved in the modulation of memory, learning, and cognitive
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function (23).  Patients with AD show a marked decrease in the activity of choline
acetyltransferase, an enzyme involved in the synthesis of acetylcholine in the cerebral
cortex and hippocampus (6).  Other neurotransmitters possibly involved in the AD
process, such as noradrenaline, seretonin, dopamine, and norepinephrine are also
affected by estrogen (63, 66).
Estrogen’s neuroprotective role seems to operate not only through neuronal, but
also vascular actions.  MRI was used to document ischemic brain injury in 210
postmenopausal women for ten years (67); the 70 women taking ERT in this study had
fewer and smaller damaged areas than the 140 controls. Improving cerebrovascular
function is considered a viable option in AD treatment, as many vascular abnormalities
are observed in AD patients (57).  Estrogen may also effectively improve cerebral blood
flow, although study findings have been inconsistent (57).
Often AD is conceptualized as an imbalance between neuronal injury and repair
(50).  Evidence suggests that estrogen not only decreases the risk of dementia through
the suppression of the neurotoxic stimulus itself, but lessens the extent of injury
sustained by increasing the resilience of the brain to a given injury (68).  Estrogen
stimulates production of nerve growth factors, thereby promoting neuronal growth and
viability, repair of damaged neurons, and dendritic branching (63).  Through estrogen’s
actions, HRT may play a role in repairing the damage that would otherwise lead to AD
and other dementias.
Importantly, once the damage is present in the brain, HRT might be less
effective in treating dementia.  HRT seems to be more effective in the initiation phase
of neurodegeneration rather than just prior to clinical onset (69).  He c , if estrogen is
deemed beneficial, it should be used earlier on for the primary prevention of dementia
for the most favorable outcome.
2.5   ApoE and Dementia
Recent epidemiological studies have shown ApoE to be an important genetic
risk factor for AD and other dementias.  The CSHA found that seniors with any copies
of the ApoE-4 allele were almost three times more likely than those without to develop
AD (70).  It has been suggested that HRT may ameliorate the detrimental effects of
ApoE-4 on cognitive decline.
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ApoE is a protein with three common alleles – ApoE-2, ApoE-3, and ApoE-4.
All people have two copies of this protein, which may include different alleles
(heterozygous versus homozygous).  In a study of the Canadian population, the allele
frequencies were reported to be 7.8% (E2), 77.0% (E3) and 15.2% (E4) (71).  The E3
allele is the most common in the general population, however approximately 40% of
AD patients have the E4 allele (72).  This overrepresentation of the E4 allele in persons
with AD suggests a role for ApoE as a genetic risk factor in the AD process.
As a component of various lipoproteins, including very-low-density-lipoproteins
(VLDL) and a subset of high-density lipoproteins (HDL) (73), APOE is a critical
modulator of cholesterol and phospholipid transport between cells (74).  It is essential
for the repair, growth, and maintenance of membranes that occur during development or
after injury (71, 75, 76). As an injury response protein, ApoE may transport cholestrol
and other molecules to the injured neurons to be used in repair, with the E4 allele being
less effective in this process (50). Therefore, ApoE may influence the impact that head
injuries and other environmental toxins have on the brain, and on subsequent
development of cognitive impairment.  For instance, the risk of developing AD with a
history of head trauma was increased up to ten times in E4 carriers compared to non-
carriers (77, 78).  This evidence leads to the belief that dementia, and specifically AD,
is a multi-causal disease with certain genetic factors partially determining how other
neurological insults will manifest their damage in the brain.
The increased risk with E4 appears to be due to the fact that it accelerates the
age of onset (48).  In AD, the risk is increased with E4 in a dose-dependent manner
(48).  That is, the risk of AD increases, and the age at onset decreases, with the number
of E4 alleles (72, 79).  Compared to people with no copies of E4, the risk of developing
AD in a person with two E4 copies is from eight to thirty times greater (80, 81), whil
those with one E4 allele have an increased risk of about three times greater (80, 82).  In
contrast, the E2 allele appears to be protective for the disease and is associated with a
later age of onset if AD does develop (26, 80, 82, 83)
Evidence substantiates the biological importance of ApoE in neurological
functioning.  ApoE is present in the senile plaques of AD brains even in the early stages
of formation (84) suggesting that ApoE accumulation precedes ß-amyloid deposition
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(85).  In contrast to the E4 genotype, the E2 and E3 alleles have different binding
properties and may help to protect against the formation of amyloid aggregates,
therefore hindering the development of senile plaques (86).  The E4 allele is less able to
limit the growth of the prerequisite plaque deposits in AD.  ApoE also has an effect on
tau protein.  It is thought that E4 has a decreased binding to tau protein, which facilities
neurofibrillary tangles leading to eventual neuronal loss (50).
Aside from AD, the development of other dementias and CIND (87), have been
linked to ApoE-4 as well.  ApoE-4 appears to increase risk of progression from mild
cognitive impairments to dementia (r ference).  ApoE gentoype may also contribute to
the neuropathological process in Lewy Body Disease (88), however it has not yet been
found to influence the growth of AD lesions in Parkinson’s disease (89). The frequency
of ApoE-4 is increased in patients with vascular disease (48).
ApoE-4 does not predict AD with certainty.  ApoE does seem to play a role in
amyloid deposition and tau phosphorylation, but it is probable that it’s only one of
many factors (90).  Although when AD is suspected and a clinical workup finds an
ApoE-4 allele, the ApoE genotype has a positive predictive value of 94-98% (91).
ApoE is a risk factor for the development of AD, but it is not necessary or sufficient to
cause this illness (48).  Rather than acting as a causative mechanism it seems to modify
disease expression (50).  Scientists continue to search for other contributory genes.
2.6    The Potential Interaction between ApoE and HRT
It is thought that HRT interacts with ApoE, thereby modifying its effects on the
process of AD development. Studies have shown plasma levels of ApoE to be inversely
correlated to the estrogen concentration in blood (92, 93).  HRT may actually suppress
APOE levels in women with low serum estrogen levels (59, 94).  Furthermore, estrogen
receptors have been shown to interact with the ApoE-4 genotype in determining onset
susceptibility (91).
The mediation of ApoE-4’s effects may be a crucial component of HRT’s
neuroprotective effect.  Some of the benefits of estrogen may be related to the
regeneration of the injured brain brought on by the neurotrophic action of ApoE itself
(73).  If this is the case, then HRT may be particularly important for postmenopausal
women carrying E4 alleles.
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2.7   HRT and Risk Reduction for Dementia
Considering estrogens putative neurological impact, it is a plausible hypothesis
that HRT may preserve cognition function in aging women.  Studies have shown that
HRT may delay or prevent the development of dementia in postmenopausal women.  It
has been suggested that the risk of developing AD is reduced by 30 to 40% in estrogen
users (95) with the severity of the disease also being reduced (96),(97).  A meta-analysis
of 10 observational studies, both retrospective case-controlled and prospective cohort
studies, found that estrogen users had a 29% lower risk of developing AD (94).  Still,
research results are conflicting, with some studies finding no association.
Costa et al. (1999) found that postmenopausal women using estrogen have lower
rates of possible and probable Alzheimer’s disease (AD), than never users, and
significantly higher rates of the lesser diagnoses of cognitive impairment and no
dementia (98). Similar research, in both case-control and cohort studies, confirms that
HRT users are at a decreased risk for developing AD as compared to non-users ( 96, 97,
99, 100-102). Most of the literature reviewed examines the development of AD
specifically and not other forms of dementias.  Of the ten studies found (See table 1),
six show a clear protective association between HRT and AD.  While two studies found
no significant association (103, 104), both had smaller sample sizes, failed to assess
duration of hormone use, and one relied solely on a prescription database as a marker of
HRT use and compliance.  Yet another study observed a protective association, but only
after HRT was used for seven or more years (105).  And recently, the WHI-MS
observed an increased risk for dementia associated with HRT treatment (47). However,
this effect was found in women beginning HRT at ages 65 and older, and therefore the
disease process may have already been well underway. While some studies show
support for a protective association, other studies have shown HRT to have no
significant effects on cognitive functioning or the development of dementia.  Therefor ,
further research needs to be conducted in order to discern the relationship between HRT
and risk reduction for AD and other dementias.
Table 2.1: Literature Examining HRT as a Risk Factor for Alzheimer’s disease and Dementia
First
Author
Year
Sample
(n)
Study Design Participants
With
Dementia
Sample age &
education
Significant Findings
OR (95%CI)
Covariates Diagnostic
criteria/
evaluation
Duration/ type/
dose of HRT
Comments on
Methods
Shumaker,
2003 (47)
N=4894 Randomized,
placebo-
controlled,
double-blind,
clinical trial.
Women’s Health
Initiative Memory
Study.
61 cases
probable
dementia (32
AD cases)
before non-
adherence.
34 cases
occurred
after non-
adherence.
65 years &
older.
Dementia-free
@ baseline.
HRT-treated women
were at twice the risk of
general dementia
(HR=2.05; 95% CI, 1.21-
3.48).
Risk was still significant
when excluding non-
adherent participants.
Did not differ
according to age,
education, smoking,
diabetes,
presence/absence of
past hormone use,
regular aspirin use,
3MSE scores @
baseline.
Screening
interview, neuro
battery, and
annual clinical.
Conjugated equine
estrogen &
medroxy-
progesterone
acetate
(combination
therapy).
-Treatment @ 65 &
older
-Grouped AD & VaD
together
-HRT group (45%) &
placebo group (47%)
had used hormones
prior to the study.
Duration not assessed.
-Blinding difficult
-52% of women were
non-adherent during the
trial.  More common in
treatment group.
-No APOE info
-Many cases diagnosed
after stopping HRT.
Geerlings,
2001 (106)
N=3601 Rotterdam Study.
Pop-based,
prospective cohort
study.
Median FU: 6.3
yrs
199 Incident
cases of
dementia
(159 AD)
Ages 55 and
over.
Mean age @
baseline= 71.7
years.
Dementia-free
at baseline.
Women w/ longer
reproductive period w/
APOE4 had an increased
risk for dementia
(RR=4.2; 1.97-8.92) and
AD (RR=3.42; 1.51-
7.75).  In non-APOE4
carriers, no clear assoc.
Age, education,
smoking and
alcohol use, BMI,
use of HRT, # of
children, and APOE
genotype.
Screening
interview, neuro,
clinical, and blood
sampling.
HRT use was
included as a
confounder.
10% of sample
were HRT ever
users.
-Looked at both AD &
general dementia.
-More comprehensive
list of covariates.
Seshandri,
2001(104)
N=280 Nested case-
control in a cohort
study.
Population-based.
Age-matched
(within 5 years).
59 incident
AD cases
Mean age=
66.7 (cases) &
65.2 (controls)
Used General
Practice
Research
Database.
Current vs. never: 1.18
(0.59-2.37)
Current and past vs.
never: 1.19 (0.62-2.27).
BMI was found to be an
independent risk factor
for AD.
Body Mass Index,
smoking,
hypercholesterol-
emia, diabetes
mellitus, and
ischemic heart
disease.
Neuro assessment,
clinical
information
obtained through
physicians’ notes;
final Dx made by
study neurologists.
# of prescriptions
filled.
Current, past, and
never.
22% of cases &
21% of controls
used HRT.
-Very few past users.
-mean sample age=66
-Used records,
participants were not
seen.
-no adjustment for other
risk factors
Waring,
1999 (102)
N=444 Case-control
study, population
based.
Matched by age
and length
enrolled in record
linkage system.
222 AD
cases.
All
postmenopausa
l women.
Median
Education:
12.0 yrs.
0.42 (0.18-0.96) p=0.04
Longer use significantly
decreased risk for AD.
Education, age @
menopause, and
parity
Less standard;
based on medical
records.
Diagnostic tests
differed for each
participant – not
all had neuro tests.
Dose and
duration.
-many women had other
conditions.
-used medical records
linkage system.
-Excluded ERT use < 6
months
Baldereschi
1998 (99)
N=1568 Cross-sectional
population-based,
multi-centre
survey in  Italy.
92 AD
patients
65-84 years of
age.
Mean
education:
5.1 (HRT never
users) 6.1
(HRT ever
users)
0.28 (0.08-0.98)
*No difference in age of
onset for AD.
Age, education, age
@ menarche,
smoking, alcohol
habits, body weight
@ age 50 & # of
children.
Screened using
MMSE, risk factor
interview, neuro
assessment, and
clinical exam.
-Never vs. ever
-Mean duration =
3 years
-11.6% used ERT
after menopause
Excluded non-AD
dementia cases
*Retrospective
*ERT users younger,
more educated, and
drank more wine.
Kawas,
1997 (101)
N=514 16-year
prospective cohort
study.
34 incident
cases of AD.
Mean age @
baseline= 61.5
years (28-94);
87% graduated
college or
greater
OR:  0.46 (0.209- 0.997)
*No sig. effect of
duration found.
Age, age at
menopause,
education, surgical
menopause, and
NSAID use.
Interview, clinical
exam and neuro
assessment.
Reassessed every
2 years
Ever versus never
users.
45% ERT users.
Paganini-
Hill,
1996 (97)
N=1488 Case-control
nested within a
prospective
cohort.
Leisure World
Laguana Hills.
Subset of those
dying between
1981 and 1995.
Age & death
matched
248 AD
cases. Dx
taken from
death
certificates.
Mean age @
death:  87.7
(cases) 87.3
(controls)
OR  for AD:  0.65 (0.49-
0.88)
Risk decreased with
increasing dosages and
duration of therapy
(p=.01).  Risk decreased
for certain preparations.
Age @ menarche,
weight, type of
menopause, age @
last menstrual
period, and BP
meds.
Retrieved death
certificate
information for
those dying b/t
1981-95.
Participants did a
health survey in
1981.
Non-standardized
diagnostic criteria.
Duration &
dosage.
Premarin most
common.
96 cases used
ERT & 578
controls used
ERT.
--Time of dementia
onset unknown.
-Participant & proxy
gave ERT info.
-no clinical / neuro.
-Age of onset of
dementia not known.
-No control for other
risk factors.
Tang,
1996 (96)
N=1124
(all without
dementia
@
baseline)
36% Black
38%
Hispanic
26%
Caucasian
Cohort Study
Assessed annually
up to 5 years.
167 Incident
AD cases.
Mean age 74.2
; Mean
education 9.2
years
Overall: Adjusted RR for
AD=0.40 (0.22-0.85)
ERT > 1 year:
RR for AD = 0.13 (0.02-
0.92)
Age of onset was sig.
later for users than for
never users.  RR= 0.13
(0.02-0.95) for APOE4
hetero-zygous ERT users.
Education, APOE
genotype, ethnic
origin, and age.
Screen, Neuro
assessment,
clinical exam, and
blood sampling.
156 ERT users
(12%); Premarin
was the most
common.
Ever vs. never
Average duration
of use = 6.8 years.
Brenner,
1994 (103)
N=227 Pop-based, nested
case-control,
cohort study.
Age-and sex-
matched. Includes
women with
hysterectomy.
107 AD
cases
Mean age=78.7
(cases) & 76.6
(controls)
OR:  1.1 (0.6- 1.8)
No significant findings.
Education marital
status, ethnicity,
history of smoking
and progesterone.
Medication
history, MMSE,
neuro assessment,
clinical exam, lab
tests, and imaging.
Current, past, and
never users.
Number of
prescriptions
filled.  No
duration or dose.
Computerized
pharmacy data
confirms HRT use
Unknown if women
actually took ERT.
61% of controls
completed Grade 12,
while only 12% of cases
did.
Henderson,
1994 (100)
N=235 Retrospective
case-control study.
Volunteer
community
sample.
143 Probable
AD cases
Mean age 76.0;
Mean education
12.2 (cases)
and 13.9
(controls)
AD patients were less
likely to use ERT than
controls (7% vs. 18%).
AD patients using ERT
did sig. better on MMSE
than non-users.
Age, education,
dementia symptom
duration.
Interview, clinical
exam, neuro
assessment, and
lab tests.  Autopsy
confirmed 70 of
the AD patients.
Premarin was the
most common
ERT.
Dose or duration
not known.
*Volunteer sample
*Retrospective
*Only assessing current
use.
* Past ERT status not
known.
Paganini-
Hill,
1994 (105)
N=790 Case-control study
nested within a
prospective cohort
study.  Leisure
World.
Age & death date
matched
138 AD
cases
Mean age =
86.5 (cases) &
86.8 (controls)
Risk of AD for ERT
users: 0.69 (0.46-1.03);
ERT >=7 years OR= 0.49
(0.27-0.88) ; Dose>=1.25
OR = 0.46 (0.22-0.94).
All other findings were
not sig.
Age @ menarche
ERT usage, type of
meno-pause, age@
last menstrual
period, BP meds,
and stroke.
Mailed survey.
Follow-up survey
and hospital
records.
Pulled death
certificates for
those who died b/t
1981 & 1992.
Risk decreased
with dose &
increasing
duration.
Premarin most
common.
No control for
education, head injuries,
NSAIDS use (other
known risk factors).
2
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2.8    HRT as a Treatment for AD
In addition to being aprotective agent, HRT has also been studied as a potential treatment
for AD.  In the literature reviewed (see table 2), three studies found HRT to improve AD
symptoms and three found no significant change in patients receiving treatment.  Honjo et al.
(1989) documented that ERT was associated with improvement in memory, orientation and
calculation in patients with dementia (107).   A study by Ohkura (1994) also provides evidence
that dementia symptoms improve with ERT use (108).  In a volunter cohort study, Henderson,
Watt, & Buckwalter (1996) selected three types of AD patients -- female HRT users, female
HRT non-users, and men (109).  They found that female AD patients using HRT scored better on
the Boston Naming, digit spans forward and backward, and one drawing tests compared to
female non-users.  No differences were observed between HRT users and male patients.
Conversely, in the Alzheimer’s Disease Cooperative Study  (ADCS), women who had had a
hysterectomy and who had mild- to moderate- dementia were treated with ERT and no effect
was found (110).  If HRT is found to be an effective treatment for dementia, this would provide
encouraging evidence for HRT’s neuroprotective mechanism of action.
Currently, the only drugs approved to treat the cognitive dysfunction in AD are
acetylcholinesterase inhibitors (57), such as donepezil and rivastigmine.  However, this type of
treatment can compensate for only part of the neuronal dysfunction in AD, and may not modify
the oxidative damage or vascular dysfunction contributing to this illness (57).  Estrogen has been
shown to increase acetylcholine levels by enhancing the uptake of choline and activity of choline
acetyl transferase in the hippocampus and frontal cortex (54), and therefore may provide benefits
similar to current drug therapies.  In addition, HRT may improve the effectiveness of current AD
drug treatments.  Estrogen appears to interact with tacrine suggesting that the choline
acetyltransferase inhibitors require estrogen for their effects on cognitive function (111).
Although clinical trials using HRT as a treatment for AD have not provided compeling evidence
of effectiveness, they also cannot establish whether HRT is protective for AD when used prior to
disease onset.
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Table 2.2: Literature Examining HRT as a Treatment for Alzheimer’s Disease
First
Author
year
Sample size Study design Sample
characteristics
Significant
effects OR (95%
CI)
Covariates Diagnostic criteria/
evaluation
Duration/ type/
dose of HRT
Comments on
methodology
Henderson
(112)
2000
N=42
(21 placebo &
21 ERT)
Randomized,
double blind,
placebo-
controlled,
parallel-group
trial.
All mild to moderate
AD.
Mean age:  78
(placebo) 77 (ERT
treated group)
Education:  71%
(placebo) and 81%
(ERT treated group)
completed grade 12
No sig.
differences
found.
At baseline the
treatment & placebo
groups did not differ
acc. to characteristics.
ADAS-Cog; CGIC;
ADL/IADL.  Mood
assessed.  Neuropsych test
battery.
Treatment: Premarin
1.25mg/ day for 6
weeks.
-80% power.
-Difficult to blind
women b/c of bleeding.
-Short treatment
duration.
Mulnard
2000
(110)
N=120 Randomized
double-blind,
placebo-
controlled, clinical
trial b/t 1995-99.
Assessed @
baseline, 2, 6, 12,
& 15 months.
All mild to moderate
AD.
*All had a
hysterectomy
*Mean age = 75
*Mean education =
12 yrs
No significant
improvements in
ERT-treated
group.
Age, APOE4 allelle
frequency, and
education.
CGIC (Clinical Global
Impression of Change)
ADL’s, and other neuro
tests.
0.625 mg/ day of
Estrogen (n=42);
1.25 mg/ day of
Estrogen (n=39);
Placebo (n=39)
treatment: 12
months of premarin.
-Assessed intent-to-treat.
-30% of placebo group
were past ERT users
Wang (69)
2000
N=50 (25
placebo & 25
treatment
group)
Randomized
double-blind,
placebo-controlled
12-week trial.
All mild to moderate
AD patients.
60 yrs and older.
Mean age = 72.6
(ERT treated group)
71.0 (placebo)
Mean education = 6.9
(ERT treated group)
4.9 (placebo)
No sig.
differences found
b/t treatment and
placebo group.
No sig. differences b/t
treatment groups.
CASI, CDR, CIBIC-plus.
BEHAVE-AD: HARS,
HDRS.  Cerebral blood
flow.  Blood tests used to
assess compliance.
Premarin
1.25mg/day vs.
placebo.
*all patients were
not taking any other
anti-dementia meds
during this 12-week
period.
80% of power
-quite a healthy sample.
Asthana
(113)
1999
N=12 Placebo-controlled
double-blind,
parallel-group
design pilot
clinical study.
All participants had
mild-to-moderate
AD. Mean age of
ERT users = 79.5; of
placebo = 77.6.
Mean education of
ERT users = 11.3; of
placebo = 13
Sig. effects of
ERT on attention
(p<0.03) &
verbal memory
(p<0.02).
*Effects
decreased after
stopping
treatment.
Not specified Evaluated @ baseline, 1,
3, 5, and 8 weeks.  And at
9, 10, 11, and 13 weeks
off treatment.
*Neuro tests
*Blood samples to
measure estrogen in blood
8-week ERT
(estradiol) to 6
participants via skin
patch and 6
participants received
placebo via skin
patch.
Several markers of
neuroendocrine activity
may serve to index the
magnitude of estrogen-
induced facilitation on
cognition.
All participants free of
depressive symptoms
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Schneider
(114)
1997
N=323 30-week
randomized,
double-blind,
placebo-
controlled,
multicentre
clinical trial
All with dementia.
50 yrs and older.
Women receiving
HRT & tacrine
improved sig.
more than
women not
receiving HRT &
who were
randomized to
placebo or tacrine
as assessed by
caregiver (p =
0.006) and
clinical (p =
0.02).
Not specified. AD Assessment Scale-
Cog. Scale (ADASc) &
clinician’s interview
based impression of
change (CIBI) &
caregiver’s impression of
changed (CIC).
-14.5% of women
were currently using
HRT)
-Treatment: Placebo
& one of three doses
of tacrine.
-HRT was not
administered.  Only
assessed for current
users.  Most
common was
Premarin (86%) and
estradiol (12%).
Tacrine was the only
treatment randomized
(not HRT).  Duration
and  dose of HRT not
known.   HRT users
were younger (67 years
+-9 vs. 74 years +- 8),
and more non-HRT
users did not complete
high schools (16% vs.
4%).
-did not control for age,
education, or duration of
HRT use b/c of
randomization, which
didn’t create totally
equal groups.
Henderson
(109)
1996
N=62 Case-control
study.  Drawn
from volunteer
cohort study.
Matched for age,
education, and age
dementia
symptoms first
appeared.
All AD patients.
Selected 9 women
using ERT & 27
women not using
ERT & 26 men.
Mean age=74.7 (ERT
users) & 74.3 (ERT
non-users)
Mean education:
12.7 (ERT users)
&13.3 (ERT non-
users)
Women with AD
using ERT scored
better than non-
ERT using
women on
Boston Naming ,
digit spans
forward &
backward, & 1 of
the drawing
tasks.  No sig.
differences
between ERT-
treated group &
men.
Matched on age,
education, and age
symptoms first
appeared.
Screen, neuro, clinical,
CT & MRI scans of the
brain.
Premarin most
common.
Of the ERT non-users:
12 had no known use of
ERT, 6 used ERT in the
past, and 9 participants
did not know.
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2.9     HRT and Cognition in Women Without Dementia
Studies have examined HRT’s effects on cognition by using younger,
female populations without dementia (See Table 3).  Research in this area has generally
shown better test performance for HRT users, both past and present, over never users (65,
115-123).  Two studies found no significant differences in cognitive ability (18, 124),
while one study’s only significant protective effect was seen in women with surgically-
induced menopause (125).  Any improvement in test performance induced by HRT, even
in a younger sample, may lend support for HRT as a protective factor in cognition.
Similar to other research in this area, there are methodol gical limitations in this line of
research.  Lack of test standardization, clinical evaluation, small sample sizes, and limited
control for confounders are some such biases.
Table 2.3: Literature Examining HRT as a Risk Factor for Cognitive Decline
First
Author
Year
Sample
(n)
Study design Sample
characteristics
Significant findings Covariates Cognitive tests Duration/ type/dose of
HRT
Comments on
methodology
Rapp, S.
(126), 2003
N=4381 Randomized,
placebo-controlled,
double-blind,
clinical trial.
Women’s Health
Initiative Memory
Study.
65 years & older.
Dementia-free @
baseline.
HRT did not improve
global cognitive
function when compared
to placebo. More
womem n the HRT
group as compared to
the placebo (6.7% vs.
4.8%) declined by 2 SDs
on the 3MSE.
Did not differ according
to age, education,
smoking, diabetes,
presence/absence of past
hormone use, regular
aspirin use, 3MSE scores
@ baseline.
Screening interview,
neuro battery, and annual
clinical. Main outcome
measure was global
cognitive function
Conjugated equine
estrogen & medroxy-
progesterone acetate
(combination therapy).
- assessed effect of
prior use and
duration of prior
use.
Shumaker,
S. (47),
2003
N=4894
(includin
g
dementia
cases)
Randomized,
placebo-controlled,
double-blind,
clinical trial.
Women’s Health
Initiative Memory
Study.
65 years & older.
Dementia-free @
baseline.
HRT had no treatment
effect on Mild Cognitive
Impairment (MCI).
Did not differ according
to age, education,
smoking, diabetes,
presence/absence of past
hormone use, regular
aspirin use, 3MSE scores
@ baseline.
Screening interview,
neuro battery, and annual
clinical.
Conjugated equine
estrogen & medroxy-
progesterone acetate
(combination therapy).
-removed prevalent
MCI & dementia
cases
-151 MCI cases in
total
Carlson,
MC.  (127),
2001
N=2073 Community-
dwelling females
anges 65 & older
Age, lower education,
depression, and APOE
were all associated with
lower baseline 3MS
scores.  Lifetime HRT
use was associated with
improved global
cognition & attenuated
decline over a 3-yr
interval.  Improvements
greatest in the oldest
old.
Multivitamins, calcium
supplements, APOE-4,
age, education,
concurrent depression,
chronic disease, self-
perceived general health.
Modified MMSE, phone
interview, clinical
assessment.
Current and past HRT
meds @ baseline & 3
year later recorded.
-Dementia cases
removed from
model.
Fillenbaum
(124)
2001
N=1907 Cohort study.
Stratified random
sample.
Black and white
women
Ages 65-100
Mean age = 72.8
(64-100); Mean
education = 9.5 yrs
All cognitively
normal.
Crude OR: 0.42 (0.21-
0.86) and 0.32 (0.13-
0.81)
No significant  findings
after adjusting for
confounders.
Age, sex, education, race,
marital status, smoking,
drinking, NSAIDS, and
health behaviours,
conditions, and self-rated
health status.
Screen: SPMSQ
Evaluated @ baseline, 3
and 6 years.
Cross-checked ERT use
with records.  Recent,
past, continuous, and
intermittent use of ERT
assessed.  Dose &
duration   used.
After adjustment
effects were non-
significant.  Only a
screen used to
determine cognitive
impairment and
decline.  No clinical
exam.  Deceased
participants not used
in analysis.
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Duka (118)
2000
N=37 Randomized,
double-blind,
placebo-controlled
clinical trial.
Ages 55 to 75 yrs
(mean 65)
Memory function &
spatial abilities sig.
improved with ERT
independently of mood
or general well-being.
N/A Psychometric test battery
& verbal IQ test. POMS
ERT for 3 weeks (n=19)
or placebo (n=18)
Estrogen plasma levels
tested.
Only 1 participant
has previously used
ERT.  Very healthy
sample (eg. BMI
15% of normal
nonsmokers)
Rice (116)
2000
N=837 Cohort Study.
FU:  2 yrs.
Postmenopausal
Japanese-American
women.  65 and
older.
Modest increase in
cognition in ERT users
vs. never users.
Age, education, language,
surgical menopause, and
baseline CASI score.
CASI 455 never users
186 past users, 132
current estrogen users,
64 current HRT users
-only one test of
cognition.
-no clinical
evaluation
Shaywitz
(128)
2000
N=46 Randomized,
double-blind,
placebo-controlled,
crossover trial
Volunteer sample
No dementia;
all healthy
postmenopausal
women
Ages 33-61 (mean
50.8)
No effects of ERT on
performance of verbal &
nonverbal tasks.
Changes in brain
activation patterns.
None mentioned. Brain activation patterns
measured using imaging
during verbal &
nonverbal tasks.
No hormones for at least
3 months prior to study.
2 periods of 21-days of
ERT and placebo.
participants had
normal MRI
findings, an IQ of at
least 85, in good
health, and had a
menstrual period at
least 5 months prior
to entry. Past ERT
use unknown.
Matthews
(120)
1999
N=9651 Prospective cohort
study FU @ 2 & 6
yrs.
65 & older Mean
age = 71.7; mean
education=12.6 yrs
Current & past users of
ERT had sig. better
scores on 3MS than
never users, with better
scores for current users
most apparent in older
& less educated women.
Age, education, activity
limitations, stroke, and
depression scores.
MMMSE, digit symbol
substitution, & Trails B
test.
Past, current, and never
use of ERT.  79% of
hormone users used
ERT.
Avg. duration for
current users (14.3 yrs);
past (5.2 yrs)
Estrogen users were
younger, better
educated, more
likely to be
nonsmokers and less
obese than never
users.  No
difference b/t self-
reported health
status of groups.
Steffens
(117)
1999
N=2338 Cross-sectional
study.
Healthy women (in
a Mormon
community).
Excludes patients
with stroke or
dementia, as well as
those with 3MSE
scores under 65. 65
& older.
Mean age = 75.1
After adjustment, HRT
never use, current
depression, poorer
perceived health status,
and APOE-4 allele(s)
predicted poorer 3MSE
scores.
-Current & past ERT
3MSE scores > than
never-users.
Education, Age, health
status, APOE, depression,
& history of head injury.
Modified Mini-Mental
State Examination
(3MSE)
*clinical and neuro
assessments were used to
exclude participants with
dementia.
Never, current, & past
users.  Duration
assessed.
 -Very healthy
sample.
-Type of HRT not
asked.
Jacobs
(119)
1998
N=727 Community-based
longitudinal study.
FU: 2.5 yrs
Mean age = 74.2
Mean education =
9.4 yrs
White, African-
American &
Hispanic
ERT users scored sig.
higher on tests @
baseline than nonusers
& ERT users improved
slightly over time.
Effects of ERT indep. of
APOE status.
Age, education, ethnicity,
and APOE genotype.
Clinical and neuro test
battery.  Selective
Reminding test, WAIS-R
Similarities, Boston
Naming, and delayed
recall on Selective
Reminding test.
11% ever users.  Avg.
duration of ERT use =
4.5 yrs.  Only 2% were
current users.
Current ERT users
were sig. younger &
better educated
others.  When
removed from
analysis there was
no change.
Excluded all
dementia sufferers
Resnick
(122)
1997
N=288 Prospective cohort
study
Baltimore
Longitudinal Study
of Aging
All postmenopausal
women
ERT users had fewer
errors on the BVRT.
ERT seemed to protect
against age changes in
BVRT performance in a
subset 18.
Not specified. Benton Visual Retention
Test.
116 ERT current users
172 never users
Duration not
assessed.
Szklo (125)
1996
N=6110 Longitudinal study;
FU: 3 yrs.
ARIC study.
No dementia.
Ages 48-67; both
African-American
and white.
Only affect seen in
surgically menopausal
women.
No consistent effects.
Age, education, race,
marital status, self-
reported health status,
depression score,
smoking, drinking,
hypertension, diabetes,
plasma fibrinogen, BMI,
sport index, & time fr
menopause for PM
women.
 Delayed Word Recall,
Digit Symbol Subtest of
the Weschler Adult
Intelligence Scale-
Revised, and the Word
Fluency test of the
Multilingual Aphasia
Exam.
Current vs. never users
Duration assessed.
-No clinical
examination.
-only 3 cognitive
tests used.
-sample selection
not given.
Fielding
(115)
1992
N=18 Clinical trial
8 estrogen deficient
&10 pre-
menopausal women.
No dementia;
all healthy
women
Ages 35-64
Estrogen deficient
women improved in all
areas, with sig. increase
in emotional status.
Not known 13 brief neuro tests @
baseline.
Retested after 2 months
of treatment.
ERT administered for 2
months to estrogen
deficient group.
-Estrogen-deficient
women’s profile
differed from
estrogen normal
participants.
-no clinical
-short-term ERT
duration.
Phillips
(65)
1992
N=19 Randomized,
double-blind,
placebo-controlled,
clinical trial
Women with a
hysterectomy &
oophorectomy for
benign disease
Scores on the immediate
& delayed recall of
paired-associates
unchanged for ERT
group, but placebo
declined. Immediate
recall of paragraphs
improved in ERT group,
no change in placebo.
N/A Weschler Memory Scale,
Menopausal Index, &
Multiple Affect Adjective
Check List.
Injected ERT (n=10) &
placebo (n=10).  2
months.  Blood test for
estrogen levels.
All participants had
never used HRT
prior to trial.
28
2.10     Methodological Issues in Current Research on HRT and Cognition
There have been important methodological limitations in previous studies that
explore the relationship between HRT and cognition.  In particular, differences in
neuropsychological test batteries, research designs, duration of treatment, type of
hormone used or administered, age of participants, sample size, sample selection, proxy
and participant recall of past hormone use, differing adjustments for confounders and
effect modification in analyses are examples of discrepancies between studies.
Together these variations in the research process may have a significant impact on the
nature and strength of any association found.
Known risk factors for dementia and AD are age, educational attainment,
APOE-4 genotype, NSAID use, and past head injury (70).  These important known
dementia risk factors have not been taken into account in numerous studies examining
HRT’s effects, thereby potentially distorting findings.  NSAID use and ApoE genotype
have not been routinely controlled for in HRT analysis, with only a few studies
assessing NSAID use (101, 122, 124) and ApoE status (96, 106).  As well, the
interaction between estrogen use and APOE-4 presence has been largely overlooked
(94).  Furthermore, age at menopause and type of menopause have not been consistently
controlled for (100, 103, 104, 106, 124) (96), yet both may be a measure of length of
estrogen deprivation and therefore highly relevant.  Age and educational attainment are
the standard risk factors included in analysis (99-101, 124) (96, 102, 103, 106).  Even
while controlling for the known risk factors, results have been inconsistent.  After
adjusting for covariates several study findings became no longer significant, therefore it
is crucial that independent risk factors, confounders, and effect modifiers be taken into
account when attempting to provide evidence for causation.
When relevant factors are identified they can be controlled for in analysis,
however some other factors may be less evident.  At present, the nature of the
relationship between HRT and cognition has not been fully explored.  The failure to
measure significant factors such as differences in the health-seeking behaviour (129) or
socioeconomic status (SES) of women using or not using estrogen(130) is an important
limitation to current research.  As will be discussed in the following section, differences
between users and non-users of HRT may exist and may confound the HRT-cognition
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relationship.  If explored, these factors may help to clarify the association between HRT
and cognition, thereby explaining the myriad of findings to date. To resolve important
unanswered clinical issues, new information from basic research and from large
randomized treatment studies, cohort studies, and case-control studies is needed (19).
Each study design, whether it is cross-sectional, case-control, cohort, or a
clinical trial, has the potential for bias.  In general, case-control and cross-sectional
studies experience more biases stemming from their research design (131).  As they are
done only at one point in time, cross-sectional studies are not able to trace the
progression of a disease and lend little support for cause-and-effect relationships.
Likely because of their shorter duration and cost, case-control studies have been more
commonly used to investigate HRT’s association to cognitive decline and dementia.
Limitations of case-control studies include:  methods of case ascertainment, selection
and matching of controls, methods of obtaining ERT information (participant, proxy,
medical records), and exposure of interest (current use versus lifetime use).  Controls
may also have CIND or be in pre-clinical phases of dementia.  Due to their retrospective
nature, recall bias is a concern, especially by participants with dementia and by proxies
unaware of ERT use decades earlier.  Prospective cohort studies are less likely to be
affected by these biases.  Using a cohort design allows the investigator(s) to follow
participants over time (sometimes decades), while prospectively gathering exposure
information at regular intervals.
The multitude of findings in studies reported in the literature can be puzzling,
however differences in research designs may offer a partial explanation.  Particularly, in
observational studies where the form of HRT cannot be manipulated, different types of
HRT preparations may have disparate affects.  In one study, estrogen and progesterone
combined were found to be neuroprotective, however medroxyprogesterone acetate
(MPA), a different type of progesterone, failed to do the same, but instead decreased the
estrogen-induced neuroprotection when co-administered (132).  Fu thermore, there may
be differences in the estrogen response between women.  Age-related physiological
changes, such as body composition, nutritional status, plasma proteins, and their
estrogen-binding capacity, and metabolic changes due to liver and kidney malfunction
may affect the clinical response to estrogen (57).
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As a means of avoiding biases inherent in the observational studies, clinical
trials are often deemed the “gold standard” in epidemiology.  However, caution must be
used in interpreting the results from experimental studies.  If HRT is a useful
preventative factor for dementia, randomized, placebo-controlled, clinical trials may not
be able to detect long-term effects because of their usual shorter duration. In clinical
trials, women not using HRT therapy may have been estrogen deprived for many years,
and this produces irreversible changes in the structure and function of estrogen target
neurons in the brain and their sensitivity to estrogen (57).  It would follow that the
estrogen-responsive neuronal and vascular elements may not be responsive to estrogen
administration (57). Moreover, blinding women in double blind, placebo-controlled
trials is difficult, if not impossible, due to frequent breakthrough bleeding and other
notable side-effects of HRT therapy.
2.11    Prevention Bias
An important question that needs to be answered when studying the effects of
HRT is -- “do HRT users differ from non-users?” (129).  That is, prior to starting HRT,
do the personal characteristics, lifestyle choices, health behaviours, and health status of
users confer some protection over and above that of non-users?  This issue needs to be
considered before any beneficial effect can be attributed to HRT, especially in
observational studies where participants are not randomized to treatments.  Even in
clinical trials, researchers must control for differences that are not eliminated through
randomization.  If there are pre-existing differences between HRT-users and non-users
that are not controlled for in analysis, such as SES, education, and health-seeking
behaviour (129), then the protective effects of these characteristics may be erroneously
attributed to HRT use.
There are two significant biases that may skew study findings when examining
HRT’s relationship to dementia.  First, do HRT-users differ characteristically from
women not using HRT?  Finley, Gregg, Soloman, and Gay (2001) in a study on the
socio-demographic, psychological, and behavioural correlates of HRT use, found that
higher income, hysterectomy, younger age, regular adherence to cervical screening, and
physician encouragement of hormone therapy were all significantly associated with its
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use (133).  In addition, Barret-Connor (1991) observed that HRT-users in an upper-
middle class cohort exhibited healthier behaviours such as more reported exercise,
weight loss, stress reduction, increased dietary fiber, potassium, and calcium than non-
users (129).  Even within socioeconomically homogenous groups, differences can exist
between users and non-users with regard to health promotion and disease prevention
measures (129).  In another study, HRT-users were more likely than non-users to get a
mammogram, stool test, cholesterol check, and Pap smear (129, 134), however these
factors would likely influence coronary heart disease and cancer more than dementia
(129).  In a national population-based cohort study, HRT use was almost four times
more common among college graduates than those not graduating from high school, in
non-smokers, women with a lower body mass index, and less common among diabetics
(135).  In the Canadian National Population Heath Survey (NPHS), women using HRT
were found to have more frequent contact with their family physician, as well as to have
had a mammogram, blood pressure check, and to be currently using anti-depressants
(26).  However, doctor visits are often used to refill prescriptions and physicians often
recommend screening tests to HRT users (31).  Many of these factors associated with
HRT use could potentially confound the HRT-dementia relationship and need to be
accounted for in data analysis.
Another important bias associated with HRT use is survival bias.  Because
dementia studies rely on older, female participants, any effect of HRT on longevity is
important.  One study found that estrogen use was associated with a 46% lower age-
adjusted risk of mortality, with longer durations of use being more protective than
shorter periods of estrogen treatment (136).  Reduction in mortality from CHD and
cardiovascular disease accounted for most of this increased survival (136), a finding
that may impact the survival of women who may be potentially at risk for developing
vascular dementia and AD.  Survival bias is not easily assessed in studies that include
women of advanced age at baseline.  Still studies of HRT must consider the extent to
which these biases can explain some or all of the observed differences (129).
2.12   Other Risk Factors For Dementia
At present, epidemiological research has identified several risk factors that may
contribute to, or protect from, dementia.  Taken together these factors may help to
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determine the likelihood of an individual developing this illness.  Because the presence
of each exposure may increase or decrease one’s risk profile, it is imperative that these
factors be statistically controlled for in analyses.  Each of the following is thought to be
an independent risk factor for the development of dementia, although studies findings
for each variable may conflict.  These covariates may also act as effect modifiers in the
relationship between HRT use and susceptibility to dementia.
Age
Changes in cognitive abilities may be natural as people age, however the degree
of change, and the process responsible for this change, is quite different in dementia as
compared to normal aging.  The risk of AD increases by 23% each year after 65 (137).
A direct relationship between age and incidence of dementia has been consistently
observed, thereby making age a definite risk factor.
Education
In the CSHA, participants with 0-6 years, 7-9 years, or 10 or more years of
education had odds ratios of 4.0, 1.72 and 1.00, respectively (70). The exact relationship
of education to dementia has not yet been determined, because low education may be a
surrogate marker for other risk factors or may bias neuropsychological test results.  The
“brain reserve hypothesis” postulates that greater educational attainment increases brain
reserve by increasing synaptic density, therefore delaying AD’s clinical onset by 4 to 5
years in more educated individuals (138).  Although study results differ, low or no
education seems to put one at the greatest risk.
NSAID Use & Arthritis
In theory, an important component of the AD process is inflammation in the
brain.  Studies have revealed that anti-inflammatory agents like NSAIDs are associated
with a decreased risk of AD, especially with prolonged use (139).  In CSHA, an OR of
0.65 was found with NSAID use (137). NSAIDs, such as ibuprofen, are often used to
relieve the pain associated with arthritis – a condition common in seniors – that has also
been found to be independently associated with decreased risk of AD (137).
Past History of Head Injury
Using the combined data from 11 case-control studies, the European Action
Group on the Epidemiology and Prevention of Dementia (EURODEM) Risk Factors
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Research Group found that participants with a history of head trauma with loss of
consciousness had a Relative Risk (RR) of 1.82 (1.26-2.67) (140).  This finding was
independent of family history of dementia, education, and alcohol consumption.  As
previously described, exposure to head injury and ApoE-4 presence have been found to
interact as well.
Regular Physical Activity
A physically active lifestyle can be protective for a variety of illnesses.  In the
CSHA, participants who had regular physical activity had a decreased risk for AD
(OR=0.69; 95%CI 0.50-0.96) (137).  This association was similar for cognitive
impairment and other dementias, with a significant trend for increased protection with
greater activity being observed (141).
Wine Consumption
Wine drinking has been found to improve vascular function and decrease risk
for heart disease.  In the CSHA, weekly consumption of wine appeared protective for
AD (OR=0.49; 95%CI 0.28-0.88) (137).
Alcohol Consumption
Studies have found that not only wine drinking, but hard liquor consumption can
have a beneficial effect on the development of dementia.  In one particular study,
moderate drinkers (one - three drinks/ day) showed a reduced risk for any dementia
(hazard ratio 0.58 [95% CI 0.38-0.90]) and for vascular dementia (hazard ratio 0.29
[0.09-0.93]) than for nondrinkers – without any evidence to suggest that this
relationship depended on the type of alcoholic beverage (142).
Coffee and Tea Drinking
Tea has been found to contain disease-fighting antioxidants known as catechins
and flavonoids (143).  These antioxidants may protect from the development of
dementia.  Recent analysis by McDowell (49) revealed that coffee drinking also may be
a protective factor in the disease process.  It is possible that caffeine is responsible for
this beneficial effect, although other studies with similar findings are not known.
Smoking
In the CSHA, the mean age of onset of AD was significantly lower in smokers
(80.07) than in nonsmokers (83.85).  However, smoking was only a significant risk
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factor for AD in heavy smokers (37+ pack-years) (OR=2.79; 1.27-6.14) (70).  In terms
of its relationship to HRT, moderate smoking results in less biologically available
estradiol in women taking estrogens (20), therefore may interact with HRT’s effects.
Occupational Exposures
Exposure to glues, pesticides, and fertilizers appear to be risk factors for AD,
even after controlling for age, sex, and residence (70).  In the CSHA,when stratifying by
level of education, the risk remained elevated for the lower two levels (0-6yrs and 7-9
yrs), but not for the highest level (10 or more yrs).  The association between fertilizers
and pesticides was not significant after controlling for education.
Health Conditions
Vascular disease is known to contribute to the development of dementia. Heart
attack, stroke, Parkinson’s disease, diabetes, thyroid conditions, kidney disease, high
blood pressure and arthritis will be included in this analysis to control for the effects of
such chronic illness.  Often in dementia-related research, these variables are not
consistently accounted for.
Income
Although income has not been well-established as an independent risk factor for
dementia, some evidence suggests that it may be a significant predictor of disease
development (144).  Level of income is often combined in a measure with education
and occupation called socioeconomic status (SES).  By using income in this analysis,
factors related to economic disparities may be controlled for separately from the
influence of education. 
Statin Use
Epidemiological research suggests that statins, often used to treat hypertension,
may significantly decrease one’s risk for developing dementia (145).  Recent clinical
data indicates that statins may protect against disease by modifying the effects of
APOE-4 (146).
Vitamin Use
Vitamin use has been linked to cognitive impairments (147).  Antioxidants such
as vitamin E and C have been studied more closely, while research is being carried out
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looking at Vitamins B.  High levels of the amino acid homocysteine have been found to
increase Alzheimer's risk, which can be lowered by taking folic acid(148).
Head Injury
Research has linked head injury and dementia, although the findings have been
inconsistent.  In so much as head injuries can damage the brain, the impact of head
trauma on disease development appears to interact with APOE status.
Marital Status
Marriage may benefit cognition in both men and women, in that the prevalence
of dementia is lower in people who are currently married or who have been previously
married than in those who have never married (149).
Depression
Meta-analysis has confirmed depression is related to dementia (150).  The exact
nature of the relationship is unclear.  In a large prospective study, the hypothesis that
older women without dementia but with depressive symptoms have worse cognitive
function and greater cognitive decline than women with few or no symptoms was
tested.  It was found that cognitive change scores were directly correlated with the
number of depressive symptoms (P<.001) (151).  The results were similar after
adjusting for education, age, health status, exercise, alcohol use, functional status, and
clinic site.  Evidence suggests that history of depression may not only diminish
cognitive ability, but is also risk factor for dementia (150).
2.1  Overall Conclusion
The relationship between HRT status and cognition is not yet resolved.  With
many studies reporting positive results; some reporting no association; and the WHI-
MS reporting a negative association, it is difficult to navigate through the research and
be able to comfortably draw conclusions.  Methodological problems in HRT studies
such as study design, sample size, exposure ascertainment, and outcome assessment
limit the reliability and validity of study conclusions.  Similarly, biases such as
prevention bias confound the association between HRT and cognition making
interpretation of research results problematic.   Finally, many new risk factors for
cognitive decline and dementia are being explored and there are likely many unknown
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risks associated with disease development.  This emphasizes the importance of adequate
control for group differences and suspected covariates.
2.2  Significance of Study
Understanding the relationship between HRT and cognitive decline is highly
relevant to clinicians and women in general.  Doctors and researchers need to know if
HRT, in fact, does have a protective effect on cognition and if this effect is clinically
significant.  Identifying the cognitive advantages of HRT is an essential element of each
woman’s risk-benefit considerations.  This thesis will add to literature by using a strong
study design, controlling for relevant and unexplored risk factors, relying on incident
cases, and including a thorough clinical examination used to determine cognitive status.
It will also assess group difference between HRT users and never users, thereby
examining any impact these variations may have on the study findings.
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CHAPTER 3: METHODOLOGY
3.1  Study Design
In studying the relationship between cognitive impairments and HRT, the
CSHA-1 and -2 datasets were used for all analyses.  The CSHA is a population-based,
prospective, cohort study with a nested case-control sub-study.  It involves 18 study
sites across Canada and is coordinated by the University of Ottawa.  Of people 65 and
older, 10,263 study participants were randomly selected from 36 communities across
Canada and interviewed three times in 1991-92, in 1995-96, and again in 2001-02.  At
baseline, samples were drawn from both the community (n=9008) and institutions
(n=1255).    Participants are fluent in either English or French.  The 1991-92 data
collection provides baseline, prevalence, and risk factor data for cognitive impairments
and dementias.  The 1995-96 and 2001-2 data supply incidence, risk factor, and
outcome data. For those individuals who died between study phases, the cause of death
information was retrieved and a family member or close friend interviewed.  The most
recent data collection phase (CSHA-3) was unavailable at the time of thesis analysis
and write-up.
A variety of different sources were used to obtain information regarding the
participants’ risk factor exposures and cognitive status.  During CSHA-1, a risk factor
questionnaire was completed inquiring about both current and past exposures and
illness. If the participant scored above the cut-off (77/100) on the cognitive screening
test, this information was obtained from the participant; if at or below the cut-off, then
the closest family member or friend was asked to act as a proxy respondent.  During all
study phases, able participants met with interviewers to complete a general, in-person
interview that deals with the respondent's physical, mental, and social health. The
Modified Mini-mental State exam (3MS), a neuropsychological test sensitive to
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impaired cognitive functioning, was used as a screening tool.  Potential cases, both
those exhibiting cognitive impairment (according to 3MS scores) and age, sex, and
residence matched-controls, were asked to participate in further neuropsychological
tests, a physical examination, and blood sampling.  If the participants were unable to
attend a screening interview, they were asked to go directly for clinical assessment.
3.2 Identification of Cases
Each potential case was discussed at a consensus conference, which included the
study physician and neuropsychologist, to obtain a diagnosis.  Prior to the consensus
conference, both the study physician and neuropsychologist made a preliminary
diagnosis based on their own assessments, the screening interview, and the informant
questionnaire (physician only).  During CSHA-2 and -3, final diagnoses also included
the examination of previous neuropsychological test scores, 3MS scores, and activities
of daily living (ADLs).  Possible diagnoses include:
-no cognitive impairment (without CLoND)
-no cognitive impairment (with CLoND)
-Cognitive impairment no dementia (CIND) (without CLoND)
-Cognitive impairment no dementia (CIND) (with CLoND)
-Alzheimer’s disease (possible or probable)
-Vascular dementia (acute onset, cortical, subcortical, mixed cortical /
subcortical)
-other specific dementia (Parkinson’s, Pick’s, Huntington’s, Creuztfeldt-Jacob,
post-head injury and other)
-unclassifiable dementia
Severity of all diagnoses were rated using a three-point scale at time-one and Reisberg’s
Global Deterioration Scale(25) at time-two and -three.  As well, the presence of co-
existing disease and the contribution, or lack thereof, of such disease to the diagnosis of
CIND or dementia was specified.  For participants unable to complete screening or
neuropsychological testing, the clinical assessment was the basis for diagnosis.
At time-one (CSHA-1) general dementia diagnoses were based on the
Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., evised (DSM-III-
R)(152) and at time-two and -three diagnostic criteria followed DSM-IV(24).
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Alzheimer’s disease diagnoses followed the National Institute of Neurological and
Communicative Disorders and Stroke and Alzheimer’s disease and Related Disorders
Association (NINCDS-ADRDA)(153) criteria at time-one and DSM-IV at time-two and
-three.  The International Classification of Diseases, 10th revision (ICD-10) (154)
criteria was used to diagnose vascular dementia at time-one and the National Institute of
Neurological Disorders and Stroke criteria (NINDS-AIREN)(27) at time-two and -three.
During CSHA-2 and-3 consensus conferences, two diagnoses were made using both of
the criteria specified above.  This was done in an effort to standardize each study wave.
Data collection at each phase followed the same format – in addition to tracking deaths
at CSHA-2 (1995-96) and CSHA-3 (2001-2). For the purposes of this thesis research
work, the most current diagnostic criteria have been used to identify cases at each
phase.
Table 3.1: Screening Cut-off and Diagnostic Criteria at Each Study Phase
CSHA-1 CSHA-2 CSHA-3
Screening Interview
cut-off
Severity of
Diagnosis
Dementia Diagnosis
Alzheimer’s Disease
Vascular Dementia
78
Three Point Scale
DSM-III-R
NINCDS-ADRDA
ICD-10
78
Reisberg’s Global
Deterioration
DSM-IV
DSM-IV
NINDS-AIREN
90
Reisberg’s Global
Deterioration
DSM-IV
DSM-IV
NINDS-AIREN
3.3 Study Sample
3.3.1 Inclusion and Exclusion Criteria
Initially, 6,255 women participated in the first phase of the CSHA.  However, in
order to be included in this particular analyses, female participants must have had
available HRT information at time-2 and been dementia free at baseline. Since HRT
information was only obtained during CSHA-2, this required that women who had died
between CSHA-1 and -2 be excluded from the sample.  After accounting for those
participants with missing HRT information, lost to follow-up, deceased, or with
dementia at CSHA-1, 3,384 women remained for analysis.
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3.3.2 Sample Size and Statistical Power
The program Epi Info 2002 was used to calculate statistical power based on the
study’s sample size.  Power calculations were completed for each outcome, since the
incidence of each outcome differed.  For AD, at a 4% incidence in the unexposed group
(HRT never users), an estimate of power for this sample size with a maximum
detectable effect of OR=0.50 is 80%.  For CIND, at 11% incidence in the unexposed
group, power estimates of 80% for an OR of 0.65 was expected. [See Table 3.2].
Finally for VaD, which has a 1% incidence in the unexposed group, 80% power was
estimated for an effect no larger than OR=0.10.  Although the overall sample is quite
large, the sample sizes for each outcome are smaller as they include only one outcome
(eg. CIND, AD, or VaD), and then the cognitively normal group.  Consequently, the
statistical power is quite low for VaD, and lower than expected for CIND and AD.
Nonetheless, for the outcomes CIND and AD, the power of this study allows for the
detection of moderate to large effects, which are more likely to be clinically significant
at a 95% confidence interval.
Table 3.2: Power Estimate Calculations According to Incidence and Effect Size
AD VaD CIND
Maximum
Detectable Effect
(OR)
0.50 0.10 0.65
Incidence (%) 4 1 11
Confidence Interval
(%)
95 90 95
Power Estimate (%)80 80 80
3.4 Variable Coding
3.4.1 Variable Selection
The decision of which specific variables to include in analysis was based on the
literature, where evidence is mounting for a range of potentially relevant exposures.  In
this way, this study not only tests the importance of HRT as a predictor of cognitive
decline and disease, but also it is to some extent a gender-based analysis examining the
impact of many other indeterminate risks on women’s cognition in general.
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In addition to the risks identified in the literature, other general indicators of
lifestyle and health status were also examined at the bivariate level, and if significant,
were included in the multivariable analysis.   These additional factors were included to
assess and control for interaction and confounding.  Although some potentially relevant
information was not obtained during the course of the CSHA; and therefore, variables
such as hysterectomy status, age at first and last menstrual period, and use of natural
sources of phytoestrogens were not available for analysis.  In addition, self-rated health
status and Body Mass Index were only asked for a portion of the female sample and
were also omitted from consideration as covariates.  All of these factors could
potentially impact the relationship between HRT and cognitive decline.
3.4.2 Risk Factor Information
The CSHA is a comprehensive study that aims to identify many of the
potentially important risk factors for cognitive decline, and conversely, healthy aging.
Data was collected on a variety of different lifestyle, environmental, social, familial risk
factors along with data on different health conditions and diseases.  These include both
risk factors present at the time of interview and even some dating back to the
participant’s youth.
Risk factor information was obtained from several sources (i.e. screening and
informant interview, clinical assessment, and risk factor questionnaire) throughout the
CSHA.  Notably, there was a good deal of missing variable information in the CSHA.
Therefore it became necessary to combine data sources in order to create the necessary
profile of risk for each individual.  This is largely due to the study’s nested case-control
component, which was created specifically to examine risk and protective factors and
the contribution of such factors to cognitive decline, impairment, and dementia
development.  The study was structured so that many of the risk factor variables were
located in the informant and clinical interviews; hence, data were more complete for
those who received a clinical examination. While comprehensive, this approach runs the
risk of gathering sometimes conflicting information.  The lack of consistency poses a
dilemma for researchers trying to get a reliable history of risk factor exposure.
However, the above method of combining variables from different sources will allow
for more complete risk profile information for the entire sample.
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At baseline, both participants and proxies were given risk factor questionnaires
to fill out following a screening interview.  If the participant screened above the cut-off,
the participant was asked to complete the questionnaire.  If the participant screened
below the cut-off, a proxy (the person most familiar with the participant) was given a
questionnaire to complete – they may or may not have asked the participant to give
them help answering these questions.  These forms were mailed back to the study
centres.
In order to compile the necessary risk factor information for this particular
research, coding guidelines were necessary.  Such coding decisions were limited by the
location of each variable and the amount of missing information.  For baseline risk
factor data, the participants’ responses to the risk factor questionnaire were used when
available.  If the participant scored under the cut-off at screening, the proxy risk factor
information was taken.  Although an agreement study has been carried out by the
CSHA Working Group, kappa values for the female sample were calculated in case they
differed from the larger sample (See Table 3.3).
Table 3.3:  Agreement Between Proxy and Participant Risk Factor
Variables
Variable 1 Variable 2 Kappa
Value
P-value
Participant RF Down SyndromeProxy RF Down Syndrome 1.00 .000
Participant RF Mental
Retardation
Proxy RF Mental Retardation1.00 .000
Participant RF Diabetes Proxy RF Diabetes .880 .000
Participant RF Smoker Proxy RF Smoker .861 .000
Participant RF Stroke Proxy RF Stroke .789 .000
Participant RF Thyroid Proxy RF Thyroid .739 .000
Participant RF Parkinson’s Proxy RF Parkinson’s .665 .000
Participant RF Heart Proxy RF Heart .664 .000
Participant RF Arthritis Proxy RF Arthritis .658 .000
Participant RF High BP Proxy RF High BP .636 .000
Participant RF Head Injury Proxy RF Head Injury .610 .000
Participant RF Tea Proxy RF Tea .585 .000
Participant RF Spirits Proxy RF Spirits .584 .000
Participant RF Coffee Proxy RF Coffee .579 .000
Participant RF Psychiatric
Illness
Proxy RF Psychiatric Illness .565 .000
Participant RF Alzheimer’s Proxy RF Alzheimer’s disease.559 .000
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Participant RF Regular ExerciseProxy RF Regular Exercise .539 .000
Participant RF Depression Proxy RF Depression .524 .000
Participant RF Epilepsy Proxy RF Epilepsy .492 .000
Participant RF Influenza ShotProxy RF Influenza Shot .462 .000
Participant RF Kidney Proxy RF Kidney .453 .000
Participant RF Painkiller regular
use
Proxy RF Painkiller regular use.451 .000
Participant RF Wine Proxy RF Wine .444 .000
Participant RF Senile DementiaProxy RF Senile Dementia .384 .000
Participant RF Occupational
exp to Pesticides
Proxy Occupational Exp to
Pesticides
.366 .000
Participant RF Tetanus ShotProxy RF Tetanus Shot .364 .000
Participant RF Polio Shot Proxy RF Polio Shot .337 .000
Participant RF Occupational
exp to Solvents
Proxy Occupational Exp to
Solvents
.279 .000
Participant RF Diptheria ShotProxy RF Diptheria Shot .272 .000
Participant RF Occupational
exp to Glues
Proxy Occupational Exp to
Glues
.198 .007
Interpretation of the kappa values is as follows: poor (<0.20), fair (0.21 – 0.40),
moderate (0.41 – 0.60), good (0.61 – 0.80), and very good (0.81 – 1.00) (131).   All
values were significant at the p<.05 level.  The majority of kappa values demonstrate
moderate or higher agreement.  It is worth acknowledging that kappa is an imperfect
measure since it depends on proportion of participants in each category.  Nonetheless, it
is commonly used and seems to be the most appropriate approach to judging agreement
(131).
After combining the participant and proxy information, there still were missing
risk factor data.  This was a result of participants not returning their questionnaires.  In
this case, variables from the screening interview, the informant interview, and the
clinical assessment where available to fill in only the missing risk factor information.
Refer to Appendix B for a detailed breakdown of percentage of data taken from each
source to create individual variables.  Notably, my initial concerns with using the
clinical information, due to its possible superior quality, subsided once I realized the
questions I used were predominantly based on self-report from the participant.  For
some variables, missing information at the previous phase was filled in when the
participant responded ‘no’ at the following phase.  For example, if the participant
answered ‘no’ to ‘have you ever had a heart attack’ at time-2 and this information was
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missing at time-1 – then I went back and changed time-1 to ‘no’.  This could not be
done for ‘yes’ responses, since it was not known when the event occurred.
Kappa values were calculated examining the level of agreement between
screening, informant, and clinical data and the newly created risk factor variables.
Again, the risk factor variables, which included a combination of self- and proxy-
reported data, were used as the core time-1 predictors.  However, the degree of missing
information made it necessary to use data from other sources.  At time-1, screening
information was used first to fill in missing values, then clinical data and finally
information from the informant.  This was done in attempt to use data from the
participant first and then from proxy respondents if needed. Although if the participant
screened positive for cognitive impairments, the proxy information was favoured. Since
at time-2 many of the participants had developed dementia, the informant and clinical
variables were used for these individuals.
Table 3.4:  Agreement Between Variable Sources (CSHA-1 and –2)
CSHA-1
RF S&P Diabetes Informant1 Diabetes .922 .000
RF S&P Diabetes Clinical1 Diabetes .908 .000
RF S&P Diabetes Screening1 Diabetes .901 .000
RF S&P Stroke Informant1 Stroke .810 .000
RF S&P High BP Screening1 High BP .794 .000
RF S&P Parkinson’s Informant1 Parkinson’s .775 .000
RF S&P Stroke Clinical1 Stroke .750 .000
RF S&P Parkinson’s Screening1 Parkinson’s .738 .000
RF S&P High BP Informant1 High BP .698 .000
RF S&P Stroke Screen1 Stroke .613 .000
RF S&P High BP Clinical1 High BP .605 .000
RF S&P Heart Informant1 Heart .561 .000
RF S&P Heart Clinical1 Heart .311 .000
RF S&P Heart Screen1 Heart .298 .000
RF S&P Parkinson’s Clinical1 Parkinson’s (missing)------ ------
CSHA-2
Screen2 Diabetes Clinical 2 Diabetes .893 .000
Screen2 Diabetes Informant 2 Diabetes .882 .000
Screen2 HRT Use Nurse/Inform2 HRT Use .802 .000
Screen2 Stroke Informant 2 Stroke .587 .000
Screen2 Stroke Clinical 2 Stroke .574 .000
Screen2 Parkinson’sInformant 2 Parkinson’s .571 .000
Screen2 High BP Clinical 2 High BP .545 .000
45
Screen2 High BP Informant 2 High BP .537 .000
Screen2 Heart Nurse 2 Heart .226 .000
Screen2 Heart Clinical 2 Heart .217 .000
Screen2 Parkinson’sClinical 2 Parkinson’s .193 .344
3.4.2.1  HRT Variables
HRT status was assessed during CSHA-2.  Female participants were asked,
retrospectively, if they had ever used hormones since their menopause or “change in
life”.  This question was used both in the screening interview and in the informant
interview.  During the latter, HRT status was obtained from either the participant or
from a proxy respondent.  Although CSHA-2 relied on self and proxy reported use of
HRT, past recall of HRT use by participants has been shown to be fairly accurate (155).
The informant interview was administered by the study nurses, and therefore was
judged to be the most reliable source of information.  The nurses’ HRT data was used
first, but when not available, then the screening interview data was used.  There was
high agreement between the two data sources (kappa = 0.802).  If both the screening
interview and the nurse’s information report ‘yes’ HRT has been used, but either had
missing or unknown duration or type of hormone; then the available information for
either source on duration and type was used.
Information on women’s age when the first HRT treatment began, type of
hormones used (estrogen and/or estrogen-progesterone combinations), and duration of
treatment was retrieved from many participants using HRT. There was a considerable
amount of missing data for the type of HRT preparation used and hence this variable
will not be used in analysis.  This is likely because past users may not have been aware
of the whether they have used combination or estrogen-only therapy in previous years,
since current users were asked to present the pill packaging.  Durations were recorded
for each HRT type.  For instance, a woman may have changed her HRT prescription
several times over the years, and therefore the length of use for each preparation was
noted.  For the purposes of this research, durations of all HRT preparations used were
collapsed into a combined ‘length of use’ variable.  Nonetheless, variables will be
included in the models to assess the impact of the timing and duration.
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3.4.3 Treating Time-dependent Variables as Time-Independent
The partial likelihood function of Cox Extended model allows for consideration
of the effect of time-dependent explanatory variables (156).  An explanatory variable is
time-dependent if its value for any given individual can change over time.  Certain
variables in this study fell into this category since with age, the likelihood of health
problems increases (eg. emergence of high blood pressure, stroke, heart attack).  Even
though these variables change over time, it seems appropriate to treat them as time-
independent in the analysis if the impact of the change on survival risk depends mainly
on the value at only one measurement (156).  This meant that Cox Proportional Hazards
model was used in place of the Cox Extended model. Therefore, in this study, if two
variables were present (measured both at CSHA-1 and-2) then the most recent measure
was used in analysis.  Since these conditions are generally not reversible, this approach
is reasonable.  It is also worth noting that some risk factors are more stable; and while
some exposures may change, they are likely to have exacted their damage by the time
one has entered their senior years.  For instance, if an individual quits smoking at age
70, the effects of lifelong smoking habits have likely already done the damage.
3.4.4 Cognitive Status
In an effort to avoid prevalence-incidence bias, only incident cases were
included in analysis, thereby excluding dementia and CIND cases present at baseline.
For the purposes of this thesis, outcomes include: no cognitive impairment (NCI),
CIND, CLoND, VaD, and AD.  Participants were classified as NCI when they either
scored above the 3MS cut-off at screening or were diagnosed as cognitively normal
following neuropsychological and clinical examination. In this dataset, there were a
small number of women who screened positive for cognitive impairment (below the
3MS cut-off score) but who did not go onto clinical for a variety of reasons.  If the
participant participated in the subsequent study phase, the 3MS scores and follow-up
diagnoses were used to impute a diagnosis for the previous phase (n=37).
The classification of CIND was used in two ways – all cases together were
termed ‘all-cause CIND’ and a ‘reduced CIND’ group was created using only the
causes believed to be most closely related to the dementia pathology.  This is because
CIND is a heterogeneous group, and therefore some causes will likely have a more
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similar pathology to Alzheimer disease and vascular dementia.  Causes such as
Parkinson’s disease, age-associated memory impairment, depression, cerebral vascular
and general vascular disease will be included in the reduced-cause group; while CIND
due to delirium, chronic alcohol abuse, chronic drug intoxication, psychiatric illness
(not depression), mental retardation, multiple sclerosis, socio-cultural and blind/deaf
causes will be excluded from the secondary analysis.  Although several causes may
have been specified for each CIND diagnosis at clinical assessment, the primary cause
was used for the above classification.
When a participant was diagnosed as either cognitively normal or as having
CIND, a secondary distinction was made indicating whether or not there was a
significant cognitive decline from the previous phase.  Those who experienced this
decline were given a CLoND diagnosis.  At time-2, there were four CLoND groupings
– (1) Cognitively Normal with CLoND, (2) Cognitively Normal without CLoND, (3)
CIND with CLOND, and (4) CIND without CLoND.  Because most participants with
CLoND were also classified as being CIND sufferers (227/248), there were only a very
small number of cognitively normal participants with CLoND (21/248).  Intuitively, it
would seem that the cognitively normal CLoND cases would differ from the CIND
CLoND cases.  Since sample size was limited for the normal CLoND group, only the
CLoND participants from the CIND group were considered for analysis and were
compared to the cognitively normal participants without CLoND.  Using the same logic
as for the reduced-CIND group, the CLoND sample was limited to cases drawn from
the reduced-CIND group.
3.4.5 Time-to-Event
Survival analysis was used to identify risk factors associated with AD and VaD,
specifically in examining HRT’s effect.  Here the outcome was time-to-event (in
months), with the event being dementia onset.  Once the participant was determined to
have dementia, follow-up ended for the analysis purpose.
There are several variables in the CSHA that could be used to calculate time-to-
onset.  In using six variables altogether from the informant and clinical interviews, the
time-to-event variable was based on an algorithm proposed and explored in detail by
Rouah and Wolfson (157).    Rather than taking the mean of all dates provided, a
48
hierarchical structure was created.  This meant that whenever possible, certain variables
took precedence over others since they are viewed to be more indicative of the true
time-of-onset.
When the time-to-event information was missing for all variables, then a date
was imputed.  Since a month and year were both required, there was some dates missing
a month value; in this case, the seventh month was imputed.  A small number of
participants were missing the entire date, and when this occurred, the halfway point
between study phases was used as time of disease onset.   Finally, there were
participants who had a negative follow-up time, which meant that time-of-dementia
onset was before CSHA-1 and making them ineligible (i.e. prevalent cases).  For these
participants, it was assumed that the baseline diagnosis was accurate.  As a result, if a
later, positive date was specified in one of the time-to-onset variables then it was used;
if not, then a follow-up time of one month was imputed.
3.5 Data Analysis
3.5.1 Descriptive Analysis
Descriptive analysis was conducted detailing general information about the
study sample.  This included HRT use, duration of use, type of HRT used, age at first
use, prevalence and incidence of cognitive outcomes at each study phase, and
description of the samples demographic characteristics. The initial analysis involved a
description of the distribution among CIND, CLoND, Alzheimer's disease, vascular
dementia and no disease (normal) among HRT users versus never users.
3.5.2 Bivariate
All risk factors were examined for statistically significant associations.
Differences between HRT users and non-users were described, and the implications for
this study in terms of prevention bias discussed.  Pearson’s chi-square test was used to
assess significant differences according to HRT status and cognitive status (NCI versus
CIND and CLoND).  For AD and VaD, potential risk factors were entered one-by-one
into the Cox Proportional Hazards survival model to test for significant relationships.
Based on this initial analysis of the data, any variable whose bivariate test had a p-value
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of equal to or less than 0.25 was considered a candidate for the multivariate model
along with all other variables of known biological, clinical, and/or scientific importance.
3.5.3 Multivariate
Analysis was performed using the CSHA-1 and –2 datasets (Refer to Table 3.5).
Two different analyses were conducted.  First, the Cox Proportional Hazards (PH)
Model, a popular survival analysis technique, was conducted using SPSS version10 for
MacIntosh (SPSS Inc., Chicago IL)(158).  The Cox PH Model can handle missing or
censored data while considering the impact of predictor variables on survival times.
Rather than simply looking at the presence or absence of an outcome, such as with
logistic regression, the Cox Model uses more information by taking into account the
time to each event.   Participants who are lost to follow-up or who die before the study
was completed are classified as censored.  Largely due to its robustness as a
nonparametric model, this technique is widely used (156).  The Cox model was used to
assess the risks associated with Alzheimer’s disease, and vascular dementia.  For this
type of analysis, a date of onset of disease must be available.   Because a date for CIND
and CLoND onset was not available, in so much as it would be hard to distinguish their
onset from dementia onset, logistic regression was conducted using SPSS.
Multivariate models were used to examine the combined effect of the various
factors of interest adjusting for potential confounders and effect modifiers.  This type of
analysis will allow for calculation of estimates of the adjusted relative risk, which
identifies the risk attributable to the risk factor of interest when risk from the other
factor(s) is statistically removed (159).
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Table 3.5: Approach to Multivariate Analyses
Outcome Type of
Variable
Statistical
Method
Statistical
Algorithm
Software
CIND DichotomousLogistic
Regression
Maximum
Likelihood
SPSS Binary Logistic
Regression
CLoND DichotomousLogistic
Regression
Maximum
Likelihood
SPSS Binary Logistic
Regression
Time-to-
occurrence of
AD or
VaD
Survival
Type Data
Cox Proportional
Hazards Model
Partial LikelihoodSPSS Survival
Analysis
Age of AD or
VaD onset
Continuous Linear Regression
Analysis
Maximum
Likelihood
SPSS Linear
Regression
3.6 Ethics
In terms of the larger study, the Coordinating centre in Ottawa obtained ethics
approval at each study phase, as did all individual centres.   Formal ethics approval for
this thesis work was received from the Behavioural Science Research Ethics Board at
the University of Saskatchewan (See Appendix A).  These data were analyzed in
anonymous form, and therefore there are no risks of individual participants being
identified.
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CHAPTER 4:  RESULTS
4.1 Descriptive Analysis
4.1.1 Characteristics of Study Sample: Baseline and First Follow-up Phase
Characteristics of study sample are shown in Table 4.1.  At baseline, most
participants were 84 years of age and younger, with 49% in the 65-74 age group, 41%
in the 75-84 age group, and 10% in the 85 years and older age group.  The mean age for
women participating was 74.7 years.  In terms of education, the average time spent in
school was 10.4 years.  Sixty percent of this female cohort attended school until grade
10 or higher.   Women were sampled equally across the country from the Atlantic
(19%), Quebec (21%), Ontario (19%), Prairies (22%), and British Columbia (19%)
regions.  Most women were currently married (38%) or widowed (49%), while the
remainder were either divorced/separated (4%) or had never married (9%).  Most of the
sample resided in urban centres (89%) and in the community (97%).
During the first follow-up phase (CSHA-2), the same participants were visited
and interviewed once again.  As expected, most women now belonged to the 75-84 year
age group (50%), with fairly equal proportions falling into the 65-74 (27%) and 85 and
over (23%) age groups.  There was little mobility in terms of the region of residence,
however a greater proportion of women were living in institutions (9%) as compared to
five years previous (3%).  In terms of marital status, 59% of participants were now
widowed, leaving fewer married women (28%).  As the importance of socioeconomic
status was increasingly being recognized, questions regarding current income were
included during CSHA-2.  Unfortunately, information was not collected on past income
or overall adequacy throughout the life course.  Nonetheless, the majority of women
reported an income less than $19,999 (46%), $20,000-34,999 (21%), $35,000-49,999
(9%), with just 6% of participants reporting income levels at $50,000 or more.
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Table 4.1:  Sample Characteristics
CSHA-1     n (%) CSHA-2      n (%)
65-74 years
75-84 years
85 years & over
1655 (49%)
1396 (41%)
333 (10%)
Mean=74.7 yrs
SD=6.56
923   (27%)
1687 (50%)
774   (23%)
Mean=79.7
SD=6.57
Less than 6 years
7- 9 years
10-12 years
13 years and over
409   (12%)
909   (27%)
1231 (36%)
822   (24%)
Mean=10.4
SD=3.48
----------
Less than $19,999
$20,000 – 34,999
$35,000 – 49,999
$50,000 and over
----------- 1550 (46%)
 718   (21%)
 295   (9%)
 203   (6%)
Urban
Rural
3023 (89%)
  353 (10%)
-----------
Community
Institution
3275 (97%)
  109 (3%)
3083 (91%)
  301 (9%)
Atlantic
Quebec
Ontario
Prairies
British Columbia
649 (19%)
711 (21%)
651 (19%)
744 (22%)
629 (19%)
648 (19%)
708 (21%)
657 (19%)
739 (22%)
632 (19%)
Never Married
Married
Common Law
Divorced/ Separated
Widowed
305   (9%)
1281 (38%)
11     (0%)
142   (4%)
1642 (49%)
307   (9%)
954  (28%)
11     (0%)
124   (4%)
1983 (59%)
4.1.2 Cognitive Status
Tables 4.2, 4.3 and 4.4 provide data on cognitive status for each study phase,
causes of CIND by study phase, and CSHA-2 CLoND cases.  During our first visit and
assessment, 93% of our study participants were classified as having no cognitive
impairment (NCI) and 7% as having CIND.  In an effort to avoid including women with
pre-clinical cognitive deficits during time-1, the baseline CIND cases were not used in
the multivariate models, but simply included to report baseline cognitive status.  Refer
to section 3.3 for exclusion and inclusion criteria. The follow-up clinical assessments
(CSHA-2) found that 80% of participants had NCI, 12% had CIND, 5% developed
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possible or probable AD, 1% had VaD, and an additional 1% fell into the other
dementias category.  Since risk for cognitive decline is known to rise with age, the
increase in the proportion of impairment and disease was anticipated.  At baseline, the
most commonly identified causes of CIND were age-associated memory impairment
(20%), depression (10%), cerebral vascular (7%), and general vascular (6%), although
there were a number of CIND cases where the cause was unknown or not specified
(45%).  A very similar distribution occurred for CIND cases at time-2.  CLoND was
assessed during CSHA-2 for those who attended clinical and received a NCI or CIND
diagnosis.  Here participants with CLoND were drawn only from the reduced-cause
CIND sample (refer to Methods Section 3.4.4 for more detail).
Table 4.2:  Cognitive Status By Study Phase
CSHA-1       n (%) CSHA-2       n (%)
NCI
All-Cause CIND
Possible/Probable AD
Vascular Dementia
Other Dementias
3153 (93)
231 (7)
2698 (80)
390 (12)
161 (5)
41 (1)
25 (1)
Table 4.3:  CIND Causes By Study Phase
CSHA-1
(n=231)       n (%)
CSHA-2
(n=390)         n (%)
Age-Associated Memory
Impairment
47 (20) 69  (18)
Depression 24 (10) 38  (10)
Cerebral Vascular 16  (7) 60  (15)
General Vascular 14  (6) 19   (5)
Parkinson’s Disease   1  (0)  8    (2)
Social Isolation -- 10   (3)
Other/ Unknown 105 (45) 113 (29)
Delerium   1  (0)  4    (1)
Chronic Alcohol Abuse
and Drug Intoxication
  9  (4)  6    (2)
Psychiatric Illness   8  (3) 16   (4)
Mental Retardation   1  (0) 1     (0)
Multiple Sclerosis   1  (0) 1     (0)
Socio-cultural   3  (1) 16   (4)
Blind/Deaf   1  (0) 27   (7)
Epilepsy -- 2     (1)
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Table 4.4:  CSHA-2 CLoND  (n=541)
HRT Ever
n
HRT Never
n
NCI-CLoND 5 19
All-Cause CIND-CLoND 57 225
Reduced-Cause CIND-CLoND 50 185
4.1.3   HRT Utilization
In this study sample, 27% of women had used or were currently using HRT,
leaving 73% who had never used HRT (refer to table 4.5).  This is fairly consistent with
the earlier mentioned estimates from the 1994/95 NPHS where 22% of Canadian
women 45-64 reported ever using HRT following menopause (31).  Of the HRT users,
most used estrogen-only preparations (70%) and began using hormones by age 50
(57%).  The duration of use varied widely with a number of women using HRT for 12
months or less (25%), and conversely with many using for 10 years or longer (25%).
Table 4.5:  HRT Descriptives
HRT Use
                 Ever
                 Never
 n (%)
  909 (27)
2475 (73)
HRT Ever Users   (n=909)
Duration
                 1 year or less
                 13 months – 5 years
                  61 months to 10 years
                  Over 10 years
                  Missing
228 (25)
183 (20)
141 (16)
225 (25)
132 (15)
Type of HRT Preparation
                 Estrogen Only
                 Combination
                 Progestogens Only
                 Unspecified (“hormones”)
                 Missing
633 (70)
    3 (0)
  17 (2)
212 (23)
  44 (5)
Age at First HRT Use
                 40 years and under
                 41-50 years
                 51-60 years
                 61 years and over
                 Missing
125 (14)
393 (43)
214 (24)
101 (11)
  76 (8)
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Looking at incident cognitive outcomes according to HRT status (table 4.7), a greater
proportion of HRT users had the lesser diagnosis NCI (90%) as compared to HRT never
users (83%).  However, HRT never users had more CIND (11% versus 7%), AD (4%
versus 2%), and VaD (1% versus .3%) as compared to ever users.
Table 4.6:  CSHA-2 Cognitive Status According to HRT Use (Prevalent and
Incident Cases)
HRT
Users
n (%)
HRT
Never Users
n (%)
NCI 791 (88) 1907 (79)
CIND 72 (8) 318 (13)
AD 27 (3) 134 (6)
VaD 3 (.3) 38 (2)
Other Dementias 8 (1) 26 (1)
Table 4.7:  CSHA-2 Cognitive Status According to HRT Use (Incident Cases Only)
HRT
Users
n (%)
HRT
Never Users
n (%)
NCI 785 (90) 1885 (83)
CIND 59 (7) 245 (11)
AD 19 (2) 93 (4)
VaD 3 (.3) 26 (1)
Other Dementias 4 (1) 20 (1)
4.2 Bivariate Analysis
4.2.1 Covariate Identification For Multivariate Analysis
Bivariate analysis was used to determine which variables to include in the
multivariate models.  According to the standard approach, any variable with a p-value
equal to or less than 0.25 will be included in multivariable analysis.  As discussed
previously, Pearson’s chi-square test was used for the variable CIND and the Cox
model was used to test variables for significance for AD and VaD.  All outcome
variables were dichotomous – presence or absence of impairment/ disease. Table 4.8
lists all variables significant at the p<.25 level for the outcomes all-cause CIND,
reduced CIND, reduced-CLoND, AD, and VaD.  For a more detailed breakdown of this
analysis see Appendix C.
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Table 4.8: Covariates significant at the p<.25 level:  results of bivariate analyses
for CSHA-2
Potential Covariates All-cause
CIND
Reduced
CIND
Reduced
CLoND
AD VaD
Demographics
Age Ö Ö Ö Ö Ö
Education Ö Ö Ö Ö Ö
Income Ö Ö Ö Ö Ö
Residential Status T-1 and -2 Ö Ö Ö Ö Ö
Marital Status T-1 and –2 Ö Ö Ö Ö Ö
Rural-Urban Ö Ö
Region T-1 and-2 Ö Ö Ö Ö
Health Conditions and Illness
Arthritis Ö
Thyroid Condition Ö Ö Ö Ö
Heart Attack Ö
Kidney Disease Ö Ö Ö Ö
Epilepsy Ö Ö Ö Ö
Diabetes T-1 and -2 Ö
Stroke T-1 and -2 Ö Ö Ö Ö Ö
High Blood Pressure T-1 and -2 T2 only T2 only Ö Ö Ö
Parkinson’s Disease T-1 and-2 Ö Ö Ö T2 only T2 only
Depression T-1 and -2 Ö Ö Ö Ö Ö
Psychiatric Illness Ö Ö Ö Ö
Medication Use
HRT Use Ö Ö Ö Ö Ö
HRT Duration Ö Ö N/A
Age at First HRT Use N/A
Regular Painkiller Use Ö Ö
Current Use of Statins Ö Ö Ö N/A
Lifestyle Factors
Regular Coffee Ö Ö
Regular Tea Ö
Regular Wine Ö Ö Ö Ö
Regular Spirits Ö Ö Ö Ö Ö
Regular Shellfish Consumption Ö Ö Ö Ö
Regular Exercise Ö Ö Ö Ö Ö
Smoking Status Ö Ö Ö Ö Ö
Vitamin B
Vitamin C Ö Ö Ö Ö
Vitamin E Ö Ö Ö Ö N/A
Multi-vitamin Ö Ö Ö Ö
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History of Head Injury Ö
Familial and Genetic Factors
APOE Status Ö Ö
Family History of AD Ö Ö Ö Ö
Family History of Senile Dementia Ö Ö
Family History of Mental RetardationÖ N/A
Family History of Down Syndrome Ö Ö N/A
Other Exposures
Influenza Shot(s)
Polio Shot(s) Ö Ö Ö Ö Ö
Diptheria Shot(s) Ö Ö Ö Ö Ö
Tetanus Shot(s) Ö Ö Ö Ö Ö
Occupational Exposure to Solvents Ö
Occupational Exposure to Pesticides Ö Ö
Occupational Exposure to Glues
T2 only – Significant only at CSHA-2; NA- not enough cases to test; Ö  - significant at the p< 0.25 level
In terms of demographic variables, age, marital status, education, income, and
residential status were consistently significant for all outcomes.  Both AD and VaD
differed significantly by rural-urban status, while region was significant for all
outcomes except VaD.
When testing a variety of different health conditions and illnesses for significant
contributions to each outcome, there was substantial variability.  However, stroke, high
blood pressure, Parkinson’s disease, and depression were significant for all outcomes.
Psychiatric illness was significant for both CIND outcomes, CLoND, and VaD, but not
for AD.
HRT was significantly associated with all outcomes.  Duration of HRT use was
found to be significant only for the reduced-CIND and CLoND groups, although neither
duration nor age at first use had sufficient VaD cases to test for an association.
Many of the lifestyle factors were found to be significantly associated with the
outcome measures.  At the p<.25 level, regular consumption of coffee, tea, wine, spirit,
and shellfish, exercise, smoking, and current vitamin C, E, and multi-vitamin intake
were all related to AD.  Only regular spirit and shellfish consumption, exercise, and
smoking status were found to be significant for VaD.  There was much overlap between
the CIND groups and AD.  Similarly, variables significant for reduced-CIND showed
the same for reduced-CLoND.  One unexpected finding was for history of head injury,
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which only revealed significance for VaD.  APOE status, a definite risk factor for
dementia, was found to differ (p<.25) according to AD and VaD outcomes; however,
this genetic risk factor was not significant for the CIND  or CLoND groups.
Immunizations, including polio, diptheria, and tetanus, were associated with all
outcomes.  The variables vitamin B and occupational exposure to glues were the only
two factors that did not show to be significant for any of the outcomes.
Notably, bivariate analysis was only used for selecting statistically significant
variables to be included in model building and multivariate analysis.  These findings did
not control for the effects of age and other relevant factors, hence they were simply
correlated with the outcomes and do not indicate causal relationships.
4.2.2 Comparison Between HRT Users and Never Users
In an effort to identify significant differences between HRT users and never users,
Pearson’s Chi-square test was used to examine a variety of factors.  These factors may
help to identify important differences between these two groups; variations that may
contribute to cognitive health outcomes.  Using bivariate analysis, the following factors
differed significantly (p<.25) according to HRT use:  heart attack, other heart condition,
diabetes-2, thyroid disease, arthritis, kidney disease, epilepsy, depression at time-1,
psychiatric illness; age, marital status, education, income, region, residential status,
rural/urban status; smoking status, regular consumption of wine, spirits, coffee, and
shellfish, exercise, current vitamin E, C, and multi-vitamin intake; painkiller and statin
use; and immunizations for influenza, polio, diptheria, and tetanus.
Looking in more detail at the distribution of HRT users and never users according
to each risk factor, some trends were evident (p<.05).  In terms of physical health, a
greater proportion of HRT users had thyroid conditions, arthritis, and kidney disease
than never users.  HRT users also belonged more often to the younger age groups and
were more likely to be currently married than the never user group.  A greater
proportion of HRT users were living in Quebec and British Columbia, while more never
users resided in the Atlantic region. HRT use differed according to residential status,
with a greater proportion of never users living in institutions as compared to users.  In
general, the bivariate analysis found that lifestyle factors differed according to HRT use.
HRT users were more likely to smoke regularly and to drink spirits, wine, and coffee
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than never users.  Moreover, a greater number of HRT users engage in regular exercise,
take painkillers, and use vitamins E, C, and multi-vitamins.  Finally, more HRT users
received immunizations (influenza, diptheria, polio, and tetanus) than never users.
4.3 Multivariate Analysis
4.3.1 Model Building Strategy
Hosmer and Lemeshow’s (160) model building strategy was employed for the
analysis of all outcomes.  In an attempt to fit a best model, backward stepwise
elimination was carried out manually using the ‘enter’ method. First, all relevant
independent variables were entered into the model.  These included factors that were
significant (p<.25) in bivariate analysis and other biologically or clinically important
factors.  When the sample size permitted, I erred on the side of being over-inclusive
since this investigation was somewhat explorative in nature.  The vascular dementia
model was the exception here since the small number of cases required that covariates
be kept to the minimum. After fitting a model with all significant covariates, variables
that were removed earlier from the model were re-entered to ensure they did not add to
the model.  The result was a main effects model where significant (p<.05) and clinically
important predictors remained.  Next, all possible interaction terms were entered into
the model one-at-a-time.  The interaction terms were retained if the Wald statistic was
significant at the p<.05 level.  Confounding was assessed by comparing the ß values of
important predictors in the reduced main effects model to those in a model including the
potential confounder.  A change greater than 20% in ß values between models was an
indication of confounding, and hence the confounder was retained in the model.  Once
the final model was constructed, it was assessed for goodness of fit using the likelihood
ratio test (161).
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4.3.2 Prevention Bias:  HRT Ever Users as Compared to HRT Never Users
4.3.2.1 Predictors of HRT Use
Binary logistic regression was used to further explore the differences between
HRT ever and never user groups.  The final main effects model identified several
predictors significant at the p<.05 level.  Refer to Table 4.9 below.  As expected, the
likelihood that one would have used HRT decreased with increasing age. Women
belonging to the younger age groups were much more likely to have used HRT as
compared to women in the 85 years and older category.  When compared to women in
the lowest income category ($19,999 or less), those participants with higher incomes
($35,000 or more) were more likely to report HRT use.  There were also regional
differences in HRT Use.  For instance, women living in Quebec were more likely than
British Columbia residents to have used HRT.  In terms of overall health, women
without diabetes were more likely than women with diabetes to have used HRT.
Conversely, women with a thyroid condition, arthritis, or a kidney condition were more
likely to report HRT use.  Current use of vitamin E or multi-vitamin supplements were
also predictors of HRT use, with women who currently use these vitamins being more
likely to report HRT use.  Women who had received flu shot(s) were more likely than
women not receiving a flu shot to have used HRT.  There are clear differences in
relevant predictors between HRT users and never users.  These differences may account
for some of the HRT effect on cognition.  Such variations need to be taken into account
in analysis.
4.3.2.2 Model Diagnostics
To assess the goodness of fit of the model, the likelihood ratio (LR) test was
used.  The LR test subtracts the LR statistics from the full and reduced models, thereby
examining whether the final or reduced model is significantly a better fit than the larger,
more inclusive model.  For the model presented in Table 4.9, the log likelihood statistic
was highly significant (LR=675.33. c 231 = 52.62, p<0.001).  This indicates that the final
main effects model was the better, more parsimonious model.  As a result, the model is
acceptable.
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Table 4.9: Final Main Effects Model: HRT Never Use Versus HRT Ever Use
Variable (reference) ß (S.E.) Sig. Exp (ß) 95% C.I. for Exp (B)
Lower         Upper
Age
           65-74 years 1.287 (.176).000 3.621 2.565 5.110
           75-84 years .753 (.165) .000 2.123 1.537 2.933
           85 years + (ref) .000
Arthritis  (no) .394 (.112) .000 1.483 1.191 1.848
Current Vitamin E Use (no) .493 (.183) .007 1.638 1.144 2.344
Current Multi-Vitamin Use (no) .405 (.132) .002 1.499 1.157 1.942
Diabetes-2 (yes) .501 (.180) .005 1.650 1.160 2.346
Income
          $19,999 or less (ref) .043
          $20,000-34,999 .215 (.127) .090 1.240 .967 1.589
          $35,000 + (ref) .337 (.142) .018 1.400 1.060 1.849
Influenza Shots (no) .246 (.106) .021 1.279 1.038 1.575
Kidney Disease (no) .437 (.160) .006 1.548 1.131 2.119
Region
          Atlantic -.315 (.174).071 .730 .519 1.028
          Quebec .318 (.159) .045 1.374 1.006 1.876
          Ontario -.201 (.165).221 .818 .592 1.129
          Prairies -.141 (.153).359 .869 .644 1.173
         British Columbia (ref) .003
Regular Spirit Consumption (no) .272 (.133) .042 1.312 1.011 1.703
Stroke-2 ( no) .422 (.208) .043 1.525 1.014 2.292
Thyroid Condition (no) .391 (.124) .002 1.478 1.159 1.884
*Exp(ß) can be interpreted as a measures of odds ratios, which is an approximation of
relative risk.
4.3.3 All-Cause CIND
4.3.3.1 Independent Variables
The relationship between HRT and all-cause CIND was examined using logistic
regression, while controlling for other covariates. There were 304 incident cases of all-
cause CIND and 2670 participants with NCI included in this model.  Once the
participants’ with missing data were removed from the model, 210 CIND cases and
1794 normal participants remained for analysis.  A number of predictors were found to
be significant (See Table 4.10). Consistent with the literature, there is a dose-response
relationship between age and educational attainment and CIND, with lower education
and advanced age considerably increasing one’s risk.  Women in the 85 and older age
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group were almost seven times more likely than those in the 65-74 age group to have
all-cause CIND (OR=7.13); while women from ages 75-84 remained at an increased,
but lower, risk (OR=2.368).  Participants with a history of stroke or Parkinson’s disease
were over three times more likely than participants without these conditions to be
diagnosed with all-cause CIND. Women reporting a history of psychiatric illness
(including anxiety) and current depression were more likely to have all-cause CIND,
although depression was of borderline statistical significance (p=.051).  In terms of
residential status, individuals who resided in an institution were almost five times more
likely than those living in the community to have been diagnosed with all-cause CIND.
Both family history of Alzheimer’s disease and mental retardation were found to
increase one’s risk.  Conversely, regular exercise, use of NSAIDs, and regular
consumption of shellfish were found to protect for cognitive impairment.   HRT status
did not reach significance in this model.  HRT duration was then tested for significance,
first in finer categories (1 year or less; more than 1 year up to 5 years; more than 5 years
up to 10 years; more than 10 years) and then collapsed into a more broad classification
(no use; 5 years or less; greater than 5 years).  Neither of the two duration variables was
found to be a significant predictor of all-cause CIND.
 Table 4.10: Final Main Effects Model: Cognitively Normal Versus All-Cause
CIND
Variable (reference group)ß (S.E.) Sig. Exp (ß) 95% C.I. for Exp (ß)
Lower         Upper
Age
           65-74 years (ref) .000
           75-84 years .862 (.252) .001 2.368 1.447 3.878
           85 years + 1.964 (.268) .000 7.129 4.219 12.046
Current Depression (no) .458 (.235) .051 1.581 .998 2.505
Education
          6 years & under 1.255 (.536) .019 3.508 1.226 10.035
          7- 9 years .991 (.466) .033 2.693 1.081 6.713
          10-12 years -.496 (.503) .325 .609 .227 1.634
          13 years + (ref) .001
Family History of AD (no)1.914 (.503) .000 6.781 2.529 18.183
Family History of Mental
Retardation (no)
.928 (.454) .041 2.529 1.040 6.152
HRT (yes) .265 (.483) .583 1.304 .506 3.360
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NSAID Use (yes) .681 (.239) .004 1.977 1.238 3.156
Parkinson’s Disease-2 (no)1.314 (.410) .001 3.722 1.668 8.307
Psychiatric Illness (no) .473 (.191) .014 1.604 1.102 2.334
Regular Consumption of
Shellfish (yes)
.629 (.246) .011 1.876 1.157 3.041
Regular Exercise (yes) 1.049 (.341) .002 2.854 1.464 5.563
Residential Status
(community)
1.049 (.341) .000 4.679 2.656 8.242
Stroke-2 (no) 1.242 (.252) .000 3.462 2.113 5.672
HRT*Education .023
6 years or less*HRT .625  (.619) .313 1.868 .555 6.286
7-9 years*HRT -.361 (.552) .513 .697 .236 2.058
10-12 years*HRT 1.149 (.577) .047 3.156 1.018 9.786
HRT*Family History AD -1.325 (.594).026 .266 .083 .852
HRT*Regular Exercise -.823 (.391) .035 .439 .204 .944
*Exp(ß) can be interpreted as a measures of odds ratios, which is an approximation of
relative risk.
Final Model for All-cause CIND
Log (p/1-p) = b 0 + b 1(age 75-84) + b 2 (age 85+) b 3 (depression) + b 4 (educ <=6 yrs)  + b 5
(educ 7- 9 yrs) + b 6 (educ 10-12 yrs) +b 7 (family history of AD) + b 8 (family history of mental
retardation) + b 9 (HRT use) + b 10 (NSAID use) + b 11 (Parkinson’s disease) + b 12 (psychiatric
illness) + b 13 (shellfish) + b 14 (regular exercise) + b 15 (residential status) + b 16 (stroke) + b 17
(Educ <+6 yrs*HRT) + b 18 (educ 7-9 yrs*HRT) + b 19 (Family history of AD* HRT) + b 20 (Regular
exercise*HRT)
*Where p=probability of occurrence of all-cause CIND.
4.3.3.2   Interaction Assessment
In the final model, HRT status was found to interact with the variables regul r
exercise, ducational attainment, and family history of AD.  Cr ss-tabulations were
initially carried out in order to ascertain a descriptive view of the type of relationship
that exists between these interacting variables.
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4.3.3.2.1 HRT-Education Interaction
Table 4.11: Cognitively Normal Participants and HRT-Education Interaction
(n=2661)
                                            EDUCATION         n (%)
6 years or less       7 - 9 years          10-12 years          13 years +
HRT User 69 (9) 182 (23) 311 (40) 222 (28)
HRT Never
User
173 (9) 508 (27) 703 (38) 493 (26)
Table 4.12:  All-Cause CIND and HRT-Education Interaction (n=303)
                                            EDUCATION            n (%)
6 years or less    7 - 9 years       10-12 years        13 years +
HRT User 14 (24) 22 (37) 11 (19) 12 (20)
HRT Never User 59 (24) 64 (26) 88 (36) 33 (14)
Looking at women with all-cause CIND (Table 4.12), one can observe a trend
where a higher proportion of HRT users fall into the highest level (13 years or more) of
educational attainment as compared to never users. The lowest level of education is
known to put individuals at the highest risk for dementia, however the proportion of
women having 6 years or less of education was the same for both groups. Therefore
differences in educational attainment between the two groups may have little impact on
the outcome of CIND.  Notably, a greater proportion of HRT users (37%) fall into the
7-9 years of education category as compared to HRT never users (26%).  This
educational level seems to also confer risk for cognitive decline, albeit not as much as
the 6 year or less category.
4.3.3.2.2 HRT-Exercise Interaction
Table 4.13:  Cognitively Normal Participants and HRT-Exercise Interaction
(n=2340)
                     Regular Exercise        n (%)
              Yes                                  No
HRT User 508 (72) 202 (29)
HRT Never User 1087 (67) 543 (33)
Table 4.14:  All-Cause CIND and HRT-Exercise Interaction (n=262)
                     Regular Exercise         n (%)
              Yes                                  No
HRT User 25 (48) 27 (52)
HRT Never User 112 (53) 98 (47)
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When assessing the interaction effect between HRT status and exercise in the
normal sample (Table 4.14), HRT users appear somewhat more likely to exercise
regularly as compared to never users (72% vs. 67%).  The opposite is true for the all-
cause CIND group, where more HRT never users exercised regularly as compared to
users (53% vs. 48%).
4.3.3.2.3  HRT-Family History of AD Interaction
Table 4.15:  Cognitively Normal and HRT-Family History of AD Interaction
(n=2135)
                   Family History of AD       n (%)
              Yes                                  No
HRT User 38 (6) 620 (94)
HRT Never User 93 (6) 1384 (94)
Table 4.16:  All-Cause CIND Participants and Family History of AD Interaction
(n=241)
                   Family History of AD      n (%)
              Yes                                  No
HRT User 8 (14) 620 (86)
HRT Never User 25 (11) 1384 (90)
By breaking down the interaction effect between HRT status and family history
of AD, one can see that a slightly greater proportion of HRT users with all-cause CIND
have a family history of AD as compared to never users (Refer to Table 4.16).
Table 4.17:  Calculation of Odds Ratios for All-Cause CIND When Interaction
Present
Effect Among Exp ( ) 95% CI
Education*
6 years or < HRT Users 3.51 1.26 – 10.04
7-9 years HRT Users 2.69 1.08 – 6.71
10-12 years HRT Users 0.61 0.23 – 1.63
6 years or < HRT Never Users 6.55 3.49 – 12.29
7-9 years HRT Never Users 1.88 1.34 – 3.78
10-12 years HRT Never Users 1.92 1.14 – 3.23
HRT Never Users** 6 years or < 2.44 0.95 – 6.23
66
HRT Never Users 7-9 years 0.91 0.52 – 1.58
HRT Never Users 10-12 years 4.11 1.68 – 10.10
HRT Never Users 13 years + 1.30 0.51 – 3.360
Exercise**
No Regular ExerciseHRT Users 2.85 1.46 – 5.56
No Regular ExerciseHRT Never Users 1.25 .085 – 1.86
HRT Never Users No Regular Exercise0.57 0.17 – 1.93
HRT Never Users Yes Regular Exercise1.30 0.51 – 3.36
Family History of AD***
Yes History HRT Users 6.78 2.53 – 18.18
Yes History HRT Never Users 1.80 1.00 – 3.24
HRT Never Users Yes History 0.35 0.09 – 1.31
HRT Never Users No History 1.304 0.51 – 3.36
*   Reference group is HRT users with 13 years or more education
** Reference group is HRT users who exercise regularly.
*** Reference group is HRT users without a family history of AD.
When interactions were present, calculations of odds ratios for all-cause CIND
were carried out according to Hosmer and Lemeshow’s approach (160).  Through this
technique, it was found that educational level significantly increased one’s risk for a
diagnosis of CIND in both user groups, with the exception of the 10-12 year category in
HRT users (Table 4.17).  When comparing HRT never users to users, it appeared that
low education (6 years or less) more than doubled never users risk for CIND
(OR=2.44), although this association was only borderline significant.  Women
belonging to the 10-12 year educational category who had never used HRT were at a
substantially increased risk (OR=4.11) for CIND as compared to users with similar
education.  In terms of HRT’s interaction with regular exercise, it seemed that lack of
regular exercise increased HRT users risk for CIND (OR=2.85), but the same was not
true for the HRT never users.  Finally, looking at family history of AD and its
interaction with HRT, it was found that having a family history of AD greatly increased
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HRT users risk for CIND (OR=6.78), but did not have the same significant effect on
HRT never users.
4.3.3.3  Confounding
Potential confounders were entered into the model and the ß-values were
compared between models with and without the variable.  If the difference in the ß-
values was greater than 20% or if it changed the statistical significance of the primary
independent variable, then confounding was present.  Age, residential status, NSAID
use, and education were all identified as confounders; since they were already in the
model as covariates, the model did not change. However, depression was borderline not
significant, but remained in the model due to its confounding effect.
4.3.3.4 Model Diagnostics
To assess the goodness of fit of the model, the likelihood ratio test was used.
For this present model, the log likelihood statistic was significant (LR=374.47. c 232 =
52.62, p<0.001).  This indicates that the final main effects model fit better than the full
model, which contained more variables.  As a result, the model is acceptable.
4.3.4 Reduced-Cause CIND
4.3.4.1     Independent Variables
Logistic regression was used to examine the relationship between HRT and
reduced-cause CIND while controlling for covariates. Many factors achieved
significance (Table 4.18). Similar to the more inclusive all-cause CIND outcome, there
is a dose-response relationship between age and educational attainment and reduced-
cause CIND.  Women with up to 6 years of education were over three times as likely to
receive a reduced-cause CIND diagnosis as compared to those with 13 or more years;
while women with 7-9 years remained at an increased risk, albeit lower (OR=2.36).
Participants with a history of stroke or Parkinson’s disease were over three times more
likely than participants without these conditions to be diagnosed with reduced-cause
CIND.  Depression was highly significantly related to reduced-cause CIND, with
current depression doubled one’s risk of a diagnosis.  Psychiatric illness did not reach
significance, as it did for the all-cause CIND outcome.  This is likely due to the fact that
CIND caused by psychiatric illness was removed from the reduced-cause group.  In
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terms of residential status, individuals who resided in an institution were almost four
times more likely than those living in the community to have been diagnosed with all-
cause CIND.  Family history of Alzheimer’s disease, but not of mental retardation, was
found to increase one’s risk.  Regular exercise and use of NSAIDs were protective.
HRT status was not a significant predictor of reduced-cause CIND, nor was duration of
HRT use (p=.731).
Table 4.18:  Final Main Effects Model:  Cognitively Normal Versus Reduced-
Cause CIND
Variable  (reference group) (S.E.) Sig. Exp
(B)
95% C.I. for Exp ()
Lower         Upper
Age-2
           65-74 years .000
           75-84 years .863 (.256) .001 2.369 1.436 3.910
           85 years + (ref) 1.919 (.273) .000 6.813 3.987 11.643
Current Depression .804 (.218) .000 2.235 1.457 3.429
Education
           6 years & under 1.202 (.504) .017 3.328 1.239 8.940
           7- 9 years .946 (.438) .031 2.576 1.091 6.084
           10-12 years -.625 (.492) .204 .535 .204 1.405
           13 years + (ref) .001
Family History of AD (no)1.780 (.467) .000 5.929 2.376 14.799
HRT (yes) -.196 (.424) .644 .822 .358 1.887
NSAID Use (yes) .557 (.235) .018 1.745 1.101 2.765
Parkinson’s Disease-2 (no)1.289 (.421) .002 3.628 1.589 8.283
Regular Exercise (yes) .442 (170) .009 1.556 1.115 2.171
Residential Status
(community)
1.357 (.289) .000 3.886 2.208 6.841
Stroke-2 (no) 1.233 (.247) .000 3.433 2.116 5.569
HRT*Education .011
6 years or less*HRT .603 (.596) .311 1.828 .568 5.878
7-9 years*HRT *HRT -.410 (.534) .443 .664 .233 1.889
10-12 years*HRT 1.250 (.568) .028 3.490 1.146 10.630
HRT*Family History AD -1.581 (.590).007 .206 .065 .654
*Exp(ß) can be interpreted as a measures of odds ratios, which is an approximation of
relative risk.
Final Model for Reduced-cause CIND
Log (p/1-p) = b 0 + b 1(age 75-84) + b 2 (age 85+)  b 3 (depression) + b 4 (educ <=6 yrs)  + b 5
(educ 7- 9 yrs) + b 6 (educ 10-12 yrs) +b 7 (family history of AD) + b 8 (HRT use) + b 9 (NSAID use) +
b 10 (Parkinson’s disease) + b 11 (regular exercise) + b 12 (residential status) + b 13 (stroke) + b 14
(Educ <+6 yrs*HRT) + b 15 (educ 7-9 yrs*HRT)+ b 15 (Family History AD*HRT)
*Where p=probability of occurrence of reduced-cause CIND.
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4.3.4.2 Interaction Assessment
As with the all-cause CIND model, HRT status was found to interact with
educational attainment and family history of AD.  The interaction between HRT and
exercise was not significant in this model.  Cross-tabulations were carried out in order
to determine the type of relationship that exists between these variables.
4.3.4.2.1    HRT-Education Interaction
Table 4.19: Cognitively Normal Participants and HRT-Education Interaction
(n=2661)
                                            EDUCATION                  n (%)
6 years or less     7 - 9 years         10-12 years        13 years +
HRT User 69 (9) 182 (23) 311 (40) 222 (28)
HRT Never
User
173 (9) 508 (27) 703 (38) 493 (26)
Table 4.20:  Reduced-Cause CIND Participants and HRT-Education Interaction
(n=247)
                                            EDUCATION                  n (%)
6 years or less     7 - 9 years       10-12 years         13 years +
HRT User 12 (23) 20 (38) 10 (19) 11 (21)
HRT Never
User
49 (25) 48 (25) 69 (36) 28 (14)
When looking at the reduced-cause CIND sample (Table 4.20), one can notice a
trend where HRT users fall into the highest levels of educational attainment as
compared to never users.  Here 21% of HRT users had 13 or more years of education,
while only 14% of never users belonged to this category.  In addition, a greater
proportion of HRT users (38%) fell into the 7-9 years of education category as
compared to HRT never users (25%).  Although the proportions differ slightly, the same
type of HRT-education interaction appears in both the reduced- and all-cause CIND
models.
70
4.3.4.2.2   HRT-Family History of AD Interaction
Table 4.21:  Cognitively Normal Participants and HRT-Family History of AD
Interaction (n=2135)
                   Family History of AD        n (%)
              Yes                                  No
HRT User 38 (6) 620 (94)
HRT Never User 93 (6) 1384 (94)
Table 4.22:  Reduced-Cause CIND Participants and HRT-Family History of AD
Interaction (n=241)
                   Family History of AD        n (%)
              Yes                                  No
HRT User 8 (16) 43 (84)
HRT Never User 15 (8) 175 (92)
An interaction effect between HRT status and family history of AD was not
found for the cognitively normal sample (Table 4.21).  Although for women in the
reduced-cause group (Table 4.22), it seems that a greater proportion of HRT users had a
family history of AD as compared to HRT never users (16% versus 8%).  This
interaction effect is similar to that observed with the all-cause CIND group, however it
is more pronounced.
Table 4.23:  Calculation of Odds Ratios for Reduced-Cause CIND When
Interaction Present
Effect Among Exp ( ) 95% CI
Education*
6 years or < HRT Users 3.33 1.24 – 8.94
7-9 years HRT Users 2.58 1.09 – 6.08
10-12 years HRT Users 0.54 0.20 – 1.41
6 years or < HRT Never Users6.08 3.27 – 11.30
7-9 years HRT Never Users1.71 0.92 – 3.18
10-12 years HRT Never Users1.87 1.07 – 3.25
HRT Never Users** 6 years or < 1.50 0.63 – 3.61
HRT Never Users 7-9 years 0.55 0.28 – 1.08
HRT Never Users 10-12 years 2.87 1.31 – 6.28
HRT Never Users 13 years + 0.82 0.36 – 1.89
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Family History of AD**
Yes History HRT Users 5.93 2.38 – 14.80
Yes History HRT Never Users 1.22 0.64 – 2.34
HRT Never Users Yes History 0.17 0.05 – 0.61
HRT Never Users No History 0.82 0.36 – 1.89
*   Reference group is HRT users with 13 years or more education
** Reference group is HRT users without a family history of AD.
As with the all-cause CIND model, hand calculations were completed in order to
calculate odds ratios for each level of interaction (Refer to Table 4.23).  The
interactional effects found in the reduced model were very similar to the all-cause
CIND model.  Educational level significantly increased one’s risk for a diagnosis of
CIND in both user groups, with the exception of the 10-12 year category in HRT users
and a borderline not significant association for HRT never users in the 7- 9 year
category.  When comparing HRT never users to users, only the 10-12 year educational
level significantly increased never users risk over that of users (OR=2.87).  The
borderline significant association seen for those with 6 years of education or less in the
all-cause CIND model disappeared in the reduced-cause model.  Then looking at family
history of AD and its interaction with HRT, a family history of AD greatly increased
HRT users risk for CIND (OR= 5.93), but did not have the same significant effect on
HRT never users.
4.3.4.3    Confounding
Potential confounders were entered into the model and the ß-values were
compared between models with and without the variable.  Age, depression, residential
status, NSAID use, education, and exercise were all identified as confounders; however
since they were already in the model as covariates, the model did not change.
4.3.4.4   Model Diagnostics
To assess the goodness of fit of the model, the likelihood ratio test was used.
For this present model, the log likelihood statistic was significant (LR=463.48. c 232=
52.62, p<0.001).  This indicates that the final main effects model was the better, more
parsimonious model.  As a result, the model is a very good fit.
72
4.3.5 CLoND
4.3.5.1 Independent Variables
By using logistic regression, HRT was examined for an association with
CLoND.  After adjusting for the effects of other important covariates, HRT status did
not show a significant effect on the CLoND outcome (See Table 4.24).  When broken
down into duration of use, the results were the same (p=.854).  However, numerous
other variables were found to be significant predictors for CLoND.  Age and
educational attainment were both strongly associated with cognitive loss.  As with the
two previous model CIND models, both illustrated a dose-response relationship with the
outcome.  Participants with a history of stroke or Parkinson’s disease were over three
times more likely than participants without these conditions to be diagnosed.
Interestingly, thyroid conditions appeared to be protective.  Depression was highly
significantly related to CLoND, where current depression almost tripling one’s risk.  In
terms of residential status, individuals who resided in an institution were three times
more likely than those living in the community to have received a CLoND diagnosis.
Family history of Alzheimer’s disease was found to greatly increase one’s risk.    When
using British Columbia as the reference category, women living in Quebec and Ontario
were at higher risk.  When the Quebec region was used as the comparison group, the
Prairies and B.C. were found to be at a lower risk.  Quebec had the highest proportion
of CLoND cases out of all the regions.  Although marital status was included only as a
confounder, it seems that women who were divorced or separated were at an increased
risk for CLoND.  Conversely, regular exercise, use of NSAIDs, and regular
consumption of shellfish were protective.
Table 4.24:  Reduced Main Effects Model: Cognitively Normal Versus CLoND
Variable (reference group)  (S.E.) Sig. Exp ( ) 95% C.I. for Exp (B)
Lower         Upper
Age-2
           65-74 years (ref) .000
           75-84 years 1.052 (.317) .001 2.864 1.538 5.335
           85 years + 2.205 (.347) .000 9.074 4.599 17.902
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Current Depression (no) .990 (.242) .000 2.691 1.675 4.325
Education
           6 years & under 1.215 (.348) .000 3.371 1.703 6.671
           7- 9 years .619 (.299) .039 1.856 1.032 3.338
           10-12 years .374 (.285) .190 1.454 .831 2.544
           13 years + (ref) .005
Family History of AD (no) 1.612 (.535) .003 5.012 1.756 14.309
HRT (yes) .138 (.240) .565 1.148 .717 1.839
Marital Status-2
   Married/Common Law (ref) .096
   Separated/Divorced 1.137 (.477) .017 3.117 1.224 7.940
   Widowed .289 (.273) .288 1.336 .783 2.279
    Never Married .011 (.408) .978 1.011 .455 2.251
NSAID Use (yes) .783 (.279) .005 2.188 1.265 3.783
Parkinson’s Disease-2 (no) 1.396 (.481) .004 4.039 1.574 10.361
Region
      Atlantic .512 (.346) .139 1.668 .847 3.288
      Quebec .845 (.318) .008 2.328 1.249 4.339
      Ontario .691 (.334) .038 1.997 1.038 3.842
      Prairies -.176 (.352) .617 .838 .420 1.672
      British Columbia (ref) .004
Regular Exercise (yes) .470 (.192) .015 1.599 1.097 2.332
Regular Shellfish Consumption (yes) .564 (.285) .048 1.757 1.005 3.074
Residential Status (community) 1.115 (.335) .001 3.048 1.581 5.876
Stroke-2 (no) 1.195 (.282) .000 3.304 1.901 5.742
Thyroid Condition (no) -.612 (.282) .030 .542 .312 .942
HRT*Family History of AD -1.353 (.666).042 .258 .070 .953
*Exp(ß) can be interpreted as a measures of odds ratios, which is an approximation of
relative risk.
Final Model for CLoND
Log (p/1-p) = b 0 + b 1(age 75-84) + b 2 (age 85+) b 3 (depression) + b 4 (educ <=6 yrs)  + b 5
(educ 7- 9 yrs) + b 6 (educ 10-12 yrs) +b 7 (family history of AD) + b 8 (HRT use)  + b 9 (family history
of mental retardation) + b 10 (Separated/Divorved) + b 11 (Widowed) + b 12 (Never Married) + b 13
(NSAID use) + b 14 (Parkinson’s disease) + b 15 (region, Atlantic) + b 16 (region, Quebec) + b 17
(region, Ontario) + b 18 (region, Prairies) + b 19 (regular exercise) + b 20 (regular shellfish) + b 21
(residential status) + b 22 (stroke) + b 23 (thyroid condition) + b 24 (Family History of AD*HRT)
*Where p=probability of occurrence of CLoND.
4.3.5.2 Interaction Assessment
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In the final model, HRT status was found to interact with family history of
Alzheimer’s disease.  Cross-tabulations were carried out in order to ascertain the type of
relationship that exists between these interacting variables.
4.3.5.2.1    HRT-Family History of Alzheimer’s Disease Interaction
Table 4.25:  Cognitively Normal Participants and HRT-Family History of AD
Interaction (n=2128)
                  Family History of AD       n (%)
              Yes                                  No
HRT User 38 (6) 619 (94)
HRT Never User 93 (6) 1378 (94)
Table 4.26:  CLoND Participants and HRT-Family History of AD Interaction
(n=195)
                   Family History of AD      n (%)
              Yes                                  No
HRT User 7 (17) 35 (83)
HRT Never User 14 (9) 139 (91)
Looking at women with CLoND (Table 4.26), one can detect a trend where a
greater proportion of HRT Users have a family history of AD as compared to never
users.  It is believed that having a family history of AD increases one’s risk for
cognitive decline and impairments.  From this data, one would be unable to discern if a
family predisposition towards AD influences women’s decision to use or not use HRT.
Interaction between HRT and education was assessed and the term was borderline not
significant (p=.059), and therefore it was removed from the model.
Table 4.27:  Calculation of Odds Ratios for CLoND When Interaction Present
Effect Among Exp ( ) 95% CI
Family History of AD*
Yes History HRT Users 3.37 1.70 – 6.67
Yes History HRT Never Users 1.30 0.59 – 2.84
HRT Never Users Yes History 0.30 0.09 – 1.01
HRT Never Users No History 1.148 0.72 – 1.84
* Reference group is HRT users without a family history of AD.
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Hand calculations assessing the interaction effect between HRT and family
history of AD in the CLoND model found that family history of AD significantly
increased risk for CLoND in HRT users (Refer to Table 4.27).  This association was not
identified in the HRT never user group.  This finding was also seen in the all- and
reduced-cause CIND models.  Almost reaching significance, HRT never users with a
family history of AD were less likely to have CLoND as compared to HRT users with a
family history of AD.
4.3.5.3       Confounding
Marital status was tested positive for confounding and therefore was included in
the model as a confounder.  Age, depression, residential status, regular exercise, and
NSAID use were all identified as confounders; however since they were already in the
model as covariates, the model did not change.
4.3.5.4      Model Diagnostics
To assess the goodness of fit of the model, the likelihood ratio test was used.
For this present model, the log likelihood statistic was significant (LR=322.90. c 232 =
52.62, p<0.001).  This indicates that the final main effects model was the better, more
parsimonious model.  As a result, the model is a very good fit.
4.3.6  Alzheimer’s Disease
4.3.6.1   Independent Variables
Cox PH Model was used to examine the relationship between HRT and AD.
Refer to section 3.4.5 for an explanation of time-to-event and censoring used in this
approach.  There were 112 incident cases of AD and 2670 participants with NCI
included in this model.  Once the participants’ missing data was removed from the
model, 89 AD cases and 1944 censored participants remained for analysis.  After
controlling for other covariates, HRT status was statistically significant (p<.05) (Table
4.28).  HRT never users were over ten times as likely as users to have developed AD in
the study’s five-year follow-up period.   Interestingly, HRT duration was not significant
(p=.257).  However, when plotted on a survival curve (see Figure 2) the results seem to
indicate a trend for use less than five years to be protective, whereas use longer than 5
years and no use at all confer similar risk.  Consistent with the findings of previous
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studies, both depression and high blood pressure were found to increase risk for AD.
Risk for AD was found to increase with age. Specifically, the risk was doubled for those
in the 75-84 age group and almost nine times greater for those 85 and over, as compared
to women 65-74 years of age.   Regular wine consumption, past tetanus shots, and
residing in a rural area appeared protective.  Women who had never been married were
also at a decreased risk for developing AD when compared to those who are currently
married, although being divorced, separated or widowed did not have a significant
effect.
Some variables had relatively rare events, which makes it difficult to assess their
effect on the outcome.  However, upon further examination it could be seen that there
was only one instance in the AD sample; therefore sample size would have prevented a
more accurate estimate.  In addition, marital status initially showed a peculiar
confidence interval indicating small numbers in each cell, therefore the divorced/
separated and widowed categories were collapsed to increase the number of cases in
each cell.  This stabilized the estimates, while retaining the significance of the predictor.
Table 4.28: Final Main effects for Alzheimer’s disease: Cox Proportional Hazards
Model
Variable (reference group)  (S.E.) Sig. Exp (B) 95% C.I. for Exp ()
Lower         Upper
Age-2
           65-74 years (reference) .000
           75-84 years .8441 (.461).068 2.318 .939 5.720
           85 years + 2.170 (.475).000 8.761 3.451 22.245
Current Depression ( o) .619 (.301).040 1.858 1.029 3.354
Education
           6 years & under 1.375 (1.436).338 3.955 .237 66.005
           7- 9 years 2.650 (1.102).016 14.161 1.632 122.884
           10-12 years 1.501 (1.113).178 4.485 .506 39.752
           13 years + (ref) .045
High Blood Pressure-2 (no) .528 (.220).017 1.695 1.101 2.610
HRT (yes) 2.316 (1.047).027 10.134 1.301 78.946
Marital Status
      Married (ref) .013
      Divorced/Separated//Widowed-.278 (.309).368 .757 .414 1.387
      Never Married -1.579 (.545).004 .206 .071 .600
Regular Wine Consumption (yes) 1.162 (.522).026 3.196 1.149 8.885
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Residential Status (community) 2.331 (.247).000 10.291 6.347 16.686
Rural-Urban Status (Urban) -.957 (.473).043 .384 .152 .971
Tetanus Immunization (Yes) .968 (.361).007 2.633 1.297 5.345
HRT*Education .045
6 years or less*HRT -1.335
(1.482)
.368 .263 .014 4.802
7-9 years*HRT -2.952
(1.146)
.010 .052 .006 .494
10-12 years*HRT -1.932
(1.152)
.094 .145 .015 1.386
*Exp(ß) is the hazards ratio obtained from the survival model.  It can be interpreted as a
measure of odds ratios, which is an approximation of relative risk.
The survival curve (see Figure1 below) illustrates the different interactions
between HRT use and level of education and their effects on the AD outcome.  This
graph is adjusted for all other predictors included in the Cox PH model.  The vertical
axis plots the cumulative survival of the study sample, ho here because AD is a rare
event.  In terms of the whole study sample, a very small proportion of individuals
developed AD in this five-year period.  It appears that HRT never users as a group had
quite similar survival times, as compared to HRT users, where level of education
seemed to effect AD survival.  Unfortunately, a line could not be plotted for the
interaction between HRT and the highest level of education (13 years +), since there
were too few cases.
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Figure 1.  Interaction Effects between HRT Status and Education and Survival
of Women with AD
Survival Function at mean of covariates
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Figure 2.  Duration of HRT Use and Survival of Women with AD
Survival Function for patterns 1 - 3
Follow-up Time
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4.3.6.2 Interaction Assessment
All possible interaction terms were tested after fitting the main effects model.
Interestingly, the previously observed interaction between HRT use and family history
of AD did not appear significant.  As with the other models, HRT status was found to
interact with education.
4.3.6.2.1 HRT-Education Interaction
Table 4.29: Cognitively Normal Participants and HRT-Education Interaction
(n=2661)
                                            EDUCATION                        n (%)
6 years or less          7 - 9 years             10-12 years             13 years
+
HRT User 69 (9) 182 (23) 311 (40) 222 (28)
HRT Never
User
173 (9) 508 (27) 703 (38) 493 (26)
80
Table 4.30:  Alzheimer’s Disease and HRT-Education Interaction (n=111)
                                            EDUCATION                       n (%)
6 years or less          7 - 9 years             10-12 years             13 years
+
HRT User 1 (5) 9 (47) 8 (42) 1 (5)
HRT Never
User
13 (14) 25 (27) 29 (32) 25 (27)
For the AD group, HRT users fall more heavily into the categories 7-9 and 10-
12 years (See Table 4.30).  Whereas HRT never users are more normally distributed
throughout all levels of educational attainment, with a sizeable proportion having
completed 13 or more years of schooling (27%).  HRT users had a smaller proportion of
individuals in the highest and lowest levels of education than HRT never users.
Importantly, the smaller number of HRT users in the AD group (n=19), and particularly
within each educational category, makes it difficult to assess the interaction effect and
to know if the effect would remain with a larger number of cases.
Table 4.31:  Calculation of Hazard Ratios for Alzheimer’s Disease When
Interaction Present
Effect Among Exp ( ) 95% CI
Education*
6 years or < HRT Users 3.96 0.24 – 66.01
7-9 years HRT Users 2.65 1.63 – 122.89
10-12 years HRT Users 4.49 0.51 – 39.75
6 years or < HRT Never Users1.04 0.50 – 2.17
7-9 years HRT Never Users0.74 0.40 – 1.37
10-12 years HRT Never Users0.65 0.35 – 1.21
HRT Never Users** 6 years or < 2.67 0.34 – 21.03
HRT Never Users 7-9 years 0.53 0.22 – 1.30
HRT Never Users 10-12 years 1.47 0.55 – 3.91
HRT Never Users 13 years + 10.13 1.30 – 78.95
*   Reference group is HRT users with 13 years or more education
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** Reference group is HRT users
Further exploration into the nature of the interaction between HRT and
education was done for the AD outcome.   The 7- 9 years educational level significantly
increased HRT user’s risk for AD, however the same was not true for never users.
When comparing HRT never users to HRT users, the 13 years or greater category
greatly increased never user’s risk for AD as compared to HRT users with a similar
level of education.  This was the only educational level to achieve statistical
significance.  Notably, there are low numbers in the 6 year or less and 13 years or more
educational categories for HRT users (see table 4.30).  This means that the observed
interaction effect must be interpreted cautiously and further study of this interaction in
studies with sufficient sample size is necessary.
4.3.6.3 Confounding
All potential confounders were assessed.  Age, marital status, and residential
status were shown to be confounding factors; since they were already significant risk
factors the model remained unchanged.  Stroke, Parkinson’s disease, rural-urban status,
psychiatric illness, head injury, NSAID use, Family History of AD, and smoking were
all tested for confounding; they were not shown to be confounding factors.
4.3.6.4 Model Diagnostics
4.3.6.4.1 Goodness of Fit
To assess the goodness of fit of the model, the likelihood ratio test was used.
For this present model, the log likelihood statistic was significant (LR=590.46. c 223 =
49.73, p<0.001).  This indicates that the final main effects model was the better, more
parsimonious model as compared to the full model containing a greater number of
variables.
4.3.6.4.2 Proportional Hazards Assumption
When using the Cox PH Model it is important that the covariates meet the
Proportional Hazards assumption.  This means that the hazard for an individual is
comparative to the hazard for any other individual over time (156).  Put another way,
the effect of a given covariate must not change over time.  There are different ways –
both graphical and numerical -- that the assumption can be assessed.   There is no
known evidence today that one approach is better than another at assessing the PH
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assumption (162).  There are different ways that the PH assumption can be checked.
One of the most popular methods is to use log-log survival curves (156).  If once the
curve is plotted, the lines are parallel then the assumption is met.  Log-log survival
curves were computed for important variables and those at high risk for violating the
PH assumption.  This included HRT status, age, education, diabetes, stroke, depression
(Refer to Figure 3); as well as head injury, tetanus, and high blood pressure (Figures not
shown).  All variables tested met the PH assumption.
Figure 3.  Log Minus Log Plots: Education, Age, HRT, Diabetes, Stroke, and
Depression
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4.3.7     Alzheimer’s Disease and Age at Onset
4.3.7.1   Linear Regression Model
Using a linear regression model, the effect of HRT on age of AD onset was
assessed.  Here the dependent variable was age at AD onset.  HRT status initially was
found to significantly predict for age of disease onset when entered alone into the
model.  However, once the continuous variable for age was added, HRT status was no
longer a significant predictor for age of AD onset.  No other variables entered into the
model were found to be significant.
Table 4.32: Final Main Effects Model:  Predictors of Age of AD Onset
Variable
(reference)
 (S.E.) Sig. 95% C.I. for Exp ()
Lower         Upper
Age-2 1.069 (.049) .000 .971 1.167
HRT (yes) .384 (.789) .628 -1.182 1.949
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4.3.8   Vascular Dementia
4.3.8.1   Independent Variables
Using the Cox PH Model, the relationship between HRT and VaD was
examined.  HRT status was shown to be significant with a large effect size (Table 4.33).
That is, HRT never users were five times more likely to have developed VaD in the
five-year follow-up period.  Figure 4 graphically illustrates this relationship.  The
impact of HRT duration on VaD could not be assessed due to small numbers.  Upon
closer inspection of the data using crosstabulation, one can see that only three of the 26
VaD cases used HRT at all and two of these cases had used for longer than 5 years.
Therefore the less than 5 years HRT duration category was empty making analysis of
duration impossible for this outcome.  As with all other models, age and education were
also significant predictors.  Because of the limited overall number of VaD cases in the
final model, it was necessary to treat age as a continuous variable and to further collapse
education into two categories (6 years and under, 7 years and over).  Current
depression, history of high blood pressure, and living in an institution all were found to
be significant.
Table 4.33:  Final Main Effects Model for Vascular Dementia:  Cox Proportional
Hazards Model
Variable (reference group)  (S.E.) Sig. Exp (B) 95% C.I. for Exp ()
Lower         Upper
Age-2 .068 (.031) .030 1.070 1.007 1.137
Current Depression ( o) 1.242 (.406) .002 3.462 1.563 7.669
Education (7 years+) 1.079 (.439) .014 2.943 1.244 6.960
High Blood Pressure-2 (no) 1.311 (.438) .003 3.711 1.572 8.760
HRT (yes) 1.606 (.744) .031 4.985 1.160 21.411
Residential Status (community) 2.632 (.434) .000 13.903 5.943 35.524
87
Figure 4. HRT Status and Survival of Women with VaD
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4.3.8.2  Interaction Assessment
Variables were assessed for interaction, however no terms reached significance.
4.3.8.3  Confounding
Tests for confounding were limited by sample size considerations.  However,
high blood pressure, residential status, current depression, age and education were all
found to confound the relationship between HRT and VaD.  Since all these factors were
already included in the model as risk factors, the model remained the same.
4.3.8.4   Model Diagnostics
4.3.8.4.1      Goodness-of-fit
To assess the goodness of fit of the model, the likelihood ratio test was used.
For this present model, the log likelihood statistic was significant (LR=317.31. c 226 =
52.62, p<0.001). As a result, the model is accepted as the better fit as compared to the
fuller, more inclusive model.
4.3.8.4.2   Proportional Hazards Assumption
Covariates were entered into the Cox PH Model one at-a-time in order to ensure
the PH assumption was met.   As illustrated by the parallel lines in each plot, the
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assumption was met for all of the significant predictors including HRT use, educational
attainment, age, residential status and depression (See Figure 5).
Figure 5.  Log Minus Log Plots: HRT, Education, Age, Residential Status,
Depression and High Blood Pressure
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4.3.9 Vascular Dementia and Age at Onset
4.3.9.1        Linear Regression Model
Using a linear regression model, the effect of HRT on age of VaD onset was
assessed.  The dependent variable was age at VaD onset.  HRT status was not found to
significantly predict for age of disease onset when either entered alone or with age in
the model (Table 4.34).  No other variables entered into the model were found to be
significant.
Table 4.34: Final Main Effects Model:  Predictors of Age of VaD Onset
Variable
(reference)
 (S.E.) Sig. 95% C.I. for Exp ()
Lower         Upper
Age-2 1.063 (.055) .000 .949 1.176
HRT (yes) -1.001 (1.009) .331 -3.079 1.078
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CHAPTER 5:  GENERAL DISCUSSION
1.1 Summary of Results and Discussion
1.1.1 Objective #1:  Prevention Bias:  Are the characteristics of HRT Users
different from Never Users?
Based on the model fitted for HRT status, it is apparent that certain differences
exist between the HRT User groups.  Certain differences in the characteristics of users
as compared to non-users seem almost intuitive.  Women in the younger age group may
have been exposed to a different social milieu, one more promoting and accepting of
medical intervention and hormone use to maintain a woman’s youthfulness and health,
as compared to their older counterparts.  In any case, a greater proportion of hormone
users belonged to the youngest age group.  As well, women with higher incomes
relative to those in the under $20,000 category would financially be more able to afford
the cost of monthly hormone supplements, as well as to potentially adopt different
health behaviours.   Sherwin’s healthy-user bias may be evidenced in the fact that
women using vitamin E and multi-vitamins were more likely to have used HRT,
although it would be interesting to compare other relevant health behaviours.  Still this
could be viewed as signifying a greater inclination to engage in health-promoting
activities.  Even the difference according to flu shots may possibly indicate that women
in the HRT never user group had a preference for the “natural”, although this is
speculative and cannot be ascertained from a study of this nature.  Finally, certain health
conditions may encourage or deter HRT use.  Diabetics may be less apt to add HRT to
their daily regiments because of drug interaction concerns or just the inconvenience of
using another medication.  Overall, differences between the characteristics of the two
groups exist, which is consistent with the literature (129, 133, 135).
By assessing differences between the HRT user groups, one is able to gain some
insight as to whether healthy-user bias could potentially impact study findings.  Still, it
93
is difficult to ascertain whether or not these factors mediate the development of
dementia and the manner by which they act.  However, it is important that these
variations were adjusted for in the modeling strategies for cognitive decline and disease.
Unfortunately, it is unlikely that all of the confounding effects can be controlled for,
even with a well-designed study.  Put another way, it would be improbable that
statistical analysis could ‘erase’ the differential effects that certain lifestyle factors and
behaviours confer on the individual.  Subtle differences in the lifestyles and behaviours
between groups also can have an impact on disease development, particularly since
there may be other group distinctions that have been overlooked.  Variations, such as
found here, may differ in other study populations and must be considered.  In terms of
the problem of prevention bias, research on HRT and cognition must aim to consistently
and adequately control for such differences between HRT user groups that may have an
effect on the study’s outcomes.
1.1.2 Objective #2:  Is there an increased diagnosis of cognitive impairments
and dementia in women never using HRT as compared to HRT users?
There was a difference in the distribution of cognitive decline, impairments, and
dementia in the ever and never user groups.  More HRT never users experienced
cognitive decline when compared to HRT users.  A greater proportion of HRT never
users experienced CIND (11% versus 7%), developed AD (4% versus 2%) and VaD
(1% versus .3%) as compared to HRT users.  Conversely, a larger portion of HRT users
were either diagnosed or screened as normal 90% versus 83%) than HRT never users at
follow-up.  At first glance then, it appears that the cognitive status of HRT users is
superior to the cognition of HRT never users.  Notably, these results are descriptive and
do not control for the effects of age or other intervening factors.
1.1.3 Objective #3:  Is HRT a significant predictor for CLoND, CIND, AD
and VaD?
HRT status was not a significant predictor for the CIND and CLoND models,
but did predict for AD and VaD.  HRT did predict for all- and reduced-cause CIND at
certain levels of educational attainment.  See table 4.36 for a summary of findings for
all outcomes.  The findings for each outcome are discussed below.
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Table 4.35:  HRT Status as a Predictor for All Outcomes (OR, 95% CI)
Exp ( ) 95% CI
All-cause CIND 1.304 0.506 – 3.360
Reduced-cause CIND 0.822 0.358 – 1.887
CLoND 1.148 0.717 – 1.839
AD 10.134 1.301 – 78.946
VaD 4.985 1.160 – 21.411
1.1.3.1 All-cause CIND
After controlling for other covariates, HRT status was not found to significantly
predict for all-cause CIND (95% CI, 0.506-3.360).  Since HRT was found to interact
with education and exercise, further analysis was carried out to ascertain the nature of
this interaction.  It was found that the interaction between the lowest level of education
(6 years or less) and HRT status was borderline significant.  Therefore, the risk for
women with low education who did not use HRT was double the risk for women in the
same educational group using HRT.  Interestingly, the interaction between HRT status
and the 10-12 year educational level was also significant.  It was found that women with
10-12 years of schooling who did not use HRT were 4 times more likely than women
with similar education who had used HRT to be diagnosed with all-cause CIND.
Therefore HRT may theoretically be more beneficial for high-risk individuals such as
women with low-level education.  However, it is difficult to explain the increased risk
in the 10-12 year category and the lack of a trend across different levels of education.  It
is possible that the interaction between education and HRT has masked at least some of
HRT’s effect in other studies.  Since studies on cognition or dementia generally have
not included a discussion of interaction assessment or findings, it is hard to determine if
this has been the case in other research.  In addition to education, HRT status was also
found to interact with family history of AD.   A greater proportion of women with a
family history of AD have used HRT, and it may be that women with a known
predisposition to AD are more inclined to use HRT as a preventative method.  However,
when looking at the interactional effect for all-cause CIND, no significant differences in
risk emerged between the never and ever user groups.
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In the literature, the relationship between milder cognitive impairments and
HRT has been examined to some degree.  Most of this type of research focuses on
short-term improvement on cognitive measures in normal women in the relatively
younger age groups.  Available research has found inconsistent effects of HRT on
verbal memory and reasoning, frontal functions and speeded attention (163).  Lack of
test standardization, absence of a full clinical evaluation, small sample size, and limited
inclusion of other covariates are some of the limitations in research up until now and
make generalizations difficult.  The present study has rectified some of the
methodological problems experienced by including a battery of standardized tests,
complete clinical evaluation, and assessment of change over a five-year period.
Other predictors for CIND have emerged from the analysis.  Age, particularly
being over 85 years old, is a strong risk factor for cognitive impairment.  Interestingly,
lower levels of education, current depression, family history of AD, NSAID use, regular
exercise, stroke, and residential status all were significant predictors for all-cause
CIND; all these factors have also been identified in the literature as risk factors for
dementia.
5.1.3.2    Reduced-cause CIND
As with all-cause CIND, HRT did not appear to achieve statistical significance
in this model (95% CI, 0.358-1.887).  It was interesting to compare the more inclusive
all-cause CIND group to the reduced category, since differences in risk factors may
point to distinctive features in the pathology underlying the CIND classification.  As
well, the reduced-cause CIND group is likely more homogenous than the all-cause
group.  Given that the HRT-education interaction persisted for both models, education
is likely an important modifier of HRT’s relationship with cognition.
The finding that HRT status was not a significant predictor for reduced-cause
CIND had to be interpreted cautiously due to interaction effects.   As with the all-cause
CIND model, odds ratios for each level of interaction were calculated.  The finding that
HRT never users with 10-12 years of education are at an increased risk for reduced-
cause CIND as compared to HRT ever users with the same education is puzzling.  It
was anticipated that this type of interactional effect would be found for the lowest level
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of education, which is often implicated as the highest risk category for cognitive
decline.
Several predictors changed when the CIND category was reduced in the model.
Mental retardation, psychiatric illness, and regular shellfish consumption were factors
significant in the all-cause model, but which were no longer significant in the reduced
model.  In comparing the reduced-model to the all-cause model, theoretically it was
thought there would be a difference in terms of HRT’s significance as a predictor.  The
rationale was that by removing some of the causes, the reduced-cause model might be
more similar to the dementia pathology.   No such difference was observed in HRT
status between the two CIND models, however there were variations in which other
covariates achieved significance.
5.1.3.3   CLoND
After consideration of many relevant covariates, HRT status was not found to
significantly predict for CLoND (95% CI, 0.717-1.839).  In this particular model
however, it appeared to interact with family history of AD.  Further exploration of the
interactional effect found that HRT never users with a family history of AD were at a
reduced risk for CLoND as compared to HRT users with a similar family history.  This
finding requires further examination in other study populations given that it may be
spurious.
When comparing the CLoND model to the CIND models, depression, education,
family history of AD, NSAID use, Parkinson’s disease, regular exercise, residential
status, and stroke were all similarly significant throughout the models.  Marital status,
region, and thyroid condition were predictors in the CLoND model, whereas these
variables did not reach significance in the CIND models.  Women who were divorced
or separated were found to be at an increased risk for CLoND.  The CLoND
classification is largely understudied and is a relatively new and not well-understood
concept.  This research attempted to use CLoND to gain a better understanding of the
nature of cognitive decline as it relates to HRT use.  And although there is not a striking
association between HRT and CLoND, the use of the pre-clinical cognitive decline
categories can helps us to further understand the progression from normal cognition to
disease.
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5.1.3.4      Alzheimer’s Disease
Based on the results of the final main effects model, HRT use appears highly
protective for AD.  However, the 95% confidence intervals (CI) are quite wide for the
variables HRT status, education, and for the 75-84 year age group.  The standard error
is also large in comparison to the HRT beta-coefficient.   A large confidence interval
and standard error indicates that the point estimate lacks precision and is unstable.
Since there were only 27 participants with AD that reported having used HRT, it may
be difficult for the model to consider as many covariates as were entered.  Another
possible explanation for the wide 95% CI is that there is interaction present between
education and HRT.  When interaction is assessed, the 95% CI for the levels of the
interaction term become more stable.  Interaction calculations found that HRT was
protective for women with 13 or more years of education, but not for women with other
levels of education.  When calculating risk for the highest educational category (13
years or more), the limited sample made it difficult to obtain an accurate estimate.
Importantly, the fact that fewer AD cases used HRT may strengthen the case for HRT
as a protective factor in disease development, but unfortunately it can also present a
problem for obtaining accurate and precise estimates.  These interaction effects should
be examined in future HRT-cognition research.
The model found that HRT status interacts with education.  Therefore, further
calculations were used to explore the type and strength of this interaction.  It was found
that HRT never users in women with high education (13 years or more) were over ten
times more likely to develop AD than HRT users in the same education category.   It is
difficult to know if this is a spurious finding or if women not using HRT with higher
educational levels are at increased risk for dementia as compared to women with a
similar educational background who use HRT.  In general, persons with higher
education are at the lowest risk for AD, hence even a ten-fold increase may not be
clinically remarkable.
It is difficult to explain these results when considering the variation in study
findings to date.  In the literature reviewed, six of the ten studies revealed a protective
association between HRT and Alzheimer’s disease.  However, these were all
observational research.  The only long-term RCT, which was recently carried out by the
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WHI-MS, found HRT to increase a woman’s risk for dementia (VaD and AD
combined) (47).  A notable limitation of this study was that HRT was administered to
women 65 and older, and although these women may have used HRT previously, the
duration of lifetime HRT use was not considered.  Non-adherence was a problem in this
study as well, with 52% of the sample stopping treatment at some point during the trial.
Finally, many of the participants developed dementia after becoming non-adherent.
Hence, even though RCTs are the gold standard in epidemiology, there are limitations
with the WHI-MS.
There is evidence to suggest that estrogen is the mechanism activating the
cognitive benefits of hormone therapy.  It is also believed that certain forms of
progestins may actually wash out estrogen’s benefits.  In one study it was found that
medroxyprogesterone acetate, a common progestin, blocked estrogen-induced
beneficial effects (132).  Therefore ERT may be more effective than HRT, with
combination therapy actually being unproductive altogether.  With a large portion of
women known to use ERT in this current study’s sample (70%), the findings are
consistent with this hypothesis.  The age group of the sample increases the likelihood
that estrogen-only preparations were used, at least initially, since ERT was the primary
hormone therapy used up until 1975, at which time estrogen-only preparations were
found to increase risk for endometrial cancer (164).  Another sub-component of the
WHI-MS is examining estrogen-only preparations and its affect on dementia; this will
help to decipher the complex connection between type of hormone preparation and
cognitive decline.
5.1.3.5    Vascular Dementia
According to the results of the VaD model, HRT never users are at a
significantly increased risk for disease.  Notably, the effect size for HRT status was
quite sizeable; the 95% confidence interval wide; and arguably, the standard error high.
This is undoubtedly due to the small number of VaD cases.  There were only three VaD
cases that had used HRT and the remaining 26 participants who developed the disease
had never used HRT.  This makes it very difficult to ascertain a precise point estimate
with a narrower confidence interval.  Furthermore, if the sample size had been larger,
other relevant predictors and interaction terms may have emerged that did not reach
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significance in this particular model.  The decision to collapse education into two
categories (6 years or less, 7 years or more), when all other models were constructed
using four, was necessary because of the small numbers.  As discussed previously, the
lower levels of educational attainment have been found to exact the highest degree of
risk and this reclassification of education retained the ability to observe this effect.
Age is preferably used as a categorical variable since it is easier to see its marked effect
when collapsed.  As a continuous variable in this model, age can be seen to have a small
but significant effect each year that one ages.
Research examining HRT’s effect on VaD is limited.  The only known study
including VaD in analysis is the WHI-MS study and it appeared to be protective.
However, the WHI-MS research paper considered AD and VaD cases in combination,
which makes it impossible to decipher HRT’s effects on outcomes individually.
Nonetheless, evidence suggests that HRT has vascular benefits(55, 66), which is
consistent with HRT as a protective factor for the VaD pathology.
1.1.4 Objective #4:  Is the age of onset of dementia later in women having
used HRT than in women never having used HRT?
There are still questions regarding the nature of HRT’s protective effect on
cognition.  Does HRT prevent the development of dementia or simply delay its clinical
onset?  Using linear regression with age of dementia onset as the outcome variable, the
two HRT groups were compared and assessed for differences in timing of AD and VaD
onset.  A linear regression model was fit using age of dementia onset as the outcome.
Analysis found that after controlling for the participants’ age, there was no statistical
association between age of AD onset and HRT use (p=0.628).  Similarly, there was no
significant relationship identified between age of VaD onset and HRT status (p=0.331).
Notably, factors affecting dementia’s clinical onset are not fully understood.  That is, it
is unclear how much damage must occur in the brain prior to symptom presentation and
what factors accelerate or decelerate this process; and if the threshold varies for
different people.  It is known that the APOE-4 allele is predictive of dementia timing,
however this information was not available for analysis.
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1.1.5 Objective #5:  Is there a dose-response relationship between HRT usage
and CIND, CLoND, AD and VaD?
Because some studies have shown length of hormone use to be clinically
important in terms of dementia risk (96, 97, 102, 105), HRT status was broken into
categories according to duration of use.  HRT duration was initially tested using finer
categories and then collapsed more broadly.   Both variables were tested in the all-cause
CIND, reduced-cause CIND, CLoND, and AD models, but did not reach significance.
Interestingly, HRT duration was not significant (p=.257) in the AD model, however,
there was a trend for use less than five years to be protective, whereas use longer than 5
years and no use at all confer similar risk.  The effect of HRT duration could not be
assessed in the VaD model due to small sample size.  Information on the dose
prescribed to each woman was not collected during the CSHA, and therefore this thesis
was unable to look at the effect of dose.
1.2  Study Strengths
The strengths of the CSHA lie with its large sample size, longitudinal and case-
control study design, inclusion of community and institution populations, and the
determination of cognitive status by trained clinicians using standardized measures and
diagnostic criteria.  In terms of the thesis study design, the use of incident cases;
comprehensive inclusion of covariates, confounders, and effect modifiers; thorough
assessment of prevention bias; inclusion of a spectrum of cognitive states; consideration
of HRT’s durational effect and impact on age of disease onset all served to strengthen
the study conclusions and remedy the methodological issues plaguing HRT research.  In
an effort to discern the nature and strength of the association between HRT and
cognition great care was taken to include all necessary risk and confounding factors,
using appropriate statistical modeling strategies and interaction assessment.
Although this sample included older women who are at higher risk for dementia-
related illness and cognitive decline, HRT use was considered at the time when it was
likely most effective.  The recent WHI-MS randomized women ages 65 and older to
HRT, a time when hormones may have a more limited effect since dementia risk rises
dramatically after age 65 indicating that the pathology is already in progress.  The WHI-
MS study may have essentially been assessing HRT’s efficacy as a treatment, rather
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than as a preventive method.   Whereas by using data that describes HRT exposure over
past decades, we are able to capture a more accurate picture of hormone
supplementation as a preventive technique.
1.3 Study Limitations
With any research work, there are certain to be limitations.  It is the type and nature
of these limitations that is key in validating the study’s findings.
1.3.1  Exposure Measurement
The results of the statistical analysis are only as good as the quality of data used
to estimate the effects.  Fortunately, the data collected during the CSHA was
comprehensive and quality was an important consideration.  However, a cohort study by
nature presents unique challenges in terms of accurately capturing an individual’s
exposure history.  Furthermore, missing data is a reality – information missed by
interviewers or by participants in the mail-out questionnaire and individuals unsure or
unwilling to disclose.
Validity is the extent to which a particular indicator measures what it is
supposed to measure.  Clearly, validity is an important issue in the data collection
process.  When requesting information from participants or proxy respondents, certain
questions required a summative answer.  For instance, the question “have you ever
drank wine regularly (at least once/week)” appeared on the baseline risk factor
questionnaire.   Here those responding ‘yes’ were likely not a homogenous group, in
that there will be range with some drinking wine each day for years and others once per
week for a shorter period of time; nonetheless each would have responded ‘yes’.  The
impact of these generalizations cannot be easily assessed, since some exposures may
have an important effect whether used often or intermittently.  Moreover, it may be
impractical to ask participants for an exact value, particularly if one is inquiring about
long periods of time, as was the case here.
Finally, certain information was not obtained at any of the three study phases,
while some data was only asked of the clinical sample.  APOE genotype was an
important and notable limitation. APOE-4 is a definite and important risk factor for
dementia and cognitive impairments.  APOE status was assessed through a blood
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sample for the nested case-control sample during the CSHA, and despite our initial
intention to include the variable APOE, not enough data was available to comfortably
carry out analysis using this smaller sub-sample.  APOE and HRT use may interact,
with women carrying the APOE-4 allele(s) benefiting more from HRT use.
Consideration of this interaction is suggested for future HRT-dementia research.
Variables such as hysterectomy status, age at menopause, and use of phytoestrogens
may have provided an important picture of lifelong estrogen exposure, however were
not available for analysis.
1.3.2 Bias
Out of all observational study designs, the prospective cohort study is the
strongest (131).  In comparison to case-control and cross-sectional studies, it provides
the more compelling case for causation.   Nonetheless, it is not without limitations.
Selection bias, loss to follow-up, and surveillance bias are some of the problems
encountered with cohort studies.
5.3.2.1   Selection Bias
Selection bias results when the probability of the event of interest occurring is
strongly related to how the sample was obtained (131).  In cohort studies, selection bias
is most likely to occur due to lost-to-follow-up.  Since the baseline CSHA sample did
include dementia cases, selection bias could have possibly been introduced. This would
have occurred when a participant refused to participate in a phase of the study due to ill
health or cognitive problems, which may include the outcome of interest or dementia.
This particular study required that the sample was cognitively normal in 1991 and
therefore minimizes the risk of initial selection bias.
Overall, the CSHA sampling design was population-based and representative
(165).  However, it is still possible that individuals choosing not to participate could
have introduced bias.  A study looking at the correlates of nonparticipation in the initial
CSHA sample found that older age, female sex, and living in a large city (>1 million)
were all significantly related to refusal status (166).  Aside from a slightly higher
proportion of high school graduates in the CSHA (45% vs 36%), the demographics of
its baseline sample closely approximated the 1991 Census (165).
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5.3.2.2   Loss to Follow-up
By nature, cohort studies will tend to lose a number of participants due to a wide
range of reasons.  Dementia increases mortality risk, therefore participants who died
between study phases may have developed dementia without the CSHA knowing.  As a
result, cause of death information was obtained for all participants dying between and
during study phases.  From a decedent interview and death certificate, an algorithm was
used to determine cognitive status at the time of death.  Because people who died before
CSHA-2 were not questioned about their HRT status, this thesis work was not able to
include this decedent information as a proxy diagnosis, but instead this group was
removed from the sample.  Therefore, these incident dementia cases presenting between
CSHA-1 and –2 would therefore be missed.  It is possible then that this has resulted in a
‘survival sample’, where the participants are healthier than those lost to follow-up.  The
concern is that women who did not participate at follow-up were different from women
who remained in this study.  Moreover, if HRT does confer a survival benefit (136),
then women in this sample not using HRT may be hardier than other HRT users, which
may have lead to underestimation of HRT’s effects.
5.3.2.3 Surveillance Bias
Surveillance bias occurs when one group is studied more closely than the other
(131).  In this way, more exposures or conditions may be found in one group when they
are equally present in the other.  This could happen with both the outcomes and
exposures.  Because all participants were screened in the same manner and followed a
very similar diagnostic protocol, it is less likely this would have occurred biasing the
outcome.  Although exposure information may have been more complete for those
attending a clinical assessment, particularly since both an informant interview and a
clinician’s history were completed for each participant.
5.3.2.4 Information Bias
Two forms of information bias are recall and misclassification bias.  Both are
recognized limitations to this present study and must be considered when interpreting
the findings.
Some variables within the CSHA dataset were collected prospectively, while
others required participants to recall past illness and exposure.  An inherent risk in the
104
latter approach is introducing recall bias.  HRT status was obtained by asking women to
recall past and present use of HRT.  Information recalled years or even decades prior is
likely to be imperfect.  It is difficult to know if certain women were systematically
under-reporting exposure while other women were over-reporting exposure.  As
mentioned previously, information on the type of hormone therapy utilized was omitted
from analysis because of large amounts of missing and vague (eg. “hormones”) data.
Because information on the type of HRT was not complete and therefore was not
considered in analysis, the results are not specific to one preparation or another.
Notably, most HRT users (70%) reported taking ERT and this is consistent with the
more prevalent use of estrogen-only preparations in decades prior.   Interestingly, it is
more likely that participants would have forgotten an exposure than to have fabricated
information (131).  Hence, one might postulate that women reporting HRT use would
be supplying fairly accurate information. Intuitively, one might suspect that if women
reported ‘never use’, this would be either correct or their use of HRT was for a limited
duration.  Some studies have used prescription databases to crosscheck participants’
reports of HRT use.  This was beyond the scope of this thesis study and therefore we
were unable to verify HRT self- and proxy-reported information.
Misclassification bias can occur either by misclassifying exposures, disease, or
both.  Differential misclassification is a potential concern in this study.  This happens
when the frequency of under-reporting is different for cases or controls.  Since time-2
information for participants with dementia was obtained from a proxy respondent, it is
possible that the proxy’s data would be less accurate than if given by the participant
herself.  That is, the proxy may not have been aware of HRT use.  Encouragingly, when
kappa values were run for HRT status, where cognitively normal participants and their
proxy respondents answered the HRT question, the kappa agreement was quite high
(kappa=.801).  This means that there was a high level of correlation between the two
responses, and may indicate that proxy respondents supply quite accurate history on
medication usage.
Regrettably, kappa values were not strong for all exposures.  As one might
expect, proxy respondents seemed to be less aware of certain exposures or health
conditions.   For instance, the variables for occupational exposures to glues, pesticides
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and solvents had low kappa agreement; as did the variables for diptheria, polio and
tetanus shots.  This is likely due to the fact that these exposures would have occurred
earlier in the participants’ life making proxies less aware of them.  The quality of the
data then may affected the inclusion of the variables in the final models; that is,
occupational exposures cannot be ruled out as risk factors, and the association between
tetanus shots and cognitive status requires further investigation.  When the kappa values
were low, one would expect that the data collected from the participants were of higher
quality, which means data for participants with dementia would be less accurate than for
the cognitively normal participants.
5.3.2.5 Statistical Power
Statistical power determines the maximum effect size detectable by the study.
Here statistical power was quite low for the outcome of VaD.  This was a result of the
minimal number of incident cases at follow-up and was unavoidable.  Small sample size
very likely limited the ability to control for interactions and to identify other relevant
covariates.  However, the model indicated that HRT was a strong predictor of VaD and
therefore HRT status was found to be a significant risk factor.  Since the effect size was
quite large for HRT, low statistical power did not appear to be an important concern.
5.4  Implications for Future Research
It is not prudent to treat HRT users as one homogenous group, nor it is safe to
assume that one preparation is equivalent to another.  Future research would be wise to
focus on the type of hormone therapy – estrogen-only versus estrogen-progestin
combinations – separately and to specify the means of administration (eg. pill, patch,
cream).  Although the current study did not find a significant duration effect, it is very
likely that the length of HRT use impacts both positive and negative health outcomes.
Interestingly, research indicates that use of HRT greater than five years increases HRT
users’ risk for breast cancer (30), and similarly we found a trend for HRT to have a
greater cognitive benefit when used for less than five years.  Future research should
ensure that study samples include adequate numbers for each level of duration in order
to adequately examine the effect of length of use.  Finally, an interesting and potentially
valuable interaction may exist between HRT use and APOE status.  That is, women at
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increased risk due to APOE-4 genotype may benefit more from HRT use than those not
having an E4 allele(s).  Unfortunately, we were not able to assess this interaction due to
sample size limitations for participants having APOE information.  Additional studies
may want to use datasets where APOE status is available in adequate numbers in order
to investigate this potential interaction effect.  As with research in general, the
importance of good quality study designs and the inclusion of relevant risk and
confounding factors cannot be overstated.  In the case of HRT research, conflicting
results have led to considerable confusion in terms of what the risks and benefits of
HRT truly are.
5.5 Implications for Women: The Decision to Use HRT or Not
Understanding the relationship between HRT and cognitive decline is highly
relevant to clinicians and women in general.  Doctors and researchers need to know if
HRT, in fact, does have a protective effect on cognition and if this effect is clinically
significant.  A February poll commissioned by Eli Lilly Canada in 2003 found that
forty-four per cent of women using hormone replacement therapy have stopped taking it
in the past year, and another 32 per cent say they will discontinue it in the coming
months (167).  This is likely the result of the recent flood of negative and discouraging
research indicating HRT users are at an increased risk for a variety of serious illnesses
and this cannot or should not be overlooked.  Therefore the results of the present study
must be put into context.  The protective effect found for dementia-related diseases
should not take precedence over other negative and serious illness-inducing effects.
Klein & Dumble (1994) put forth a portrayal of the demoralizing effects that HRT as a
treatment for menopause may have on women and the confusion that may accompany
the choice to use HRT (168).
“Rigid in their ‘happy’ state, heterosexually active because they must,
running from mammography to bone density test to endometrial biopsy,
coping with migraines, hypertension, and weight gain; stressed out from
surviving the cancer scare which resulted in a breast biopsy --- all from a
drug prevention of osteoporosis and heart attacks which they may never
get?  It is, we suggest, real live midlife women – albeit so far mainly
western middle-class women – who today are pressured to feel guilty
even if they don’t go on HRT and often still feel guilty if they do.”
(p.339-40).
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The same can be said for dementia. While identifying the cognitive advantages
of HRT is an essential element of each woman’s risk-benefit considerations, there is
presently no accurate way to predict which women are at risk for dementia at the time
of menopause, when HRT use is likely most effective.  Consequently, many women
would be unnecessarily relying on HRT for the prevention of a disease they may never
develop.  Furthermore, it is important to consider if the cognitive benefits override the
other potentially harmful adverse effects.  Until the time where we are able to more
accurately discern which women would receive the greatest benefits from HRT
supplementation, we run the risk of coercing all women – regardless of necessity – to
use a therapy that is unsafe for certain sub-groups and questionably effective.  We may
also further the notion that menopause is an illness and potentially affect how women
view this phase of their lives.
On the other hand, if estrogen, which seemed to be the predominantly used
preparation in this study, is protective against cognitive decline then this knowledge
cannot be dismissed either.  It may be that there are certain routes of hormones
administration that are more beneficial, with fewer side effects.  For instance, non-
systemic forms of progesterone have been found to benefit some women without having
to travel throughout their bodies, thus minimizing negative side effects such as
increased risk of breast cancer, but still countering the increased risk of endometrial
cancer.  As well, the FDA recently approved a lower-dose version of combination HRT
therapy (169).  PremproTM, made by Wyeth Pharmaceuticals, was revised probably with
the hope of decreasing the risk for negative long- and short-term outcomes.  The new
lower-dose appears to be just as effective as the higher, more commonly prescribed
dosage for the reduction of menopausal symptoms such as hot flashes (170).  It is yet to
be seen if lower-doses of HRT will qualitatively improve the viability of HRT as a
treatment of women’s menopausal concerns, or if this old-made-new technology is very
much similar to the currently used preparations.  Based on one clinical trial showing
HRT to be relatively unsafe and ineffective for the prevention of dementias, we cannot
close the book on hormone supplementation.  But neither can we mass prescribe a
substance that may only be appropriate and pertinent to certain sub-groups of women.
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The role of physicians in society is unquestionably powerful.  This reality must be
seriously considered when counseling individual women on the use of HRT, and
physicians must be responsible to keep up-to-date on current research and the hormone
controversies.  This will be the only way that practitioners can give adequate counseling
to their female patients on a case-by-case basis.  In the end, each woman will decide for
herself if HRT is the necessary and appropriate intervention for her menopausal
concerns.  Therefore it is imperative that women are armed with quality evidence and
thereby given a clearer and fuller picture to aid in this complex, obscure, and highly
personal decision.
Prevention bias can teach us a good deal in terms of the maintenance and
enhancement of women’s health as they age.  Women using HRT appeared to have
some characteristics, behaviours, and health profiles that likely confer benefits beyond
our ability to control.    However, these differences may equally contribute to wellness
over-and-above the use of hormone supplements.  Therefore one must be cautious in
contributing HRT use solely to the cognitive benefits observed, when in fact, a lifetime
of lifestyle decisions, behaviours, and environments doubtlessly play a significant role
in determining cognitive status and the overall health of women as they age.  It may be
that an exclusive focus on medical intervention is shortsighted, when a concentration on
lifestyle modification and healthy living would be more fruitful.
HRT has been confirmed here as a protective factor in the development of AD
and VaD and this cannot be disregarded.  Considering the sizeable increase in the
number of dementia sufferers expected in future years, the economic and social cost of
care provision, and the burden placed on the health care system, a genuine risk
reduction would be of tremendous public health importance (19).  In terms of using
HRT as a prevention technique, future research would do well to focus on a means of
administering estrogen in a safer manner.  Mounting dementia research will help to
identify women at the greatest risk for disease, with certain portions of the female
population being more likely to require medical intervention to maintain normal
cognitive functioning.  Unquestionably, identifying the cognitive advantages of HRT is
an essential element of each woman’s risk-benefit considerations in terms of hormone
use after menopause, but still it remains only one piece of the puzzle.
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Heart Attack-1 2423
(72)
234
(7)
68
(2)
103
(3)
117
(3)
Diabetes-1 2185
(65)
236
(7)
936
(28)
27
(1)
Diabetes-2 3029
(90)
348
(10)
Stroke-1 2095
(62)
230
(7)
1015
(30)
42
(1)
Stroke-2 3156
(93)
21
(1)
194
(6)
High Blood
Pressure-1
2377
(62)
226
(7)
739
(22)
41
(1)
High Blood
Pressure-2
Parkinson’s
disease-1
2135
(63)
239
(7)
985
(29)
23
(1)
Parkinson’s
disease-2
3163
(93)
188
(5)
Thyroid Condition 2241
(66)
234
(7)
93
(3)
769
(23)
Arthritis 2431
(72)
216
(6)
708
(21)
Kidney Disease 2161
(64)
232
(7)
962
(28)
Epilepsy 2137
(63)
236
(7)
74
(2)
245
(7)
Self/ Proxy
Reported
Depression-1
2151
(64)
251
(7)
58
(2)
Self/ Proxy
Reported
Depression-2
2067
(61)
1065
(31)
Other Psychiatric
Illness
2079
(61)
267
(8)
975
(29)
58
(2)
Age 3384
(100)
Education 3371
(100)
Income 2267
(67)
332
(10)
164
(5)
Marital Status-1 2757
(81)
229
(7)
374
(11)
22
(1)
Marital Status-2 3205
(95)
174
(5)
124
Smoking Status 2670
(79)
238
(7)
31
(1)
134
(4)
Regular Spirit
Drinking
2671
(79)
213
(6)
Regular Wine
Drinking
2665
(79)
215
(6)
Regular Coffee
Drinking
2721
(80)
227
(7)
Regular Tea
Drinking
2715
(80)
223
(7)
Regular Shellfish
Consumption
2673
(79)
218
(6)
Regular Exercise 2688
(79)
230
(7)
Regular use of
Painkillers
2640
(78)
185
(5)
HRT Use 2364
(70)
1020
(30)
APOE 707
Family History of
AD
2400
(71)
207
(6)
407
(12)
Family History of
Senile Dementia
2469
(73)
231
(7)
23
(1)
Family History of
Mongolism
2364
(70)
232
(7)
Family History of
Mental Retardation
2350
(69)
230
(7)
Exposure to Glues 2445
(72)
239
(7)
Exposure to
Solvents
2480
(73)
203
(6)
Exposure to
Pesticides
2479
(73)
206
(6)
Flu shot 2600
(77)
220
(7)
Polio shot 2516
(74)
218
(7)
Diptheria shot 2485
(73)
220
(7)
Tetanus shot 2518
(74)
218
(7)
Head Injury 2517
(74)
217
(7)
69
(2)
158
(5)
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BIVARIATE ANALYSIS:  HRT USERS COMPARED TO HRT NEVER USERS
Variable HRT Users
(n=909)
HRT Never Users
(n=2475)
p-value
Health Conditions
YesHeart Attack-1
No
51 (6)
678 (75)
*180 (20)
177 (7)
1804 (73)
*494 (20)
.107
YesOther Heart Condition-1
No
171 (19)
508 (56)
*230 (25)
376 (15)
1362 (55)
*737 (30)
.061
YesDiabetes-1
No
76 (8)
833 (92)
*0
232 (9)
2243 (91)
*0
.364
YesDiabetes-2
No
90 (10)
817 (90)
*2 (0)
326 (13)
2144 (87)
*5 (0)
.010
YesStroke-1
No
40 (4)
868 (95)
*1 (0)
94 (4)
2380 (96)
*1 (0)
.424
YesStroke-2
No
73 (8)
833 (92)
*1 (0)
202 (8)
2263 (91)
*10 (0)
.897
YesHigh Blood   Pressure-1
No
366 (40)
543 (60)
*0
989 (40)
1485 (60)
*1 (0)
.879
YesHigh Blood Pressure-2
No
415 (46)
493 (54)
*1 (0)
1085 (44)
1381 (56)
*9 (0)
.376
YesParkinson’s disease-1
No
9 (1)
899 (99)
*1 (0)
25 (1)
2449 ()
*1 (0)
.960
YesParkinson’s disease-2
No
18 (2)
885 (97)
6 (1)
57 (2)
2407 (97)
1 (0)
.577
YesThyroid disease-1
No
188 (21)
566 (62)
*155 (17)
371 (15)
1662 (67)
*442 (18)
.000
YesArthritis-1
No
608 (67)
295 (32)
*6 (1)
1514 (61)
938 (38)
*23 (1)
.003
YesKidney disease-1
No
132 (15)
771 (85)
*6 (1)
242 (10)
2210 (89)
*23 (1)
.000
YesEpilepsy-1
No
5 (1)
722 (79)
*182 (20)
26 (1)
1939 (78)
*510 (21)
.170
YesSelf or Proxy Reported
Depression-1
No
124 (14)
570 (63)
*215 (24)
251 (10)
1515 (61)
*709 (29)
.023
YesSelf or Proxy Reported
Depression-2 No
114 (13)
726 (80)
69 (8)
277 (11)
2015 (81)
183 (7)
.265
YesOther Psychiatric Illness-1
No
227 (25)
681 (75)
*1 (0)
538 (22)
1933 (78)
*4 (0)
.047
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Demographic Information
Age-1 65 to 74 yrs
75 to 84 yrs
85 yrs & over
594 (64)
279 (31)
36 (4)
*0 (0)
1061 (43)
1117 (45)
297 (12)
*0 (0)
.000
Age-2 65 to 74 yrs
75 to 84 yrs
85 yrs & over
355 (39)
451 (50)
103 (11)
*0 (0)
568 (23)
1236 (50)
671 (27)
*0 (0)
.000
Marital Status-1 Currently /
Common Law
Divorced/ Separated
Widowed
Never
425 (47)
48 (5)
365 (40)
71 (8)
*0
869 (35)
93 (4)
1277 (52)
234 (9)
*2 (0)
.000
Marital Status-2 Currently /
Common Law
Divorced/ Separated
Widowed
Never
331 (36)
48 (5)
459 (50)
70 (8)
*1 (0)
634 (26)
76 (3)
1524 (62)
237 (10)
*4 (0)
.000
Education 6 yrs & under
7 – 9 yrs
10 –12 yrs
13 + yrs
100 (11)
222 (24)
342 (38)
243 (27)
*2 (0)
309 (12)
687 (28)
889 (36)
579 (23)
*11 (0)
.057
Income-2 < $19,999
$20,000- 34,999
$35,000- 49,999
$50,000 and over
369 (41)
233 (26)
105 (12)
75 (8)
*127 (14)
1181 (48)
485 (20)
190 (8)
128 (5)
*491 (20)
.000
RuralRural/Urban
Urban
80 (9)
827 (91)
*2 (0)
273 (11)
2196 (89)
*6 (0)
.060
Region-1 Atlantic
Quebec
Ontario
Prairies
B.C.
136 (15)
223 (25)
160 (18)
203 (22)
187 (21)
513 (21)
488 (20)
491 (20)
541 (22)
442 (18)
.000
Region-2 Atlantic
Quebec
Ontario
Prairies
B.C.
135 (15)
223 (25)
163 (18)
200 (22)
188 (21)
513 (21)
485 (20)
494 (20)
539 (22)
444 (18)
.000
InstitutionResidential Status-1
Community
18 (2)
891 (98)
*0 (0)
91 (4)
2384 (96)
*0 (0)
.013
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InstitutionResidential Status-2
Community
43 (5)
866 (95)
*0 (0)
258 (10)
2217 (90)
*0 (0)
.000
Lifestyle Factors
YesRegular Smoker
No
343 (38)
503 (55)
*63 (7)
744 (30)
1484 (60)
*247 (10)
.000
YesRegular Spirit Drinking
No
182 (20)
631 (69)
*96 (11)
315 (13)
1767 (71)
*393 (16)
.000
YesRegular Wine Drinking
No
139 (15)
679 (75)
*91 (10)
265 (11)
1807 (73)
*403 (16)
.003
YesRegular Coffee drinking
No
608 (67)
214 (24)
*87 (10)
1446 (58)
679 (27)
*350 (14)
.002
YesRegular Tea drinking
No
600 (66)
222 (24)
*87 (10)
1553 (63)
563 (23)
*359 (15)
.826
YesRegular Shellfish
Consumption
No
183 (20)
628 (69)
*98 (11)
423 (17)
1658 (67)
*394 (16)
.184
YesRegular exercise
No
557 (61)
257 (28)
*95 (10)
1327 (54)
777 (31)
*371 (15)
.007
YesVitamin E
No
96 (11)
739 (81)
*74 (8)
119 (5)
2051 (83)
*305 (12)
.000
YesVitamin C
No
86 (10)
749(82)
*74 (8)
114 (5)
2056 (83)
*305 (12)
.000
YesVitamin B
No
37 (4)
798 (88)
*74 (81)
78 (3)
2092 (85)
*305 (12)
.284
YesMulti-vitamin
No
194 (21)
641 (71)
*74 (8)
334 (13)
1836 (74)
*305 (12)
.000
Medication Usage
YesRegular Painkiller Use
No
453 (50)
363 (40)
*93 (10)
1059 (43)
1003 (41)
*413 (17)
.039
YesStatins
No
26 (3)
809 (89)
*74 (8)
42 (2)
2128 (86)
*305 (12)
.052
Other Exposures
YesPast Head Injury
No
115 (13)
680 (75)
*114 (13)
285 (12)
1867 (75)
*323 (13)
.440
YesOccupational Exposure to
Glues No
67 (7)
695 (76)
*147 (16)
154 (6)
1768 (71)
*553 (22)
.507
YesOccupational Exposure to
Solvents No
52 (6)
714 (79)
*143 (16)
143 (6)
1774 (72)
*558 (23)
.545
YesOccupational Exposure to
Pesticides No
56 (6)
710 (78)
*143 (16)
143 (6)
1776 (72)
*556 (22)
.900
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YesInfluenza Shot
No
470 (52)
326 (36)
*113 (12)
1084 (44)
940 (38)
*451 (18)
.008
YesPolio Shot
No
224 (25)
535 (59)
*150 (17)
459 (19)
1516 (61)
*500 (20)
.001
YesDiptheria Shot
No
196 (22)
550 (61)
*163 (18)
413 (17)
1546 (62)
*516 (21)
.004
YesTetanus Shot
No
275 (30)
489 (54)
*145 (16)
503 (20)
1469 (59)
*503 (20)
.000
*missing data
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BIVARIATE ANALYSIS:  CLOND VERSUS COGNITIVELY NORMAL
Variable Cognitively Normal-2
(n=2686)
CLoND
(n=235)
P-value
Health Conditions
YesHeart Attack-1
No
171 (6)
1881 (70)
*634 (24)
24 (10)
206 (88)
*5 (2)
.280
YesDiabetes-1
No
236 (9)
2450 (91)
*0
23 (10)
212 (90)
*0
.605
YesDiabetes-2
No
323 (12)
2359 (88)
*6 (0)
33 (14)
202 (86)
*0
.369
YesStroke-1
No
79 (3)
2605 (97)
*2 (0)
22 (9)
213 (91)
*0
.000
YesStroke-2
No
160 (6)
2515 (94)
*11 (0)
47 (20)
187 (80)
*1 (0)
.000
YesHigh Blood Pressure-1
No
1067 (40)
1619 (60)
*0
104 (44)
131 (56)
*0
.174
YesHigh Blood Pressure-2
No
1161 (43)
1515 (56)
*10 (0)
120 (51)
115 (49)
*0
.023
YesParkinson’s disease-1
No
14 (1)
2670 (99)
*2 (0)
6 (3)
229 (97)
*0
.000
YesParkinson’s disease-2
No
49 (2)
2621 (98)
*16 (1)
10 (4)
225 (96)
*0
.012
YesThyroid Condition-1
No
455 (17)
1633 (61)
*598 (22)
27 (11)
198 (84)
*10 (4)
.001
YesArthritis-1
No
1683 (63)
995 (37)
*8 (0)
148 (63)
81 (34)
*6 (3)
.592
YesKidney Disease-1
No
288 (11)
2387 (89)
*11 (0)
39 (17)
190 (81)
*6 (3)
.004
YesEpilepsy-1
No
17 (1)
2009 (89)
*11 (0)
3 (1)
232 (99)
*0
.498
YesSelf or Proxy Reported
Depression-1
No
259 (10)
1693 (63)
*734 (27)
34 (14)
138 (59)
*63 (27)
.018
YesSelf or Proxy Reported
Depression-2 No
241 (9)
2219 (83)
*226 (8)
53 (23
182 (77)
*0
.000
YesOther Psychiatric Illness
No
544 (20)
2139 (80)
*5 (0)
72 (31)
161 (69)
*2 (1)
.000
Demographic Information
Age-1 65-74
75-84
85 & over
857 (32)
1403 (52)
426 (16)
*0
17 (7)
106 (45)
112 (48)
*0
.000
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Age-2 65-74
75-84
85 & over
1492 (56)
1042 (39)
152 (6)
*0
55 (23)
125 (53)
55 (23)
*0
.000
Marital Status-1 Currently/
Common Law
Separated/
Divorced
Widowed
Never
1125 (42)
115 (4)
1203 (45)
241 (9)
*2 (0)
55 (23)
14 (6)
147 (63)
19 (8)
*0
.000
Marital Status-2 Currently/
Common Law
Separated/
Divorced
Widowed
Never
856 (32)
101 (4)
1482 (55)
242 (9)
*5 (0)
37 (16)
12 (5)
167 (71)
19 (8)
*0
.000
Education 6 yrs & under
7-9 yrs
10-12 yrs
13 + yrs
245 (9)
699 (26)
1016 (38)
717 (27)
*9 (0)
66 (28)
59 (25)
75 (32)
34 (15)
*1 (0)
.000
Income <$19,999
$20,000- 34,999
$35,000- 49,999
$50,000 +
1161 (43)
646 (24)
271 (10)
189 (7)
*419 (16)
136 (58)
31 (13)
12 (5)
2 (1)
*54 (23)
.000
RuralRural/ Urban
Urban
273 (10)
2409 (90)
*6 (0)
26 (11)
208 (89)
*1 (0)
.652
Region-1 Atlantic
Quebec
Ontario
Prairies
B.C.
486 (18)
532 (20)
529 (20)
606 (23)
533 (20)
30 (13)
86 (37)
57 (24)
34 (15)
28 (12)
.000
Region-2 Atlantic
Quebec
Ontario
Prairies
B.C.
484 (18)
530 (20)
523 (20)
603 (22)
536 (20)
*0
30 (13)
85 (37)
58 (25)
34 (15)
28 (12)
*0
.000
InstitutionResidential
Status-1 Community
38 (1)
2648 (99)
*0
22 (9)
213 (91)
*0
.000
InstitutionResidential
Status-2 Community
105 (4)
2581 (96)
*0
46 (20)
189 (80)
*0
.000
Lifestyle Factors
YesSmoking Status
No
905 (34)
1493 (56)
*288 (11)
62 (27)
171 (73)
*2 (1)
.001
YesRegular Spirit Drinking
No
426 (16)
1917 (71)
*343 (13)
24 (10)
176 (75)
*35 (15)
.028
132
YesRegular Wine Drinking
No
354 (13)
1984 (74)
*348 (13)
21 (9)
181 (77)
*33 (14)
.068
YesRegular Coffee Drinking
No
1707 (64)
674 (25)
*305 (11)
144 (61)
61 (26)
*30 (13)
.659
YesRegular Tea Drinking
No
1721 (64)
657 (24)
*308 (11)
147 (63)
54 (23)
*34 (14)
.816
YesRegular Shellfish
Consumption
No
524 (20)
1825 (68)
*337 (13)
24 (10)
172 (73)
*39 (17)
.001
YesVitamin E
No
198 (7)
2226 (83)
*262 (10)
6 (3)
200 (85)
*29 (12)
.007
YesVitamin C
No
180 (7)
2244 (84)
*262 (10)
9 (4)
197 (84)
*29 (12)
.103
YesVitamin B
No
99 (4)
2325 (87)
*262 (10)
8 (4)
198 (84)
*29 (12)
.889
YesMulti-vitamin
No
455 (17)
1969 (73)
*262 (10)
30 (13)
176 (75)
*29 (12)
.135
YesRegular Exercise
No
1602 (60)
754 (28)
*330 (12)
95 (40)
104 (44)
*36 (15)
.000
YesHead Injury
No
326 (12)
1957 (73)
*403 (15)
37 (16)
196 (83)
*2 (1)
.543
Medication Usage
EverHRT Use
Never
787 (29)
1899 (71)
*0
50 (21)
185 (79)
*0
.009
HRT Duration <12 mths
13 mths – 5 yrs
61 mths – 10 yrs
>121 mths
.086
Age at First HRT
Use
40 yrs & under
41-50 yrs
51 – 60 yrs
60 yrs & over
.574
YesNSAID Use
No
492 (18)
1852 (69)
*342 (13)
30 (13)
158 (67)
*47 (20)
.101
YesStatins
No
63 (2)
2361 (75)
*533 (20)
2 (1)
204 (87)
*29 (12)
.148
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Familial and Genetic Factors
APOE Genotype One or Two E2
E3/E3
One E4
Two E4
.794
YesFamily History of AD
No
132 (5)
2021 (75)
*533 (20)
23 (10)
207 (88)
*5 (2)
.024
YesFamily History of Senile
Dementia No
133 (5)
1982 (74)
*571 (21)
9 (4)
197 (84)
*29 (12)
.272
YesFamily History of
Mongolism
No
22 (1)
2076 (77)
*588 (22)
4 (2)
181 (77)
*50 (21)
.171
YesFamily History of Mental
Retardation No
35 (1)
2038 (76)
*613 (23)
5 (2)
173 (74)
*57 (24)
.277
Other Exposures
YesOccupational Exposure to
Glues No
189 (7)
2019 (75)
*478 (18)
12 (5)
154 (66)
*69 (29)
.552
YesOccupational Exposure to
Solvents No
159 (6)
2049 (76)
*478 (18)
10 (4)
155 (66)
*70 (30)
.583
YesOccupational Exposure to
Pesticides No
169 (6)
2043 (76)
*474 (18)
6 (3)
160 (68)
*69 (29)
.055
YesInfluenza Shot
No
1255 (47)
1015 (38)
*416 (15)
104 (44)
87 (37)
*44 (19)
.823
YesPolio Shot
No
618 (23)
1589 (59)
*479 (18)
23 (10)
159 (68)
*53 (23)
.000
YesDiptheria Shot
No
551 (21)
1623 (60)
*512 (19)
22 (9)
162 (69)
*51 (22)
.000
YesTetanus Shot
No
709 (26)
1496 (56)
*481 (18)
30 (13)
154 (66)
*51 (22)
.000
Includes Cases of CLoND in Reduced-Cause CIND group; compared to all normals without CLoND
*missing data
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BIVARIATE ANALYSIS:  ALL-CAUSE CIND VERSUS COGNITIVELY NORMAL
Variable Cognitively Normal-2
(n=2698)
CIND-2
(n=390)
p-value
Health Conditions
YesHeart Attack-1
No
171 (6)
1893 (70)
*634 (23)
32 (8)
347 (89)
*11 (2)
.918
YesDiabetes-1
No
237 (9)
2461 (91)
* 0
43 (11)
347 (89)
*0
.150
YesDiabetes-2
No
324 (12)
2370 (88)
*4 (0)
59 (15)
331 (85)
*0 (0)
.083
YesStroke-1
No
80 (3)
2616 (97)
*2 (0)
33 (8)
357 (92)
*0
.000
YesStroke-2
No
162 (6)
2525 (93)
*11 (0)
67 (17)
322 (83)
*1 (0)
.000
YesHigh Blood Pressure-1
No
1071 (40)
1627 (60)
*0
161 (41)
228 (58)
*1 (0)
.524
YesHigh Blood Pressure-2
No
1167 (43)
1521 (56)
*10 (0)
188 (48)
202 (52)
*0
.075
YesParkinson’s disease-1
No
14 (1)
2682 (99)
*2(0)
14 (4)
376 (96)
*0
.000
YesParkinson’s disease-2
No
49 (2)
2633 (98)
16 (1)
17 (4)
372 (95)
1 (0)
.001
YesThyroid Condition-1
No
455 (17)
1645 (61)
*598 (22)
51 (13)
318 (82)
*21 (5)
.001
YesArthritis-1
No
1691 (63)
999 (37)
8 (0)
245 (63)
132 (34)
*13 (3)
.423
YesKidney Disease-1
No
289 (11)
2398 (89)
*11 (0)
53 (14)
325 (83)
*12 (3)
.059
YesEpilepsy-1
No
17 (1)
2021 (75)
*660 (24)
6 (2)
375 (96)
*9 (2)
.172
YesSelf or Proxy Reported
Depression
No
259 (10)
1701 (63)
*738 (27)
67 (17)
222 (57)
*101 (26)
.000
YesSelf or Proxy Reported
Depression-2 No
243 (9)
2229 (83)
226 (8)
82 (21)
300 (77)
8 (2)
.000
YesOther Psychiatric Illness
No
545 (20)
2150 (80)
*3 (0)
137 (35)
251 (64)
*2 (1)
.000
Demographic Information
Age-1 65-74
75-84
85 & over
1493 (55)
1049 (39)
156 (6)
114 (29)
189 (48)
87 (22)
.000
Age-2 65-74
75-84
85 & over
857 (32)
1406 (52)
435 (16)
45 (12)
172 (44)
173 (44)
.000
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Marital Status-1 Currently/ Common
Law
Separated/ Divorced
Widowed
Never
1125 (42)
116 (4)
1212 (45)
243 (9)
*2 (0)
91 (23)
23 (6)
238 (61)
37 (9)
*1 (0)
.000
Marital Status-2 Currently/
Common Law
Divorced/ Separated
Widowed
Never
856 (32)
101 (4)
1492 (55)
244 (9)
*5(0)
62 (16)
18 (5)
273 (70)
37 (9)
*0 (0)
.000
Education 6 yrs & less
7-9 yrs
10-12 yrs
13 + yrs
248 (9)
703 (26)
1020 (38)
718(27)
*9 (0)
103 (26)
113 (29)
120 (31)
53 (14)
*1 (0)
.000
Income <$19,999
$20,000- 34,999
$35,000- 49,999
$50,000 +
1167 (43)
648 (24)
272 (10)
189 (7)
*422 (16)
229 (59)
43 (11)
13 (3)
7 (2)
*98 (25)
.000
RuralRural/ Urban
Urban
275 (10)
2419 (90)
*4 (0)
45 (12)
344 (88)
*1 (0)
.411
Region-1 Atlantic
Quebec
Ontario
Prairies
B.C.
490 (18)
535 (20)
529 (20)
606 (22)
538 (20)
72 (18)
116 (30)
74 (19)
66 (17)
62 (16)
.000
Region-2 Atlantic
Quebec
Ontario
Prairies
B.C.
488 (18)
533 (20)
533 (20)
603 (22)
541 (20)
72 (18)
115 (29)
75 (19)
66 (17)
62 (16)
.000
InstitutionResidential Status-1
Community
38 (1)
2660 (99)
*0
40 (10)
350 (90)
*0
.000
InstitutionResidential Status-2
Community
106 (4)
2592 (96)
*0
85 (22)
305 (78)
*0
.000
Lifestyle Factors
YesSmoking Status
No
908 (34)
1500 (56)
*290 (11%)
104 (27)
281 (72)
*5 (1)
.000
YesRegular Spirit Drinking
No
428 (16)
1924 (71)
*346 (13)
45 (12)
275 (71)
*70 (18)
.069
YesRegular Wine Drinking
No
356 (13)
1991 (74)
*351 (13)
32 (8)
290 (74)
*68 (17)
.013
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YesRegular Coffee Drinking
No
1711 (63)
679 (25)
*308 (11)
210 (54)
116 (30)
*64 (16)
.008
YesRegular Tea Drinking
No
1726 (64)
660 (24)
*312 (12)
239 (61)
80 (21)
*71 (18)
.331
YesRegular Shellfish Consumption
No
525 (19)
1831 (68)
*342 (13)
41 (11)
273 (70)
*76 (19)
.000
YesVitamin E
No
198(7)
2235(83)
*65 (10)
10(3)
321(82)
*59 (15)
.001
YesVitamin C
No
180(7)
2253(84)
*265 (10)
13(3)
318 (82)
*59 (15)
.020
YesVitamin B
No
99 (4)
2334 (87)
*265 (10)
10 (3)
321 (82)
*59 (15)
.358
YesMulti-vitamin
No
457(17)
1976 (73)
*265 (10)
37 (9)
294 (75)
*59 (15)
.001
Yes
No
Regular Exercise
No
1607 (60)
758 (28)
*333 (12)
164 (42)
158 (41)
*68 (17)
.000
YesHead Injury
No
328 (12)
1967 (73)
*403 (15)
61 (16)
327 (84)
*2 (1)
.459
Medication Usage
EverHRT Use
Never
791 (29)
1907 (71)
*0
72 (18)
318 (82)
*0
.000
HRT Duration <12 mths
13 mths – 5 yrs
61 mths – 10 yrs
>121 mths
196 (25)
205  (26)
91  (12)
208 (26)
*91 (12)
21 (29)
14 (19)
5 (7)
9 (13)
*23 (32)
.121
Age at First HRT
Use
40 yrs & under
41-50 yrs
51 – 60 yrs
60 yrs & over
109 (14)
352 (45)
189 (24)
90 (11)
*51 (6)
12 (17)
26 (36)
16 (22)
8 (11)
*10 (14)
.747
YesRegular use of
Painkillers
No
1231 (60)
1122 (42)
*345 (13)
153 (39)
148 (38)
*89 (23)
.627
YesStatins
No
63(2)
2370(88)
*265 (10)
3(1)
328(84)
*59 (15)
.060
Familial and Genetic Factors
One or
Two E2
E3/E3
One E4
APOE Genotype
Two E4
40
229
71
1
31
146
48
1
.751
YesFamily History of AD
No
132 (5)
2029 (75)
*537 (20)
36 (9)
341 (87)
*13 (3)
.013
137
YesFamily History of Senile
Dementia
No
130 (5)
1982 (73)
*586 (22)
17 (4)
320 (82)
*53 (14)
.425
YesFamily History of Mongolism
No
22 (1)
2070 (77)
*606 (22)
5 (1)
289 (74)
96 (25)
.325
YesFamily History of Mental
Retardation
No
35 (1)
2046 (76)
*617 (23)
9 (2)
283 (73)
*98 (25)
.097
Other Exposures
YesOccupational Exposure to
Glues No
189(7)
2028(75)
*481 (18)
20 (5)
251(64)
*119 (31)
.521
YesOccupational Exposure to
Solvents No
159 (6)
2058 (76)
*481 (18)
24 (6)
246 (63)
*120 (31)
.308
YesOccupational Exposure to
Pesticides No
169 (6)
2052 (76)
*477 (18)
16 (4)
252 (65)
*122 (31)
.334
YesInfluenza Shot
No
1259 (47)
1020 (38)
*419 (16)
164 (42)
148 (38)
*78 (20)
.372
YesPolio Shot
No
621 (23)
1595 (59)
*482 (18)
42 (11)
252 (65)
*96 (25)
.000
YesDiptheria Shot
No
553 (20)
1629 (60)
*516 (19)
35 (9)
264 (68)
*91 (23)
.000
Tetanus Shot Yes 710 (26)
1503 (56)
*485 (18)
45 (12)
255 (65)
*90 (23)
.000
*missing data
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BIVARIATE ANALYSIS: REDUCED-CAUSE CIND VERSUS
COGNITIVELY NORMAL
Variable Cognitively Normal-2
(n=2698)
CIND
(n=297)
P-value
Health Conditions
YesHeart Attack-1
No
171 (6)
1893 (70)
*634 (23)
26 (9)
266 (90)
*5 (2)
.721
YesDiabetes-1
No
237 (9)
2461 (91)
* 0
30 (10)
267 (90)
*0
.450
YesDiabetes-2
No
324 (12)
2370 (88)
*4 (0)
41 (13)
256 (86)
*1 (0)
.374
YesStroke-1
No
80 (3)
2616 (97)
*2 (0)
28 (9)
269 (91)
*0
.000
YesStroke-2
No
162 (6)
2525 (93)
*11 (0)
60 (20)
236 (81)
*1 (0)
.000
YesHigh Blood Pressure-1
No
1071 (40)
1627 (60)
*0
126 (42)
170 (57)
*1 (0)
.338
YesHigh Blood Pressure-2
No
1167 (43)
1521 (56)
*10 (0)
148 (50)
149 (50)
*0
.035
YesParkinson’s disease-1
No
14 (1)
2682 (99)
*2(0)
11 (4)
286 (96)
*0
.000
YesParkinson’s disease-2
No
49 (2)
2633 (98)
*16 (1)
14 (5)
283 (95)
*0 (0)
.001
YesThyroid Condition-1
No
455 (17)
1645 (61)
*598 (22)
39 (13)
246 (83)
*12 (4)
.002
YesArthritis-1
No
1691 (63)
999 (37)
8 (0)
193 (65)
95 (32)
*9 (3)
.165
YesKidney Disease-1
No
289 (11)
2398 (89)
*11 (0)
45 (15)
244 (82)
*8 (3)
.014
YesEpilepsy-1
No
17 (1)
2021 (75)
*660 (24)
5 (2)
292 (98)
*0 (0)
.157
YesSelf or Proxy Reported
Depression-1
No
259 (10)
1701 (63)
*738 (27)
43 (15)
175 (58)
*79 (27)
.008
YesSelf or Proxy Reported
Depression-2 No
243 (9)
2229 (83)
*226 (8)
63 (21)
234 (79)
0
.000
YesOther Psychiatric Illness
No
545 (20)
2150 (80)
*3 (0)
91 (31)
204 (69)
*2 (1)
.000
Demographic Information
Age-1 65-74
75-84
85 & over
1493 (55)
1049 (39)
156 (6)
77 (26)
154 (52)
66 (22)
.000
139
Age-2 65-74
75-84
85 & over
857 (32)
1406 (52)
435 (16)
28 (9)
134 (45)
135 (46)
.000
Marital Status-1 Currently/
Common Law
Separated/
Divorced
Widowed
Never
1125 (42)
116 (4)
1212 (45)
243 (9)
*2 (0)
69 (23)
17 (6)
184 (62)
26 (9)
*1 (0)
.000
Marital Status-2 Currently/
Common Law
Separated/
Divorced
Widowed
Never
856 (32)
101 (4)
1492 (55)
244 (9)
*5 (0)
46 (2)
14 (1)
211 (8)
26 (1)
*0 (0)
.000
Education 6 yrs & under
7-9 yrs
10-12 yrs
13 + yrs
248 (9)
703 (26)
1020 (38)
718(27)
*9 (0)
77 (26)
78 (26)
96 (32)
45 (15)
*1 (0)
.000
Income <$19,999
$20,000- 34,999
$35,000- 49,999
$50,000 +
1167 (43)
648 (24)
272 (10)
189 (7)
*422 (16)
170 (57)
38 (13)
12 (4)
5 (2)
*72(24)
.000
RuralRural/ Urban
Urban
275 (10)
2419 (90)
*4 (0)
30 (10)
266 (90)
*1 (0)
.969
Region-1 Atlantic
Quebec
Ontario
Prairies
B.C.
490 (18)
535 (20)
529 (20)
606 (22)
538 (20)
41 (14)
99 (33)
65 (22)
49 (17)
43 (15)
.000
Region-2 Atlantic
Quebec
Ontario
Prairies
B.C.
488 (18)
533 (20)
533 (20)
603 (22)
541 (20)
41 (14)
98 (33)
66 (22)
49 (17)
43 (16)
.000
InstitutionResidential
Status-1 Community
38 (1)
2660 (99)
*0
27 (9)
270 (91)
*0
.000
InstitutionResidential
Status-2 Community
106 (4)
2592 (96)
*0
59 (20)
238 (80)
*0
.000
Lifestyle Factors
YesSmoking Status
No
908 (34)
1500 (56)
*290 (11%)
76 (26)
216 (73)
*5 (2)
.000
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YesRegular Spirit Drinking
No
428 (16)
1924 (71)
*346 (13)
33 (11)
214 (72)
*50 (17)
.058
YesRegular Wine Drinking
No
356 (13)
1991 (74)
*351 (13)
24 (8)
224 (75)
*49 (16)
.020
YesRegular Coffee Drinking
No
1711 (63)
679 (25)
*308 (11)
172 (58)
80 (27)
*45 (15)
.266
YesRegular Tea Drinking
No
1726 (34)
660 (24)
*312 (12)
176 (59)
67 (23)
*54 (18)
.976
YesRegular Shellfish
Consumption
No
525 (19)
1831 (68)
*342 (13)
41 (11)
273 (70)
*76 (19)
.000
YesVitamin E
No
198(7)
2235(83)
*65 (10)
10 (3)
244 (82)
*43 (14)
.017
YesVitamin C
No
180(7)
2253(84)
*265 (10)
12 (4)
242 (81)
*43 (14)
.115
YesVitamin B
No
99 (4)
2334 (87)
*265 (10)
8 (3)
246 (83)
*43 (14)
.476
YesMulti-vitamin
No
457(17)
1976 (73)
*265 (10)
33 (11)
221 (74)
*43 (14)
.023
YesRegular Exercise
No
1607 (60)
758 (28)
*333 (12)
123 (41)
123 (41)
*51 (17)
.000
YesHead Injury
No
328 (12)
1967 (73)
*403 (15)
46 (15)
251 (85)
*0
.581
Medication Usage
EverHRT Use
Never
791 (29)
1907 (71)
*0
63 (21)
234 (79)
*0
.003
HRT Duration <12 mths
13 mths – 5 yrs
61 mths – 10 yrs
>121 mths
196 (25)
205  (26)
91  (12)
208 (26)
*91 (12)
20 (32)
11 (17)
5 (8)
9 (14)
*18 (29)
.086
Age at First HRT
Use
40 yrs & under
41-50 yrs
51 – 60 yrs
60 yrs & over
109 (14)
352 (45)
189 (24)
90 (11)
*51 (6)
11 (17)
21 (33)
15 (24)
7 (11)
*9 (14)
.574
YesRegular use of
Painkillers
No
1231 (60)
1122 (42)
*345 (13)
117 (39)
117 (39)
*63 (21)
.499
YesStatins
No
63(2)
2370(88)
*265 (10)
2 (1)
252 (85)
*43 (14)
.085
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Familial and Genetic Factors
APOE Genotype One or Two E2
E3/E3
One E4
Two E4
40
229
71
1
26
116
37
1
.794
YesFamily History of AD
No
132 (5)
2029 (75)
*537 (20)
25 (8)
264 (89)
*8 (3)
.097
YesFamily History of Senile
Dementia
No
130 (5)
1982 (73)
*586 (22)
11 (4)
246 (83)
*40 (13)
.230
YesFamily History of
Mongolism
No
22 (1)
2070 (77)
*606 (22)
5 (2)
218 (73)
74 (25)
.115
YesFamily History of Mental
Retardation
No
35 (1)
2046 (76)
*617 (23)
5 (2)
216 (73)
*76 (26)
.530
Other Exposures
YesOccupational Exposure to
Glues No
189(7)
2028(75)
*481 (18)
15 (5)
191 (64)
*91 (31)
.539
YesOccupational Exposure to
Solvents No
159 (6)
2058 (76)
*481 (18)
13 (4)
192 (65)
*92 (31)
.658
YesOccupational Exposure to
Pesticides No
169 (6)
2052 (76)
*477 (18)
9 (3)
197 (66)
*91 (31)
.088
YesInfluenza Shot
No
1259 (47)
1020 (38)
*419 (16)
132 (44)
105 (35)
*60 (20)
.894
YesPolio Shot
No
621 (23)
1595 (59)
*482 (18)
33 (11)
189 (64)
*75 (25)
.000
YesDiptheria Shot
No
553 (20)
1629 (60)
*516 (19)
29 (10)
197 (66)
*71 (24)
.000
Tetanus Shot Yes 710 (26)
1503 (56)
*485 (18)
37 (12)
190 (64)
*70 (24)
.000
*missing data
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BIVARIATE ANALYSIS :  ALZHEIMER ’S DISEASE VS. COGNITIVELY NORMAL (P<.25)
Variable Name P-value Exp (B) 95% CI Exp (B)
Demographic Information
Age-1
          65-74 (ref)
          75-84
          85& older
.000
.000
.000
7.299
29.143
4.278 – 12.452
16.780 – 50.614
Age-2
          65-74 (ref)
          75-84
          85& older
.000
.001
.000
3.337
19.621
1.641 – 6.786
9.923 – 38.797
Education
          0 – 6 years
          7 – 9 years
          10 – 12 years
          13 + years (ref)
.000
.024
.795
.000
2.765
1.670
1.062
1.674 – 4.568
1.069 – 2.610
0.675 – 1.672
Income-2
          < 19,999
          20,000 – 34,999
          35,000 – 49,999
          50,000 + (ref)
.040
.847
.572
.000
2.571
1.102
0.700
1.042-6.343
0.412-2.952
0.203-2.417
Marital Status-1
      Currently (ref)
      Separated/ Divorced
      Widowed
      Never Married
.000
.178
.000
.584
.256
1.649
1.215
.035-1.861
1.833-3.827
.605-2.439
Marital Status-2
      Currently (ref)
      Separated/ Divorced
      Widowed
      Never Married
.000
.561
.000
.286
.653
2.598
1.468
.155-2.750
1.701-3.969
.725-2.972
Institutional Status-1 .000 7.403 4.578 -11.970
Institutional Status-2 .000 14.033 10.264-19.186
Rural-Urban (urban) .198 0.668 0.362-1.234
Region-1
B.C.  (ref)
         Atlantic
         Quebec
         Ontario
         Prairies
.017
.001
.005
.026
.013
2.795
2.359
2.012
2.140
1.549-5.045
1.288-4.320
1.086-3.727
1.177-3.892
Region-2
B.C.  (ref)
         Atlantic
         Quebec
         Ontario
         Prairies
.011
.000
.005
.027
.015
2.886
2.382
2.009
2.109
1.602 – 5.199
1.301 – 4.361
1.084 – 3.721
1.158 – 3.844
Health Conditions and Illness
Arthritis-1 (Yes) .554 1.101 0.800 – 1.517
Thyroid condition-1 (Yes) .172 1.342 0.880 – 2.046
Heart Attack-1 (No) .609 1.149 0.675 – 1.956
Kidney Condition or Disease-1 (No) .812 0.939 0.560 – 1.575
Epilepsy-1 (No) .153 0.361 0.089 – 1.462
Diabetes-1 (No) .999 1.00 0.567 – 1.764
Diabetes-2 (No) .348 0.775 0.456 – 1.319
Stroke-1 (No) .040 1.778 1.028 – 3.077
Stroke-2 (No) .004 2.040 1.249 – 3.331
High BP-1 (No) .199 0.808 0.585 – 1.118
High BP-2 (No) .090 1.306 0.959 – 1.779
Parkinson’s Disease-1 (No) .887 1.154 0.162 – 8.239
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Parkinson’s Disease-2 (No) .105 1.963 0.868 – 4.436
Depression-1 (No) .001 2.008 1.323 – 3.048
Psychiatric Illness-1 (No) .959 0.990 0.668 – 1.465
Medication Usage
HRT (yes) .001 2.014 1.332 - 3.046
HRT Duration
        12 months or less
        13 – 60 months
        61 - 120 months
        121- 660 months      (ref)
.718
.548
.374
.629
1.223
0.679
1.105
0.411 – 3.639
0.192 – 2.406
0.046 – 3.182
Age at 1st HRT Use
        40 yrs & under (ref)
        41 – 50 years
        51 – 60 years
        61 years & older
.537
.648
.533
.825
0.730
1.525
0.817
0.189 – 2.822
0.405 – 5.750
0.137 – 4.889
Painkiller Use-1 (Yes) .957 0.990 0.668 - 1.424
Statins (Yes) .476 1.661 0.411 – 6.713
Lifestyle Factors
Coffee-1 (Yes) .000 1.982 1.401 – 2.804
Tea-1 (Yes) .024 0.594 0.378 – 0.933
Wine-1 (Yes) .004 3.389 1.492 – 7.698
Spirit-1 (Yes) .035 1.856 1.045 – 3.297
Smoker-1 (Yes) .000 2.016 1.390 – 2.922
Exercise-1 (Yes) .000 2.233 1.577 – 3.163
Vitamin E (yes) .043 2.790 1.031 – 7.548
Vitamin C (yes) .135 1.975 0.808 – 4.827
Multi-vitamin (yes) .157 1.431 0.871 - 2.353
Vitamin B (yes) .563 1.342 0.496 – 3.630
Shellfish-1 (yes) .163 1.397 0.873 – 2.233
Head Injury-1 (No) .520 0.854 0.529 – 1.380
Familial and Genetic Factors
APOE
  One or Two E2 Alleles (ref)
  E3/E3 Alleles
  One E4 Allele
  Two E4 Alleles
.000
.449
.370
.000
0.784
1.360
7.607
0.417 – 1.472
0.694 – 2.666
2.448 – 23.638
Family History of AD (no) .018 0.545 0.330 – 0.903
Family History of Senility (no) .196 0.555 0.227 – 1.354
Family History of Mongolism (no) .552 1.528 0.378 – 6.183
Family History of Mental Retardation (no).979 1.019 0.252 – 4.125
Other Exposures
Influenza Shot (yes) .772 0.949 0.668 – 1.350
Polio Shot (yes) .000 4.387 2.299 – 8.369
Diptheria Shot (yes) .000 3.461 1.865 – 6.426
Tetanus Shot (yes) .000 4.794 2.583 – 8.898
Exposure to Solvents (no) .136 0.468 0.173 – 1.270
Exposure to Pesticides (no) .790 0.907 0.442 – 1.860
Exposure to Glues (no) .357 0.698 0.325 – 1.500
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BIVARIATE ANALYSIS :  VASCULAR DEMENTIA VS . COGNITIVELY NORMAL (P<.25)
Variable Name P-value Exp (B) 95% CI Exp (B)
Demographic Information
Age-1
          65-74 (ref)
          75-84
          85& older
.000
.000
.000
6.585
10.787
2.726 – 15.902
3.624 – 32.110
Age-2
          65-74 (ref)
          75-84
          85& older
.000
.013
.000
12.693
36.451
1.707 – 94.361
4.879 – 272.314
Education
          0 – 6 years
          7 – 9 years
          10 – 12 years
          13 + years (ref)
.000
.420
.622
.000
6.691
1.530
1.285
2.571 – 17.412
0.545 – 4.299
0.475 – 3.474
Income-2
          < 19,999
          20,000 – 34,999
          35,000 – 49,999
          50,000 + (ref)
.160
.660
.526
.023
4.181
.583
2.081
0.567-30.810
0.053-6.429
0.216-20.005
Marital Status-1
         Currently (ref)
         Separated/Divorced
         Widowed
         Never Married
.348
.970
.082
.217
.000
1.850
1.930
.000-E
.925-3.699
.680-5.479
Marital Status-2
         Currently (ref)
         Separated/Divorced
         Widowed
         Never Married
.131
.974
.019
.077
.000
2.844
2.914
NA
1.184-6.834
.889-9.548
Institutional Status-1 (community) .000 8.959 3.51-22.868
Institutional Status-2 (community) .000 19.326 10.45-35.73
Rural-Urban (ref urban) .017 2.463 1.18-5.16
Region-1
B.C.  (ref)
         Atlantic
         Quebec
         Ontario
         Prairies
.403
.732
.279
.584
.094
1.231
1.828
1.378
2.394
.375-4.043
.613-5.456
.437-4.344
.862-6.650
Region-2
         B.C.  (ref)
         Atlantic
         Quebec
         Ontario
         Prairies
.391
.720
.272
.587
.090
1.243
1.846
1.375
2.420
0.375 – 4.083
0.619 – 5.508
0.436 – 4.335
0.871 – 6.722
Health Conditions and Illness
Arthritis-1 (Yes) .631 0.849 0.437 – 1.653
Thyroid condition-1 (Yes) .891 1.053 0.501 – 2.213
Heart Attack-1 (No) .008 2.884 1.322 – 6.290
Kidney Condition or Disease-1 (No) .067 2.065 0.952 – 4.481
Epilepsy-1 (No) .041 8.153 1.085 – 61.264
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Diabetes-1 (No) .645 1.275 0.453 – 3.587
Diabetes-2 (No) .299 1.539 0.682 – 3.472
Stroke-1 (No) .000 4.614 2.131 – 9.990
Stroke-2 (No) .000 53.591 25.574 – 112.300
High BP-1 (No) .003 2.595 1.375 – 4.900
High BP-2 (No) .000 3.509 1.759 – 7.002
Parkinson’s Disease-1 (No) .755 0.049 NA
Parkinson’s Disease-2 .168 2.719 06.57-11.261
Depression-1 (No) .022 2.834 1.166 – 6.888
Psychiatric Illness-1 (No) .080 1.836 0.930 – 3.624
Medication Usage
HRT (yes) .006 5.200 1.605 – 16.845
HRT Duration (all types) NA
Age at 1st HRT Use NA
Painkiller Use-1 (Yes) .224 0.619 0.286 – 1.342
Statins .569 20.886 NA
Lifestyle Factors
Coffee-1 (Yes) .982 0.991 0.436 – 2.250
Tea-1 (Yes) .781 0.886 0.376 – 2.085
Wine-1 (Yes) .574 1.411 0.425 – 4.687
Spirit-1 (Yes) .087 5.707 0.774 – 42.061
Smoker-1 (Yes) .159 0.609 0.305 – 1.215
Exercise-1 (Yes) .020 2.415 1.149 – 5.075
Vitamin E (yes) .305 22.844 NA
Vitamin C (yes) .456 2.137 0.290 – 15.729
Multi-vitamin (yes) .291 1.907 0.576 – 6.318
Vitamin B (yes) .901 1.136 0.154 – 8.357
Shellfish-1 .045 7.711 1.048 – 56.744
Head Injury-1 (no) .118 1.807 0.860 – 3.795
Familial and Genetic Factors
APOE
  One or Two E2 Alleles (ref)
  E3/E3 Alleles
  One E4 Allele
  Two E4 Alleles
.076
.441
.094
.982
2.223
5.758
0.000
0.291 – 16.994
0.743 – 44.599
NA
Family History of AD (no) .283 1.763 0.627 – 4.962
Family History of Senility (no) .561 1.421 0.435 –4.641
Family History of Mongolism (no) .741 0.049 NA
Family History of Mental Retardation (no) .680 0.049 NA
Other Exposures
Influenza Shot (yes) .414 0.722 0.331 – 1.577
Polio Shot (yes) .089 2.844 0.851 – 9.503
Diptheria Shot (yes) .066 3.882 0.915 – 16.467
Tetanus Shot (yes) .147 2.221 0.755 – 6.529
Exposure to Solvents (no) .289 1.928 0.573 – 6.489
Exposure to Pesticides (no) .338 1.811 0.538 – 6.093
Exposure to Glues (no) .449 1.599 0.475 – 5.381
NA- not enough cases to get a stable estimate
146
APPENDIX D
Hand Calculations for Interaction Assessment












